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Abstract
Abstract
The controlled induction of cellular demise is an essential mechanism in multicellular
animals to ensure their correct development, to remove malignant cells and to maintain
tissue homeostasis. Since cell deletion in a well-organized manner is so important, several
different pathways have been evolved to ensure the organisms’ adaptation to various death
stimuli and environmental influences. Among the different cell death cascades, one of the
best-characterized mechanism, known as apoptosis, leads to a non-inflammatory removal
of cells and occurs for example in embryos during morphogenesis of fingers and toes.
Apparently, the apoptotic non-inflammatory cell deletion is beneficial for an organism
by preventing a severe immune response and thereby protecting its physical condition.
However, misregulation of apoptosis has been related to severe diseases such as cancer
or Alzheimer.
The key players during apoptosis have been determined as proteolytic enzymes of
the caspase-family, which are able to either induce (caspase-2, -8, -9 and -10) or exe-
cute (caspase-3, -6 and -7) the apoptotic signaling. Besides that, other family members
(caspase-1, -4, -5 and -12) are classified as inflammatory related peptidases. Since all the
family members share a high sequence homology, the specific targeting of a particular
caspase is limited with the contemporary available small molecules, which lack specificity
due to their targeting of the highly conserved active site. To overcome the evident prob-
lem of caspase-specificity, we have followed the approach of using bigger molecules that
provide larger binding interfaces. These interfaces may involve non-conserved residues
resulting in increased target specificity. For our studies, we have used artificial binding
proteins known as designed ankyrin repeat proteins (DARPins) as the molecule of choice
for specific caspase targeting.
Using ribosome display, we performed DARPin selections against caspase-1 to -9, which
resulted in a variety of specific caspase binders. With the exception of caspase-4, we were
able to identify highly specific DARPins for each family member with binding affinities in
the low nanomolar range. Our high-resolution crystal structures of DARPins in complex
with caspases revealed two particular different epitopes located either at the active site
forming loops or laterally at the large subunit.
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Our studies on caspase-3 selected DARPins identified D3.4S76R as a very specific
binder with high affinity (K d = 6.0 nM), which inhibits the enzyme (K i = 3.5 nM) in a
pure competitive manner. Furthermore, we could demonstrate with a complex structure
of caspase-3/D3.4S76R that inhibition is achieved by a similar mechanism as the one of
the natural caspase inhibitor XIAP.
The characterization of caspase-7 selected DARPins was primarily focused on two
particular binders D7.18 and D7.43. Both DARPins share a similar epitope with high
specificity for caspase-7 but exhibited no inhibitory effect on the active enzyme. Strik-
ingly, these molecules can also bind to the zymogenic form and thereby interfere with its
activation. Our crystal structure of caspase-7/D7.18 unraveled a binding epitope side-
ways at the large subunit explaining the high specificity of these binders. In addition, the
lateral binding of the DARPin presumably leads to steric hindrance during inter-domain
linker cleavage, which is a prerequisite for successful zymogen activation.
With these two new and highly specific inhibitors of the main executioner caspase-3
and -7, we were able to further study the effect of these enzymes inside HeLa cells. In-
terestingly, co-transfected cells expressing D3.4S76R and D7.43 displayed significantly
reduced caspase activity compared to single- or non-transfected cells indicating a suc-
cessful intracellular caspase inhibition. In fact, double transfected HeLa cells were less
susceptible for TRAIL induced apoptosis and survived longer in TRAIL complemented
medium, which we have directly monitored using live cell imaging.
Our knowledge in the selection of caspase specific DARPins was also applied for the
characterization of a second generation DARPin library with reduced hydrophobicity.
We have used caspase-3 and -7 as targets during selection and thoroughly analyzed the
selected DARPins using surface plasmon resonance and equilibrium unfolding. Although
the new DARPins exhibited a slightly reduced thermodynamic stability, their affinity
for caspase-3 and -7 were comparable to our previously selected DARPins derived from
the original library. The high-resolution crystal structure of a new DARPin C7_16 in
complex with caspase-7 not only verified an unchanged scaffold but also demonstrated
that the intended surface entropy reduction of certain residues helped to provide crystal
contacts.
Overall, this thesis will provide insights into the selection of caspase-specific DARPins
and their binding characterization. The two identified highly specific caspase inhibitors
were structurally investigated to elucidate their mode of action while application in cel-
lular assays could demonstrate their potential to target these enzymes during apoptosis.
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Zusammenfassung
Der kontrollierte Zelltod ist ein essentieller Mechanismus in mehrzelligen Lebewesen. Da-
mit wird die korrekte Entwicklung gewährleistet, bösartige Zellen entfernt und die Ho-
möostase im Gewebe aufrechterhalten. Das koordinierte Entfernen von Zellen ist für einen
Organismus sehr wichtig, weshalb sich im Laufe der Evolution zahlreiche unterschiedliche
Prozesse entwickelt haben. Unter den verschiedenen Todes Kaskaden ist Apoptose der
wohl am besten untersuchte Prozess. Apoptose entfernt Zellen ohne eine Entzündungs-
reaktion auszulösen und findet zum Beispiel während der embryonalen Entwicklung von
Fingern und Zehen statt. Auf der einen Seite ist klar, dass das Entfernen von Zellen ohne
Entzündungsreaktion eine Immunreaktion im Körper verhindert und so zur allgemeinen
Gesundheit des Lebewesens beiträgt. Auf der anderen Seite kann eine falsche Regulierung
von Apoptose auch zu schweren Krankheiten wie Krebs oder Alzheimer führen.
Während der Apoptose spielen proteolytische Enzyme der Caspase Familie eine wich-
tige Schlüsselrolle, da sie die apoptotische Signalkaskade entweder induzieren (Caspase-2,
-8, -9 und -10) oder ausführen (Caspase-3, -6 und -7). Des Weiteren wurden andere Pep-
tidasen dieser Familie (Caspase-1, -4, -5 und -12) zu unterschiedlichen Entzündungsreak-
tionen zugeordnet. Die spezifische Untersuchung einer einzelnen Caspase ist mit heutigen
Mitteln limitiert: Einerseits weisen die verschiedenen Caspasen eine hohe Sequenzhomo-
logie auf. Andererseits zielen kommerziell erhältliche Stoffe auf das enzymatisch aktive
und stark konservierte Zentrum. Um dieses Problem der Caspase-Spezifität umgehen
zu können, dürften grössere Moleküle mit ausgedehnten Bindungsoberflächen eine ent-
scheidende Hilfestellung bieten. Die vergrösserten Bindungsstellen können unter anderem
auch nicht-konservierte Aminosäuren in die Bindung miteinbeziehen und somit eine hö-
here Spezifität für das gewünschte Protein liefern. Aus diesem Grund haben wir uns für
die spezifische Untersuchung von Caspasen für ein künstlich hergestelltes Bindungsprote-
in entschieden. Diese Proteine sind bekannt unter dem Namen Designed Ankyrin Repeat
Protein oder kurz DARPin.
Mit Hilfe der Technik Ribosome Display haben wir eine Vielzahl an DARPins gegen
Caspase-1 bis -9 selektioniert. Mit Ausnahme von Caspase-4 haben wir für alle Caspase
Familienmitglieder sehr spezifische DARPins identifizieren können. Diese DARPins bin-
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den die jeweilige Caspase mit einer hohen Affinität im tiefen nanomolaren Bereich. In
unseren Bindungs-Analysen haben wir unter Anderem mit hochauflösenden Proteinkri-
stallstrukturen zwei verschiedene, favorisierte Bindungsstellen auf den Caspasen lokali-
sieren können: Während ein Epitop in der Nähe oder am enzymatisch aktiven Zentrum
liegt, gibt es ein weiteres bevorzugtes Epitop lateral an der grossen Untereinheit des
Enzyms.
Durch unsere Studien an Caspase-3 selektionierten DARPins haben wir einen sehr
spezifischen Binder (D3.4S76R) mit hoher Affinität (K d = 6.0 nM) entdeckt. Dieser
inhibiert das Enzym (K i = 3.5 nM) mittels eines kompetitiven Mechanismus. Nähe-
re Untersuchungen an der Kristallstruktur eines Caspase-3/D3.4S76R Proteinkomplexes
zeigte, dass dieser Inhibitionsmechanismus ähnlich dem eines natürlich vorkommenden
Caspase-Inhibitors (XIAP) ist.
Unsere Forschung an Caspase-7 selektionierten DARPins war hauptsächlich auf zwei
Binder (D7.18 und D7.43) fokussiert. Beide DARPins haben ein ähnliches Epitop auf
Caspase-7 und binden mit hoher Spezifität wobei die Aktivität der Peptidase nicht be-
einflusst wird. Interessanterweise können beide Moleküle auch an die Procaspase-7 binden
und verhindern dadurch deren erfolgreiche Aktivierung. Die Röntgenstrukturanalyse von
Caspase-7 im Komplex mit D7.18 zeigte eine Bindungsstelle lateral an der grossen Un-
tereinheit und erklärt, wie die hohe Spezifität für Caspase-7 zustande kommt. Zusätzlich
liefert sie Hinweise, warum die Bindung an die Procaspasen mit deren Aktivierung in-
terferiert: Die Peptidkette zwischen der grossen und kleinen Untereinheit von Caspasen
muss für deren Aktivierung proteolytisch gespalten werden. Dies wird durch einen lateral
gebunden DARPin sterisch verhindert.
Die Inhibition der zwei wichtigsten Caspasen (-3 und -7) für die Ausführung von
Apoptose haben wir mit Hilfe dieser zwei DARPins in HeLa Zellen studiert. Co-
transfektierte Zellen (D3.4S76R und D7.43) zeigten weniger Caspase-Aktivität nach der
Induktion von Apoptose als einzeln-transfektierte Zellen. Zusätzlich konnten wir mit
Lebendzell-Mikroskopie zeigen, dass doppel-transfektierte HeLa Zellen weniger empfäng-
lich für TRAIL-induzierte Apoptose sind, da diese im Vergleich zu einzeln- oder nicht-
transfektierten Zellen in Medium mit TRAIL länger überleben können.
Unsere Erkenntnisse in der Selektion und Charakterisierung von caspase-spezifischen
DARPins haben wir für die Validierung einer neuen Generation von DARPins eingesetzt.
Dazu haben wir Caspase-3 und -7 als Testproteine verwendet und die selektionierten Bin-
der genau analysiert. Auch wenn die thermodynamische Stabilität der neuen DARPins
etwas abgenommen hat, besitzen die selektionierten Binder der neuen Generation eine
vergleichbare Affinität für Caspase-3 und -7. Eine hochaufgelöste Röntgenstruktur eines
iv
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DARPins (C7_16) im Komplex mit Caspase-7 demonstrierte, dass sich die allgemeine
Struktur der DARPins nicht geändert hat, und dass die beabsichtigte Reduktion der
Oberflächen-Entropie geholfen hat, Kristallkontakte zu begünstigen.
Zusammenfassend liefert diese Doktorarbeit Einblicke in die Selektion und Charakte-
risierung von caspase-spezifischen DARPins. Die dadurch entdeckten, sehr spezifischen
Inhibitoren wurden strukturell untersucht, um den Inhibitions-Mechanismus aufzuklä-
ren. Zusätzlich konnten intrazelluläre Experimente aufzeigen, dass diese Bindungsprote-
ine hohes Potential haben, um die Funktion der Caspasen während der Apoptose weiter
aufzuklären.
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Abbreviations
Aβ Amyloid-β
AIF Apoptosis-inducing factor
Apaf-1 Apoptotic protease activating factor 1
APP Amyloid precursor protein
BH Bcl-2 homology
Bid BB3-interacting domain
BIR Baculoviral IAP repeat
C. elegans Caenorhabditis elegans
CAD Caspase-activated DNAse
CARD Caspase activation and recruitment domain
DAMP danger associated molecular pattern
DARPin Designed ankyrin repeat protein
DD Death domain
DED Death effector domain
DFF40 DNA fragmentation factor 40 also termed CAD
DIABLO Direct IAP binding protein with low pI, also termed Smac
DISC Death-inducing signaling complex
ENDOG Endonuclease g
FADD Fas-associated death domain
FLICE FADD-like interleukin-1 beta-converting enzyme, today known as
caspase-8
FLIP FLICE-inhibitory protein
HTRA2 High temperature requirement protein 2
htt Huntingtin
A. Flu¨tsch • M.G. Gru¨tter (*)
Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zu¨rich,
Switzerland
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IAP Inhibitor of apoptosis protein
ICAD Inhibitor of CAD, also known as DFF45
ICE Interleukin-1β-converting enzyme
IMS Inter-membrane space
LRR Leucine-rich repeat
MOMP Mitochondrial outer membrane permeabilization
NC-IUBMB Nomenclature Committee of the International Union of
Biochemistry and Molecular Biology
NCCD Nomenclature Committee on Cell Death
NFT Neurofibrillary tangle
NLR NOD-like receptor
NOD Nucleotide binding and oligomerization domain
PARP Poly(ADP-ribose) polymerase
PIDD p53-induced protein with a death domain
PS Phosphatidylserine
RIP Receptor-interacting protein
ROCK Rho-associated kinase
Smac Second mitochondria-derived activator of caspase, also termed
DIABLO
tBid Truncated Bid
TNF Tumor necrosis factor
TRAIL TNF-related apoptosis-inducing ligand
UBA Ubiquitin associated
XIAP X-linked inhibitor of apoptosis protein
8.1 Introduction
The theory of the cell as the basic unit of life was developed by the German
scientists Schleiden and Schwann in 1839. Shortly afterwards, cellular demise
was observed by researches in different tissues and cell types. A landmark was in
1885, when Walther Flemming morphologically described the process of dying
ovarian follicles containing “chromatin chunks”, which he termed chromatolysis
(Flemming 1885). In fact, the condensation of chromatin is nowadays well known
as a morphological feature of apoptosis.
In 1972, Kerr et al. (1972) described the morphology of cell deletion in tissues with
a reproducible and different mechanism compared to the known process of necrosis.
Disappearing cells showed aggregation of nuclear chromatin similar to Flemmings
observations. Themechanism could be dissected into two stages: A step of nuclear and
cytoplasmic condensation intomembrane-bound cellular fragments and a degradation
step performed by other cells after phagocytosis. Kerr proposed the term apoptosis for
this programmed cell death derived from the Greek word for “falling off”.
Studies on embryonic development of Caenorhabditis elegans (C. elegans) by
Ellis and Horvitz (1986) yielded in the discovery of the cell death controlling genes
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ced-3 and ced-4. A fundamental starting point in death pathway research was in
1993, when this C. elegans gene ced-3 was recognized to encode a protein similar to
the mammalian interleukin-1β-converting enzyme (ICE) (Yuan et al. 1993). Sev-
eral homologues of ICE were identified in mammals forming a proteolytic network
as the molecular basis for apoptosis. The increasing amount of identified cysteine-
aspartic-dependent proteases with inconsistent and multiple names were unified for
simplicity with the name caspase in 1996 (Alnemri et al. 1996).
Caspases were further investigated and revealed a complex network of regula-
tion and activation during apoptosis. They are known as the key-players in apopto-
sis and besides of this crucial role, caspases are involved in inflammatory pathways
and immunity and can regulate proliferation and differentiation.
Besides the caspase-mediated apoptosis, other death pathways like necroptosis,
autophagy and pyroptosis were discovered and expanded the research field of death
pathways with caspase-dependent and -independent mechanisms.
The numerous different ways of cell removal and destruction underlines the
significance of cell deletion. It is crucial for multicellular organisms to maintain the
correct numbers of cells in tissues and to shape the architecture of organs. In
addition, unspecific cell proliferation and tumor development is related to down-
regulation of apoptosis whereas its up-regulation is associated to degenerative
diseases like Parkinson and Alzheimer.
8.2 Death Pathways
8.2.1 Nomenclature
Various distinctive death pathways have been discovered till date and were histori-
cally classified by cellular morphology. Since 2012, the Nomenclature Committee
on Cell Death (NCCD) suggests a classification based not only on morphological
observations but also on biochemical data analysis (Galluzzi et al. 2012). It has
been revealed that similar morphological features in cell death show biochemical,
functional and immunological heterogeneity. This renders the nomenclature based
on morphology as not sufficient and the exact identification of a specific pathway as
a rather challenging task. The suggested classification on quantitative biochemical
analysis is less prone to misinterpretations, since morphological observations
require an experienced operator. Thus, the following pathway definitions will
consider the NCCD recommendations.
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8.2.2 Extrinsic Apoptosis
The extrinsic apoptotic pathway is a caspase-dependent mechanism, which is
initiated by extracellular stress signals. Extracellular death ligands bind to death
receptors like FAS, tumor necrosis factor (TNF) receptor 1 or TNF-related apopto-
sis inducing ligand (TRAIL) receptor 1 and 2 leading to receptor trimerization. The
activated receptor conformation triggers the assembly of an intracellular death
inducing signaling complex (DISC) involving the adaptor protein Fas-associated
death domain (FADD) and the initiator pro-caspases-8 or -10.
The DISC recruitment of pro-caspases leads to activation by dimerization and
subsequent autocatalytic processing. Then, initiator caspases catalyze the matura-
tion of executioner caspases to start the apoptotic removal of the cell. In particular
cells like hepatocytes (type II cells), caspase-8 cleaves the death agonist
BB3-interacting domain (Bid) to a truncated form (tBid) instead of activating
executioner caspases (Yin et al. 1999). Bid-cleavage leads to mitochondrial outer
membrane permeabilization (MOMP) that activates apoptosis in a similar manner
as the intrinsic apoptosis driven by caspase-9. Bid-cleavage can thus substitute a
direct caspase-8 mediated activation of executioner caspases and can provide an
amplification loop of extrinsic apoptosis through the intrinsic apoptotic pathway in
selected cells (Yin et al. 1999).
8.2.3 Intrinsic Apoptosis
Intrinsic apoptosis is triggered by intracellular stress signals such as DNA damage,
oxidative stress and accumulation of unfolded protein. The NCCD suggests a
classification into two different mechanisms due to highly heterogeneous signaling
cascades with the mitochondrion as the main control mechanism. Predominance of
pro-apoptotic proteins like Bak or Bax can lead to MOMP due to their pore forming
activity. Consequently, inter-membrane space (IMS) residential proteins are
released into the cytosol where they mediate two apoptotic pathways:
– Caspase-dependent
The release of cytochrome c upon MOMP triggers the caspase-dependent
mechanism of intrinsic apoptosis. Cytochrome c assembles together with the
apoptotic protease activating factor 1 (Apaf-1) to the recruitment platform for
pro-caspase-9, known as the apoptosome. After the activation by dimerization,
caspase-9 facilitates downstream cleavage of executioner caspases leading to
cellular demise.
– Caspase-independent
The release of IMS proteins, such as apoptosis-inducing factor (AIF) and
endonuclease g (ENDOG), leads to caspase-independent fragmentation of
DNA after relocation into the nucleus. The IMS serine protease high temperature
requirement protein A2 (HTRA2) cleaves numerous cytoplasmic substrates
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including cytoskeleton proteins and contributes to the caspase-independent
mechanism of intrinsic apoptosis.
8.2.4 Pyroptosis
Pyroptosis is a regulated death pathway highly connected to caspase-1 activation
and inflammatory responses. Brennan and Cookson (2000) described the death of
macrophages that were infected by Salmonella typhimurium and named this repro-
ducible mechanism pyroptosis (Cookson and Brennan 2001). Indeed, several other
bacteria are able to induce pyroptosis like Shigella flexneri, Bacillus anthracis toxin
and Pseudomona aeruginosa.
It became clear that activation of caspase-1 is a crucial step, which is promoted by
a multi-protein complex known as the inflammasome. In contrast to the apoptotic
pathways, executioner caspases are not involved during pyroptosis.
The caspase-1-activating inflammasome is a large protein complex, which is
formed upon infection with bacteria, viruses or parasites, as well as by host-derived
danger associated molecular patterns (DAMP). NOD-like receptor (NLR) proteins
recognize danger signals and bind via the adaptor protein ASC and its caspase
activation and recruitment domain (CARD) to pro-caspase-1. Proximity-induced
oligomerization and activation of caspase-1 leads to the maturation of
pro-interleukins. The activated cytokines interleukin-1 and -18 are secreted to recruit
and activate immune cells for an inflammatory response. The activation of caspase-1
results in cleavage of several other substrates, however the complex mechanism of
inflammasome activation and pyroptotic cell death is still not completely understood
but has recently been well reviewed by Rathinam et al. (2012).
8.2.5 Regulated Necrosis
Necrosis is commonly known as an accidental cell death with a morphotype of
disrupted membranes and release of intracellular content. Hitomi et al. (2008)
recently pointed out that there is as well a regulated form of necrosis, which can
be triggered under specific energy dependent circumstances. Key mediators of the
regulated necrotic pathway are ATP-dependent enzymes like poly(ADP-ribose)
polymerase 1 (PARP-1) or receptor-interacting protein kinase 1 (RIP1). Alkylated
DNA damage can act as an inducing signal leading to PARP-1 hyperactivation and
cytosolic ATP reduction. The depletion of the cellular energy storage results in
activation of RIP1 or its homolog RIP3, which triggers the execution of necrosis.
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8.2.6 Autophagy
Morphological features like massive cytoplasmic vacuolization were first described
in the 1950s. In most cases, autophagy is activated upon cell stress and as a
cytoprotective response of dying cells. It is a conserved, kinase-dependent cell
degradation pathway in eukaryotes with autophagy related proteins and Beclin-1 as
the key players of autophagosome biogenesis. A clear elucidation of
autophagosome formation and its regulation is beyond the scope of this chapter
but reviewed by Yang and Klionsky (2009) and Rubinsztein et al. (2012). Like
apoptosis, the autophagic cell degradation is non-inflammatory due to vacuolization
of cytoplasmic content.
8.2.7 Other Modalities
Numerous additional death pathways exist that are in some cases overlapping or
bypassing other mechanisms. Thus, a variety of cell death pathways can be
observed in cultures induced by the same stimulus. This makes a clear identification
of the exact molecular mechanism even more important. In addition to apoptosis as
the most important non-inflammatory pathway and pyroptosis as the inflammatory
pathway, the following mechanisms are known:
– Mitotic catastrophe is initiated in an arrested M-phase in the cell cycle due to
mitotic machinery aberrations. It finally leads to cell death or senescence.
– Anoikis is an apoptotic response due to loss of cell-to-matrix interactions
– Entosis or “cell-cannibalism” describes the complete engulfment of a cell into
another cell, which is never released and finally degraded.
– Parthanatos is initiated by PARP-1 hyperactivation and its resulting
ATP-depletion. It is a particular form of regulated necrosis.
– Netosis is a cell death mechanism restricted to granulocytic cells, sharing
biochemical features with autophagy and regulated necrosis.
– Cornification is important for epidermis formation and restricted to
keratinocytes.
8.3 Caspases: The Essential Proteases in Death Pathways
The caspase family members are well known as the key players in apoptosis. They
play important roles in initiation and execution of the extrinsic and caspase-
dependent intrinsic apoptotic pathways as well as in pyroptotic cell deletion. The
first hint of these pro-apoptotic proteins was found in C. elegans in 1986, when Ellis
and Horvitz (1986) identified that the genes ced-3 and ced-4 are required for the
initiation of apoptosis. Deletion of these two genes leads to the survival of cells,
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which otherwise usually died during embryonic development. Using the simple
model organism C. elegans, more apoptosis-related genes and proteins like ced-9
(Hengartner et al. 1992) and EGL-1 (Conradt and Horvitz 1998) were unraveled
decomposing the complex molecular system of apoptosis into its relevant proteins.
CED-4 dimeric proteins are blocked in an inactive form by CED-9 in living cells.
Apoptotic stimuli induce the production of EGL-1, which binds to CED-9 and thus
liberates the CED-4 dimers. The released dimers build the apoptosome by
tetramerization of the asymmetric dimers and recruitment of proCED-3, where
CED-3 is activated by proteolysis or conformational changes and then released to
trigger apoptosis.
Apoptotic research onmammalian cells and human proteins was boosted after the
discovery of ICE as a unique cysteine protease (Thornberry et al. 1992) and its
homology to the nematodic CED-3 (Yuan et al. 1993). The unified name caspase was
finally introduced after the identification of several ICE homologues and their
confusing nomenclature (Alnemri et al. 1996). In fact, the mammalian genomes
encode numerous ced-like genes that may have arisen by gene duplication during
evolution. Compared to nematodes, this emphasizes amuchmore complex apoptotic
system with more redundancy and regulatory effectors.
In 1994, the first high-resolution crystal structure of human ICE was reported at a
resolution of 2.6 A˚ and gave first insights into the catalytic mechanism and its
regulation (Wilson et al. 1994). The tetrameric enzyme consists of two identical
heterodimers made by a small (p10) and a large (p20) subunit. Two substrate-
binding pockets are shaped between the p10 and p20 of the individual heterodimer.
The active sites are formed by a catalytic diad (Cys-285 and His-237) and cleave
substrates specifically after aspartate residues. Both, the conserved catalytic diad
residues Cys-285 and His-237 as well as the requirement of a substrate with an
aspartic acid at P1 are common for all caspase family members.
Based on the structure and selective mutagenesis, an allosteric regulation of ICE
activity was proposed (Wilson et al. 1994). Mutations in the dimer interface of the
heterodimeric subunits, far away from the active site cleft, resulted in an inactive
ICE suggesting the tetrameric enzyme as a prerequisite for activity.
During the last two decades, 12 different human caspases have been identified
and biochemically characterized. Seven of them could be crystallized or studied by
NMR spectroscopy till date. Even though this progress led to one of the best-
characterized protease families among proteolytic enzymes, open questions are
still remaining.
8.3.1 Classification, Nomenclature and Family Members
The Nomenclature Committee of the International Union of Biochemistry and
Molecular Biology (NC-IUBMB) classifies the family of caspases as cysteine
endopeptidases with the enzyme category (EC) number 3.4.22 where today
caspase-1 to caspase-11 are listed in the IUBMB database with individual EC
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numbers. The MEROPS database assigned these enzymes to the clan CD with the
family C14 [http://merops.sanger.ac.uk/ (Rawlings et al. 2012)].
The term caspase was introduced in 1996 with “c” abbreviating the catalytic
residue cysteine and “aspase” referring to the required aspartic acid at position P1 of
the peptidase (Alnemri et al. 1996). Other similar terminologies for caspase can be
found in the literature like “cysteine-dependent aspartate-directed proteases”
(Eckhart et al. 2008).
The number of each family member is assigned to the date of publication and
reflects the history of caspase research. Caspases are expressed as zymogens,
indicated by the prefix “pro” (e.g. pro-caspase-1). The polypeptide chain consists
of either a N-terminal pro-domain or a short pro-peptide and a catalytic domain that
can be proteolytically separated from the former.
The architecture of the catalytic domain is made by a large and a small subunit,
connected by a short linker. The individual subunits are particularly named by their
exact molecular weight (e.g. caspase-1-p10 for the small subunit of caspase-1).
Complete caspase activation is achieved by proteolytic removal of the N-terminal
pro-domain or short pro-peptide as well as the inter-subunit linker. In addition, two
catalytic domains dimerize and form a heterotetrameric structure also known as the
caspase-fold.
A total of 16 different mammalian caspases could be identified by comparative
genomics and evolutionary analysis (Eckhart et al. 2008). The individual family
members can be classified according to their function, their length and structure of
the N-terminal pro-domain, their optimal cleavage motives or their phylogenetic
analysis of the amino acid sequence. The existing human homologues are generally
grouped according to sequence identity and functionality.
8.3.1.1 Human Caspases
Homology based analysis of the human caspases divides the family into three
subgroups that can be assigned as well to their function (Fig. 8.1).
Caspase-1, -4, -5 and -12 are inflammatory caspases according to their roles in
cytokine activation. For instance, caspase-1 gets activated by the inflammasome
formation and triggers pyroptosis, an inflammatory death pathway (Rathinam
et al. 2012). The role of caspase-5, a close homologue to caspase-1, could be
assigned to cytokine maturation and inflammasome formation (reviewed by
Martinon and Tschopp 2004) whereas caspase-4 was recently shown to be involved
in inflammasome activation (Sollberger et al. 2012). A special case is the full-
length caspase-12, known for increased susceptibility to severe sepsis. It is
expressed only in a small population of African descent, while the human majority
expresses a truncated, pro-domain-only form due to a single nucleotide polymor-
phism (Saleh et al. 2004).
Caspase-2, -8, -9 and -10 are known as apoptotic-inducing peptidases, which are
activated in response to either extra- or intracellular apoptotic stimuli. The charac-
teristic N-terminal CARD or two death effector domains (DED) are a prerequisite
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for initiator caspase activation. These domains control the oligomerization at
activation platforms like the apoptosome and provoke autocatalytic activation by
induced-proximity (Salvesen and Dixit 1999). In this manner, a pro-apoptotic
signal can be translated into a proteolytic response.
Activated initiator caspases are responsible for the proteolytic maturation of the
executioner caspases-3, -6 and -7. Executioner caspases are lacking the structured
N-terminal domains and contain only a short N-terminal peptide sequence, which is
thought to be a regulatory signal (Meergans et al. 2000; Denault and Salvesen
2003). In cells, these enzymes exist as heterotetrameric pro-forms and are activated
by proteolysis of the N-terminal peptide and the inter-subunit linker. Once
Fig. 8.1 The caspase family. The human caspase family members are ordered by their function
into inflammatory and apoptotic initiator and executioner caspases. Caspase-14 is mainly
expressed in keratinocytes and assigned to cornification processes. A human majority expresses
a truncated form of caspase-12 due to a single nucleotide polymorphism, which leads to a stop
codon at position 125 (indicated by asterisk). Numbers indicate terminal residues of domains.
UniProtKB accession numbers and alternative names are listed for the human members. More
mammalian caspase family members have been identified in other species. Caspase-11 and
caspase-13 are orthologues of human caspase-4 and thus not listed
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activated, they provoke the majority of proteolytic events leading to the known
morphology of apoptotic cells.
Caspase-14 is a special member and mainly expressed in keratinocytes
(reviewed by Denecker et al. 2008). Its function is assigned to cornification
processes and mice experiments recently showed a relationship between caspase-
14-deficiency and UVB-induced photodamage (Hoste et al. 2013).
8.3.1.2 Caspases in Mammals
Besides the well-characterized human members, numerous other homologues have
been discovered in different mammalian species increasing the family members
from caspase-1 to caspase-18 (Eckhart et al. 2008). Notably, murine caspase-11 and
bovine caspase-13 are orthologues of human caspase-4 (Koenig et al. 2001; Eckhart
et al. 2008) and thus named inconsistently with respect to the nomenclature
guidelines of Alnemri et al. (1996).
A remarkable finding was published in 2011, when Kayagaki et al. (2011)
discovered that the generally used caspase-1 knockout mouse (strain 129) is
particularly a double knockout of caspase-1 and -11. A new caspase-1-only-defi-
cient mouse strain depicts a crucial role of caspase-11 in the non-canonical activa-
tion of inflammation. Translated to humans, this suggests a similar role for caspase-
4 and -5 and thus a specific function in incidents such as sepsis. The findings
suggest a careful interpretation of the role of caspase-1 versus -11, which so far only
has been determined experimentally using the mouse strain 129.
The evolutionary relationship of mammalian caspases has recently been studied.
This revealed that the caspase family has gone through extensive changes with
numerous gene deletions and duplications (Eckhart et al. 2008) (Fig. 8.1).
8.3.1.3 Non-mammalian Caspases and Metacaspases
Identification of the cell death related gene ced-3 in C. elegans was a landmark in
the discovery of caspases (Ellis and Horvitz 1986; Yuan et al. 1993). CED-3 gets
activated upon binding to the nematodic apoptosome formed by a CED-4 octamer
and then executes the apoptotic pathway in C. elegans. A crystal structure of the
formed complex between CED-3 and CED-4 revealed a funnel shaped octamer
formed by CED-4, on which CED-3 is supposed to become activated, although no
electron density could be observed for CED-3 in the structure (Qi et al. 2010).
Caspase homologues exist as well in insects. The initiator caspase Dronc is a
caspase-9 ortholog in Drosophila and involved in apoptosis and cell proliferation
(Steller 2008). Additional initiator (Dredd, Strica) and executioner (Drice, Dcp-1,
Decay, Damm) caspases have been discovered in Drosophila (reviewed by Kumar
and Doumanis 2000; Steller 2008). Recently, another Dredd homologue was
characterized from an insect vector of human disease: Aedis Dredd (AeDredd)
from the yellow fever mosquito Aedis aegypti (Cooper et al. 2007). This finding
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could be a first step to unravel the role of apoptosis in innate immune response of
insects and in the particular case of mosquitoes to understand their exceptional
vectorial capacity.
While caspases can be found in metazoan, distant homologues could be
identified as well in protozoa, fungi and plants. These distantly related cysteine-
dependent peptidases cleave after arginine or lysine and are called metacaspases
(Tsiatsiani et al. 2011).
8.3.2 The Caspase Fold
The tetrameric caspase structure can be described as a globular fold made by two
equivalent and symmetry-related catalytic domains with a α/β topology.
Each subdomain derives from a single polypeptide chain, encoding a N-terminal
pro-domain or -peptide, and a large (17–20 kDa) and a small subunit (10–12 kDa).
The N-terminal domains are separated from the caspase structure by an inter-domain
linker, which can be cleaved during activation processes. Due to this flexible linker,
the crystallization of a full-length caspase with its pro-domain was not successful
and thus their hypothetical interactions remain unclear. However, several
pro-domain homologues have been separately crystallized or investigated by NMR
spectroscopy. These dead domains revealed a globular fold of six antiparallel
α-helices with α1–α5 forming a conserved Greek key motive (Vaughn et al. 1999;
reviewed by Kersse et al. 2011).
A tightly packed caspase catalytic domain roughly forms a cuboid with the
approximate dimension of 25 A˚ ! 35 A˚ ! 42 A˚. It is composed of a β-sheet, which
is sandwiched between two layers of overall five α-helices. The twisted β-sheet
involves five parallel strands (β1–β5) and one antiparallel strand (β6). The latter
aligns with the β6 strand of the second catalytic domain in antiparallel manner. This
results in a continuous β-sheet with 12 strands and together with ten α-helices in a
twofold symmetry related structure (Fig. 8.2a).
8.3.3 The Active Site, Substrate Recognition and
Cleavage Mechanism
The numbering of a specific amino acid in different caspase family members can
diverge due to residue insertions or deletions. In general, a facilitated numbering based
on caspase-1 sequence is used as proposed by Fuentes-Prior and Salvesen (2004).
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Fig. 8.2 The caspase fold. (a) Cartoon representation of caspase-3 crystal structure (2DKO)
representing a dimer of two catalytic subunits (colored in green/orange and gray). Twelve central
β-strands are sandwiched between ten α-helices. Active site residues His-237 and Cys-285 are
colored in blue and located after strand β3 and β4, respectively. The five parallel β-strands of a
catalytic domain points towards the substrate-binding cleft. A 90! rotation reveals a square-like
arrangement of the α-helices. (b) Substrate-binding groove of caspase-3 (2DKO) covalently bound
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8.3.3.1 Active Site Architecture and Substrate Recognition
The active site and binding groove of the catalytic domain is constructed by loops
of its large and small subunits (Fig. 8.2b). The catalytic Cys-285 resides at the end
of the central β-strand 4 whereas His-237 is located at the end of β-strand 3
(Fig. 8.2c). In a cartoon representation, the five parallel β-strands point towards
the substrate-binding groove, with the tip of β-strand 3 and 4 indicating the position
of the active site residues.
A strictly conserved Arg-179 positioned in front of helix α1 in loop-1 is crucial
for the P1 specificity. It shapes the aspartate specific binding pocket S1 together with
the conserved residues Gln-283 and Arg-341. In addition, loop-3 residue Arg-341 is
involved in the formation of the binding subsite S3 mediating main-chain-main-
chain hydrogen bonds and interacting with the carboxylate group of a preferred
glutamate at P3 (Fuentes-Prior and Salvesen 2004).
The S2 and S4 pocket residues are less conserved. This leads to more substrate
variability at P2 and P4 that can be observed directly by comparing small, peptide-
based substrates (Roschitzki-Voser et al. 2012).
In inflammatory and initiator caspases, Val-338 of loop-3 shapes a large hydro-
phobic S2 pocket that tolerates bulky side chains like His or Thr as P2 residue. In
contrast, in executioner caspases Val-338 is substituted by Tyr leading to a prefer-
ence for small aliphatic substrate residues such as Val or Ala. A similar effect is
observed at the S4 subsite, where a bulky Trp-348 in apoptotic caspases shapes a
small S4 pocket with an increased affinity for branched aliphatic residues or
aspartate at position P4 (Fuentes-Prior and Salvesen 2004). A substitution in
caspase-1 (Trp-348 by Val) or caspase-4 and -5 (Trp-348 by Ile) reshapes the S4
subsite that favors large and hydrophobic residues.
A S5 pocket could only be characterized in caspase-2 with its preferential
accommodation of a small hydrophobic substrate residue (Fuentes-Prior and
Salvesen 2004). Furthermore, residues after the scissile bond do not require special
properties to be accommodated in the less restrictive primed subsite. An exception
is the S1
0 pocket that mildly discriminates for charged or bulky residues (Timmer
and Salvesen 2007).
In summary, a consensus caspase substrate sequence can be defined as (D or W)-
E-X-D # ϕ with P4-P3-P2-P1 # P10 where Asp at position P4 is preferred by caspases
of the apoptotic subfamily, X can be substituted by any amino acid and ϕ stands for
a small uncharged residue (Timmer and Salvesen 2007). Today, a large number of
caspase substrates are commercially available with a proposed high specificity for a
single caspase family member. When looking at the consensus substrate sequence,
⁄!
Fig. 8.2 (continued) to substrate-analogue inhibitor DEVD-chloromethylketone. Binding cleft
forming loops are colored in green (loop-1), orange (loop-2), blue (loop-3) and red (loop-4).
(c) Topology map of caspases colored according to crystal structure shown in (a). Active site
residues His-237 and Cys-285 are indicated. Loop-2 is also known as 240-loop. (d) Catalytic
mechanism according to Fuentes-Prior and Salvesen (2004)
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it is evident that such specificity is difficult to achieve and in fact could not be
observed experimentally (McStay et al. 2008). This effect is not only observed for
specific caspase substrates but also for peptide inhibitors, which are designed based
on the consensus sequence and thus are not feasible for a highly specific caspase
inhibition.
8.3.3.2 Catalytic Mechanism
Fuentes-Prior and Salvesen (2004) proposed a first catalytic mechanism in 2004.
The authors suggested a mechanism with close similarity to the proteolytic reaction
of serine peptidases (Fig. 8.2d). Their mechanism is based on crystal structures with
active site covalently bound inhibitors mimicking a tetrahedral intermediate.
In a hypothetical enzyme-substrate complex, the P1 carbonyl oxygen is oriented
by hydrogen bonds towards the oxyanion hole, which is formed by backbone amine
groups of the conserved residues Gly-238 and Cys-285. A nucleophilic attack of the
Cys-285 sulfur atom on the carbonyl carbon forms a tetrahedral intermediate with
covalently bound substrate. This state is stabilized by the imidaloze moiety of
His-237, which protonates the α-amino group of the P10 residue and thus triggers
the release of the C-terminal peptide product from the S1
0 subsite. The formed acyl
intermediate is subsequently hydrolytically processed. The deprotonated pi-nitrogen
of His-237 abstracts a proton from a water molecule, which itself attacks the
thioester carbonyl. This forms a second tetrahedral intermediate followed by a
cleavage of the covalent bond formed between the carbonyl carbon and the sulfur
of Cys-285. The non-covalently bound N-terminal peptide product is released and
the regenerated enzyme starts a new catalytic cycle.
8.3.4 Activation in Death Pathways
Caspases are expressed as zymogens that undergo proteolytic activation in a highly
regulated manner. Monomeric initiator and inflammatory caspases are activated at
macromolecular platforms formed by adapter proteins. According to the induced-
proximity model, the recruitment to these platforms results in a dimerization of two
catalytic subunits followed by activation and autocatalytic processing (Salvesen
and Dixit 1999). In contrast, the executioner caspases exist as intracellular dimers
of two catalytic subunits and are activated upon cleavage by inducer or as well
active executioner caspases without the requirement of additional adapter proteins.
8.3.4.1 Caspase-Dependent Intrinsic Apoptosis: The Apoptosome
Formation of the macromolecular complex known as the apoptosome is the pivotal
point of caspase activation in intrinsic apoptosis (Fig. 8.3a). MOMP-mediated release
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of cytochrome c from the mitochondrial IMS into the cytosol triggers the assembly of
Apaf-1 into a wheel-like heptamer (Yuan et al. 2010).
The adapter protein Apaf-1 consists of a N-terminal CARD, a nucleotide binding
and oligomerization domain (NOD) and a C-terminal regulatory region with two
domains (WD1 and WD2). Its fundamental role in apoptosome formation relies on
the Apaf-1 oligomerization with a molecular mechanism proposed based on the
crystal structure of a full-length murine Apaf-1 protein (Reubold et al. 2011).
Binding of cytochrome c to the regulatory region of monomeric Apaf-1 releases
the attached NOD, which rotates upon binding of ATP to expose its oligomerization
areas and thereby relocates the now accessible CARD. This conformational change
leads to the assembly into a circular structure of seven Apaf-1 subunits with central
NOD and propeller-like regulatory regions (Reubold et al. 2011). The N-terminal
CARDs form a recruitment disk on top of the protomer, accessible for the targeted
pro-caspase-9.
Recruitment of pro-caspase-9 to the apoptosome via homotypic interactions
between the Apaf-1 and the pro-caspase-9 CARDs results in dimerization of two
catalytic domains and activation of the enzyme by cleavage (Pop et al. 2006).
Notably, inter-subunit linker cleavage is not necessary for activity (Stennicke
et al. 1999) but may provide stability to the active dimer (Fuentes-Prior and
Salvesen 2004). Thus, the Apaf-1 based apoptosome can be defined as a cofactor
of caspase-9 (Pop et al. 2006). As a last step, limited proteolysis of downstream
executioner caspases by caspase-9 promotes the execution of apoptosis.
8.3.4.2 Extrinsic Apoptosis: Death Inducing Signaling Complex (DISC)
Numerous extracellular death stimuli provoke the intracellular formation of a
macromolecular recruitment platform for caspase-8 or -10, known as the death
inducing signaling complex (DISC) (Kischkel et al. 1995). Initially, a death ligand
binds to its receptor and induces oligomerization (Fig. 8.3b). A prominent and well-
studied example is the receptor Fas (also known as APO-1 or CD95), which binds to
Fas ligand and thereby forms a trimeric complex (Kischkel et al. 1995). TRAIL
receptors (death receptor 4 and 5) are other examples that form a homotrimer upon
binding to their ligand (Chaudhary et al. 1997; Pan et al. 1997; Walczak et al. 1997).
Both receptor types are members of the death receptor family with its superfamily
of TNF receptors and trigger the intracellular DISC formation.
Death receptor oligomerization results in a conformational change that exposes
the intracellular death domains (DD) of the receptor as structurally shown for Fas
(Scott et al. 2009). Then, homotypic interactions of the accessible DDs with the
DDs of the adaptor protein FADD build the recruitment platform for the apical
caspases.
FADD is a cytosolic protein with a N-terminal DED and a C-terminal DD
(Chinnaiyan et al. 1995). The crystal structure of the protein-complex between
DDs from Fas and FADD revealed a circular assembly of 5–7 Fas-DDs and
5 FADD-DDs, which optimally orients the FADD-DEDs for caspase recruitment
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(Wang et al. 2010). Additionally, both recent structural studies on DISC formation
described the observation of higher oligomeric clusters and denote at least two
trimeric Fas receptors as a prerequisite for signal transduction (Scott et al. 2009;
Wang et al. 2010).
The complete DISC is formed upon the recruitment of pro-caspase-8 or -10 via
homotypic interactions of their N-terminal DED to FADD-DEDs. This leads to an
increased local pro-caspase concentration, a dimerization of two catalytic domains
by induced proximity and enzymatic activity of the caspase dimer (Salvesen and
Dixit 1999; Pop et al. 2007).
Caspase-8 is autocatalytically processed in the inter-subunit linker to stabilize
the active dimeric conformation (Pop et al. 2007) and cleavage of the pro-domain
linker allows the release of the peptidase into the cytosole (Martin et al. 1998).
Structural investigations on the unprocessed catalytic domain of caspase-8 by
NMR spectroscopy visualized a highly flexible inter-subunit linker and an activa-
tion induced rearrangement of loop-1 and -3 in comparison to the X-ray structure of
an active dimer (Keller et al. 2009). Included mutational studies stressed the
combination of proteolytic cleavage and dimerization as a prerequisite for full
activity.
Further studies on caspase-8 using a reconstituted DISC revealed a substrate
specificity switch between pro- and active caspase-8 (Hughes et al. 2009). Initial
dimerization of pro-caspase-8 induces activity for a limited substrate range, includ-
ing autoproteolysis of pro-caspase-8 or cleavage of c-FLIP, a caspase-related
regulatory protein involved in death survival signaling (Scaffidi et al. 1999;
Micheau et al. 2002). Autocatalytic processing then forms the fully active enzyme
with the complete substrate repertoire, including the executioner caspases and Bid
that are responsible for the downstream signaling in apoptosis.
The activation mechanism for caspase-10 is similar to caspase-8 initiation
(Wachmann et al. 2010). Induced proximity results in the formation of an active
dimer and the further autocatalytic processing accelerates the cleavage of down-
stream proteins. However, the authors could show that Bid cleavage does not
require processed caspase-10 in contrast to tBid production by caspase-8. This
finding suggested a pro-apoptotic role of this enzyme in the uncleaved form and
further research will be needed to clarify this function.
8.3.4.3 Pyroptosis: The Inflammasome
The activation of inflammatory caspases remained elusive until 2002 with the
discovery of a molecular activation platform termed the inflammasome (Martinon
et al. 2002). This intracellular protein complex triggers the activation of caspase-1
and -5 and is formed by NLRP1 and an adapter protein ASC (Fig. 8.3c). Sub-
sequently, researchers identified more NLR family members that are involved in
inflammasome formation, like NLRP3 (Agostini et al. 2004), NLRC4 (Mariathasan
et al. 2004) and others (reviewed by Rathinam et al. 2012).
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NLR proteins act as the danger-sensing molecule in the inflammasome and
contain three important domains: A leucine-reach repeat (LRR) with an assumed
function of danger signal recognition similar to Toll like receptors (Martinon
et al. 2002), a nucleotide-binding and oligomerization domain NACHT and a
death mediating domain, which is either a PYD in NLRP1 and NLRP3 or a
CARD in NLRC4. Although the initiation of inflammasomes remains unclear,
Martinon and Tschopp (2005) proposed a possible mechanism: Binding of a
danger-associated ligand to LRR induces a conformational change that exposes
the NACHT domain and thereby triggers oligomerization and recruitment of
adapter proteins and inflammatory caspases.
The activation of pro-caspase-1 by NLRP1- or NLRP3-inflammasomes involves
the adapter protein ASC, which contains a N-terminal CARD and a C-terminal
PYD. The solution structure of full-length ASC visualized the two isolated domains
connected via a flexible linker in a back-to-back orientation (de Alba 2009). This
may prevent steric hindrance between the two domains and raises the capture radius
for pro-caspases and NRL molecules. In addition, NLRP1 contains a C-terminal
CARD that is able to directly recruit pro-caspase-1 although the presence of ASC
increases caspase-1 activation (Faustin et al. 2007). A similar observation has been
reported for the NLRC4 inflammasome, which can directly recruit pro-caspase-1
via its N-terminal CARD (Miao et al. 2010) but showed an ASC-dependent increase
of activation (Mariathasan et al. 2004; Miao et al. 2010).
Insights into the activation mechanism of inflammatory caspases have been
obtained with the crystal structure of pro-caspase-1 (Elliott et al. 2009). The
inter-subunit linker of one chain occupies the central cavity of the zymogen
dimer and locates its residue Asp-297 in close proximity to the active site of the
other chain. After a possible interdimeric cleavage at Asp-297, the peptide chain is
released and the central cavity can then harbor the other inter-subunit linker to
trigger a second interdimeric processing. Additional autoproteolysis at a second
cleavage site (Asp-316) then stabilizes the active dimer by conversion of an α-helix
from one chain into an intradimer β-sheet (Elliott et al. 2009). These findings
support the induced proximity model (Salvesen and Dixit 1999) for inflammatory
caspases and emphasizes the crucial role of macromolecular oligomerization
platforms for dimerization.
8.3.4.4 Caspase-2 Activation: The PIDDosome
The activation platform for caspase-2 was termed PIDDosome after the identifica-
tion of the involved proteins by Tinel and Tschopp (2004). This large protein
complex is formed by oligomerization of PIDD (p53-induced protein with a death
domain) and the adapter protein RAIDD (Fig. 8.3d).
PIDD consists of a N-terminal LRR domain, two central ZU-5 domains and a
C-terminal DD. Autoproteolysis between or after the two ZU-5 domains has been
observed as a switch for pro-survival or pro-death signaling (Tinel et al. 2007). The
adapter protein RAIDD, a N-terminal CARD and a C-terminal DD, is responsible
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Fig. 8.3 Caspase activation platforms. Inflammatory and apoptotic initator caspases are activated
at macromolecular complexes, which induces dimerization and autoproteolytic cleavage.
(a) Apoptosome formation: released cytochrome c from the mitochondrion binds to Apaf-1 and
induces a conformational change that reorients its NOD and CARD. Seven Apaf-1 molecules then
form a wheel-like heptamer, which have been analyzed by electron microscopy (3IZA). The
structure revealed a CARD-CARD interaction between the Apaf-1 and caspase-9 that form a disc
above the central hub. (b) Death inducing signaling complex: activation of caspase-8 or -10 occurs
at the DISC, which is initiated by trimerization of death receptors. Trimeric receptors recruit
pro-caspase-8 or -10 via adapter proteins (FADD, TRADD). The assembly of FAS/FADD DDs
have been structurally characterized (3OQ9) and showed a pentameric arrangement of 5–7 Fas DD
and 5 FADD DDs. First, this structure shows a ring-like arrangement of the DDs similar to the
Apaf-1 arrangement. Second, it indicates a requirement of more than one trimeric Fas receptor to
initiate the DISC formation. (c) Proposed mechanism of inflammasome formation: NLRP as well
as NLRC proteins exist in a conformation, where its NACHT domain is blocked. Pathogen and
danger associated molecular patterns can be recognized by the LRR, which triggers a conforma-
tional change leading to a freed NACHT domain and subsequent oligomerization. Adapter
proteins like ASC are then recruiting caspase-1 or -5 for activation. (d) PIDDosome formation:
sequential cleavage of PIDD releases its DD, which recruits pro-caspase-2 via the adapter protein
RAIDD. The crystal structure of PIDD-RAIDD DD assembly (2OF5) revealed a ring like structure
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for caspase-2 recruitment via CARD-CARD interactions. Besides its involvement
in the PIDDosome, RAIDD has been observed in specific binding of RIP1, a serine/
threonine protein kinase involved in death pathway (Duan and Dixit 1997).
The crystal structure of a complex of the DDs that are involved in PIDDosome
formation discovered a stoichiometry of seven RAIDD DDs and five PIDD DD
molecules (Park et al. 2007). Five RAIDD DDs are stacked in a ring-like structure
on top of an asymmetric, pentameric ring of PIDD DDs. Two additional RAIDD
DD molecules are located in a third level on top of the RAIDD DD ring-like
structure. In principal, this complete assembly is able to recruit seven
pro-caspase-2 molecules for activation although only three active enzymes can be
formed.
8.3.4.5 Activation of Executioner Caspases
Executioner caspases exist as stable dimers in solution in contrast to the zymogens
of the inflammatory and initiator related family members. Activation occurs upon
partial proteolysis by initiator or executioner caspases and results in a rearrange-
ment of the inter-subunit linker (Riedl et al. 2001a).
The pro-caspase-7 crystal structures revealed an asymmetric blocking of the
central cavity by the inter-subunit linker (Chai et al. 2001b; Riedl et al. 2001a).
Linker cleavage at Asp-297 promotes its release from the central cavity. It then
stabilizes the active conformation via bundle formation, which is promoted
between the new C-terminus of the large subunit of one catalytic domain and the
newly formed N-terminus of the small subunit of the other adjacent catalytic
domain. This bundle is further interacting with loop-4 and enables the formation
of the active site as shown in peptide-bound caspase-7 structures (Riedl et al. 2001a;
Fuentes-Prior and Salvesen 2004).
The important role of the central cavity in caspase activation is not only depicted
by the zymogen structures of caspase-1 and -7 (Chai et al. 2001b; Riedl et al. 2001a;
Elliott et al. 2009) but also by the identification of allosteric inhibitors of caspase-3
and -7 (Hardy et al. 2004). These inhibitors bind in the central cavity and trap the
protease in a zymogen-like conformation.
⁄!
Fig. 8.3 (continued) with five RAIDD DD (dark green) stacked on top of five PIDD DD (blue).
Two additional RAIDD DD (light green) are located on a third level. (a–d) The available complex
structures of these oligomeric activation platforms point out a stoichiometric asymmetry: in
principal, one of the pro-caspase monomers will not dimerize due to the odd-numbered adapter
proteins
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8.3.5 Caspase Substrates
The commercially available short peptide substrates have been derived from a
combinatorial approach by scanning of large peptide libraries (Thornberry
et al. 1997) unraveling the caspase substrate consensus. These small molecule
substrates are coupled to a fluorophore reporter and have generally been used for
caspase characterization in-vitro (Roschitzki-Voser et al. 2012).
Diverse methods to identify in-vivo cleavage sites have been developed in the
field of degradomics, like scanning of the transcriptome using bioinformatics (Boyd
et al. 2005) as well as cell-based degradation methods, recently reviewed by Agard
andWells (2009). A growing list of identified in-vivo caspase substrates is available
in the MEROPS database [http://merops.sanger.ac.uk/ (Rawlings et al. 2012)] with
almost 900 physiological relevant entries. Undoubtedly, some of these entries are
cleaved only in specific cell types or not explicitly in cell death pathways while
others are well known for being processed during apoptosis. Proteolysis of those
proteins typically leads to a loss-of-function or a gain-of-function. While the
executioner caspases are prominent examples for the latter, several other important
substrates have been described.
8.3.5.1 Rho-Associated Kinase I (ROCK I)
The family of Rho GTPases is known as an actin cytoskeleton regulator with the
Rho-associated kinases (ROCK) as their effectors (Hall 1998). These serine/threo-
nine kinase isoforms are activated upon interaction with GTP-bound Rho proteins.
During apoptosis, caspases cleave ROCK 1 at a DETD # G motive near the
C-terminus and thereby remove a putative autophosphorylation/auto-inhibitory
domain (Coleman et al. 2001). The result is an intrinsically more active kinase,
which promotes membrane blebbing in apoptotic cells by phosphorylation of
downstream targets. It was further shown that a truncated ROCK 1 is independent
of Rho GTPases and triggers membrane blebbing without activated caspases.
8.3.5.2 Caspase-Activated DNAse (CAD)
A morphological feature of apoptosis is the degradation of chromosomal DNA
observable as a characteristic DNA ladder. A crucial nuclease for this process has
been identified as the caspase-activated DNAse (CAD, also known as DNA frag-
mentation factor DFF40) (Nagata et al. 2003). In cells, this enzyme forms an
inactive dimeric complex with the inhibitor of CAD (ICAD, also known as DFF45).
The cleavage sites DETD # S and DAVD # T are located in two flexible inter-
domain linkers of CAD and get cleaved by caspase-3. This triggers the release from
ICAD and a formation of active CAD dimers. Notably, CAD is not only responsible
for apoptotic degradation of nucleosomal DNA, it also promotes cell differentiation
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induced by DNA strand breaks (Larsen et al. 2010). Thus, CAD is an excellent
example for the caspase-3 functional dualism in cell death execution and cell
proliferation.
8.3.5.3 Poly(ADP-Ribose) Polymerase (PARP)
First notices of cleavage of poly(ADP-ribose) polymerase (PARP) have been described
in chicken cells in 1994 (Lazebnik et al. 1994). PARP is involved in repair mechanisms
of single and double strand DNA breaks. It forms branched poly(ADP-ribose)
molecules, attaches them to acceptor proteins, including itself, leading to the recruit-
ment of repair proteins to the DNA breakage site (Javle and Curtin 2011).
The executioner caspase-3 and -7 cleave the 116 kDa PARP after a canonical
sequence DEVD # G into an 85 kDa fragment having no enzymatic activity. This
loss-of-function prevents the repair of DNA fragments induced by CAD. Remark-
ably, hyperactivation of PARP can lead to a low ATP level inside cells that is a
known trigger of regulated necrosis. In this prospect, the loss-of-function supports
not only the apoptotic pathway but also prevents the activation of necrotic cell death
and inflammatory responses.
Furthermore, PARP cleavage is a good example for exosite interactions between
a protease and its target protein. It could be shown that PARP, which has been
modified with long branched poly(ADP-ribose) molecules, is cleaved with higher
efficiency by caspase-7 than by caspase-3 (Germain et al. 1999) although the latter
cleaves short peptide substrates more efficiently. The enhanced affinity to caspase-7
was assigned to exosite interactions between the caspase-7-p20 and the branched
poly(ADP-ribose) molecule.
8.3.5.4 Human Telomerase Reverse Transcriptase (hTERT)
The human telomerase hTERT maintains the length of DNA telomeres by its
reverse transcriptase activity and ensures chromosomal stability. The reverse tran-
scriptase as the catalytic domain of the protein was recently identified as a unique
caspase-6 and -7 substrate that is cleaved during apoptosis (Soares et al. 2011). Four
cleavage sites have been identified with TVTD # A and VNMD # Y cleaved by
caspase-6 and TSLE # G and PKPD # G cleaved by caspase-7. These cleavage sites
are conserved in old world monkeys and apes although the function of the persistent
fragments during apoptosis remains unclear. hTERT is a recent example for a
non-canonical substrate recognition of caspases.
8.3.5.5 Pro-interleukins and Interleukins
The starting point of caspase research was the identification of the ICE, today
known as caspase-1 (Thornberry et al. 1992). Indeed, interleukin precursors and
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their active forms are caspase substrates that either provoke inflammatory responses
or prevent inflammation during apoptosis.
For example, bacterial infections of cells can lead to caspase-mediated
processing of pro-interleukin-1β (YVHD # A) and -18 (LESD # Y) with followed
secretion of these activated cytokines. Caspases-1 and -4 are able to process the
pro-forms (Thornberry et al. 1992; Kamens et al. 1995; Akita et al. 1997; Gu
et al. 1997) and have been reported to be involved in the inflammasome-mediated
response (Sahoo et al. 2011; Sollberger et al. 2012).
Remarkably, pro-interleukins are not only activated by inflammatory caspases
but also by apoptotic members as reported for pro-interleukin-16 activation (PKPD
# G) by caspase-3 (Zhang et al. 1998). Pro-interleukin-16 is expressed in more than
90 % of all T cells (Chupp et al. 1998), is located in the cytoplasm and the nucleus,
while a nuclear presence inhibits progression (Center et al. 2004). Thus, proteolytic
modification of such a cell cycle regulator by caspase-3 illustrates the important
role of these proteases in other molecular mechanisms.
In contrast to other cytokines, interleukin-33 is expressed in its active form and
is not secreted after inflammatory stimuli (Lu¨thi et al. 2009). It is more likely to be
released after membrane disruption during necrosis, while apoptotic cell death
leads to interleukin-33 deactivation mediated by caspase-3 and -7 after cleavage
at DGVD # G (Lu¨thi et al. 2009). In principal, the proteolysis of interleukin-33 by
apoptotic executioner caspases acts as an intracellular proinflammatory extin-
guisher in a tissue protective manner.
The enormous variety of caspase substrates illustrates the important roles of
these enzymes in cell death, proliferation and inflammatory pathways. Although,
a consensus sequence has been defined (Timmer and Salvesen 2007), natural
substrates can as well be cleaved at non-canonical sites as demonstrated in rare
cases (Krippner-Heidenreich et al. 2001; Soares et al. 2011).
8.3.6 Morphological Changes upon Activation
Activation of cellular death pathways results in major morphological changes that
can be observed under the light microscope. Biochemical techniques have been
used to characterize death pathways (Galluzzi et al. 2012). Particular morphological
features (reviewed by Ziegler and Groscurth 2004) are well characterized and
especially the apoptotic morphological hallmarks can be explained by caspase-
mediated activation of effector proteins.
Nuclear condensation and DNA fragmentation during apoptosis relies on execu-
tioner caspases. On one hand, the cleavage of nuclear lamins by caspase-3 and -6
induces a loss of structural integrity and a nuclear shrinkage, which promotes a
collapse into smaller nuclear particles in a late apoptotic state (Rao et al. 1996)
(Fig. 8.4). On the other hand, CAD is activated by caspase-3 and produces DNA
fragments of 180- to 200-bp length, visible by gel electrophoresis (Nagata
et al. 2003; Larsen et al. 2010). In addition, cleavage of the DNA repair enzyme
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PARP by caspase-3 and -7 (Germain et al. 1999) prevents the repair response thus
further provoking apoptosis.
ROCK 1 cleavage by executioner caspases leads to an intrinsically more active
kinase that phosphorylates downstream targets in the actin-myosin system
(Coleman et al. 2001). Actin-myosin related cell contractility initiates the formation
of membrane protrusions commonly known as membrane blebs (Fig. 8.4). Further
progression of cell shrinkage separates these blebs into apoptotic bodies, packed
with organelles and nuclear fragments, which are subsequently engulfed by
surrounding cells via phagocytosis (Ziegler and Groscurth 2004).
Other phosphorylation targets in the Rho-ROCK signaling pathway are
flippases, which maintain the membrane asymmetry of phosphatidylserine
(PS) that is located within the inner membrane leaflet of a normal cell (Krijnen
et al. 2010). In an early stage of apoptosis, PS is presented at the outer membrane as
Fig. 8.4 Morphology of apoptosis. Jurkat cells were growing in media containing etoposide
(100 μM, lower panels) or without etoposide (upper panels). Paraformaldehyde fixation was
performed after 6 h. Etoposide treated cells show condensed and fragmented nuclei while
untreated cells possess round shaped nuclei (left panels, DNA staining with Hoechst33342).
Transmission images show round shaped healthy cells, whereas etoposide treatment leads to
apoptotic cells displaying membrane blebbing (right panels)
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an “eat-me” signal for phagocytes (Grimsley and Ravichandran 2003). First studies
on oxidatively stressed erythrocytes indicated caspase-related PS externalization
(Mandal et al. 2002) while research on cardiomyocytes identified a Rho-ROCK
signaling to be crucial for PS exposure (Krijnen et al. 2010).
8.3.7 Regulation and Specific Inhibition
A tight regulation of caspase activation is essential to avoid accidental induction of
cellular demise. Thus, a complex network involving numerous proteins has been
evolved, which in particular cases guarantees the survival or decease of a cell
(Fig. 8.5). Most of those proteins belong to the Bcl-2 family or to the inhibitor of
apoptosis protein (IAP) family. In addition, released mitochondrial proteins upon
MOMP can interact with members of these two families and facilitate the progression
of apoptosis.
Members of the Bcl-2 family are known to have cell regulatory functions and
often possess either pro- or anti-apoptotic activity, depending on the environmental
conditions (reviewed by Hardwick et al. 2012). Bcl-2 proteins (e.g. Bcl-2, Bcl-B,
Bax, Bak,. . .) consist of 3–4 Bcl-2 homology (BH) domains enumerated from BH1
to BH4. Members of this family (e.g. Bim, Bid, Puma,. . .) contain only one BH3
domain, are thus called BH3-only proteins and known as promoters of apoptosis.
Certain family members contain an additional C-terminal transmembrane domain
(e.g. Bcl-2, Bax, Bim,. . .) that localizes them at membranes. Bcl-2 proteins exist in
the cytosol, at outer mitochondrial membranes and supposedly inside mitochondria,
however this submitochondrial localization remains controversial (Hardwick
et al. 2012).
The IAP family members are multi domain proteins that directly suppress
apoptosis by caspase inhibition (Deveraux et al. 1997) or indirectly via interaction
with pro-apoptotic signaling complexes (Fulda and Vucic 2012). In addition,
several members contain a C-terminal RING domain that functions as an E3
ubiquitin ligase with increasing significance in cell survival (Vaux and Silke
2005; Vucic et al. 2011).
Intracellular apoptotic stimuli can activate BH3-only proteins, which promotes
Bax and Bak oligomerization and pore formation at the outer mitochondrial mem-
brane (Kuwana et al. 2002). This leads to the release of cytochrome c and other
mitochondrial proteins that function in a pro-apoptotic manner. The second
mitochondria-derived activator of caspases (Smac, also termed DIABLO) is
known to bind and inhibit IAP (Verhagen et al. 2000) but can itself be antagonized
by IAPs (Vucic et al. 2005). Another released protein is HtrA2 (also known as
Omi), a serine protease that is involved in apoptosis and suppression of IAP
(Verhagen et al. 2002). In addition, caspase-8 can cleave the BH3-only protein
Bid, forming a truncated form tBid and thus integrates the extracellular apoptotic
stimulus by inducing MOMP.
Furthermore, phosphorylation of caspases and upstream adapter proteins has
been reported as regulatory mechanisms in cell death pathways (Kitazumi and
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Tsukahara 2011). For instance, caspase-9 can be phosphorylated at the catalytic
domain residue Ser-196 and in the CARD at Thr-125, which both prevents caspase-
9 activation (Cardone et al. 1998; Allan et al. 2003). Phosphorylation of caspase-
8 at Ser-364 and caspase-3 at Ser-150 has been reported as survival signals during
neutrophil apoptosis (Alvarado-Kristensson et al. 2004). Other phosphorylation
sites on caspase-8 have been discovered (Tyr-310, Tyr-397, Tyr-465) and revealed
a dynamic post-translational regulation of apoptosis in neutrophils (Jia et al. 2008).
These findings strongly emphasize the important control functions of kinases and
phosphatases in death pathways.
Fig. 8.5 Regulatory network. Activation of caspase-8 or -10 at the DISC can be repressed by
cFLIPs. Once activated, these caspases cleave downstream executioner caspases that trigger the
apoptotic pathway. In addition, caspase-8 or -10 can produce tBid that stimulates the intrinsic
caspase-dependent apoptotic pathway. This pathway is also triggered by intracellular death stimuli
like DNA damage and activates pro-apoptotic Bcl-2 proteins, known as the subfamily BH3-only
proteins. These proteins are regulated by anti-apoptotic Bcl-2 family members that provide a first
threshold for death stimuli. The BH3-only proteins Bax and Bak possess a pore forming activity to
induce MOMP. Released mitochondrial proteins then trigger the progression of the intrinsic
apoptotic pathway: cytochrome c binds to Apaf-1 and induces apoptosome formation and
caspase-9 activation. Released Smac/DIABLO is binding and inhibiting IAPs and HtrA2/Omi
not only antagonizes IAPs but also cleave cellular substrates. Additional important regulators of
apoptosis are the IAPs: they specifically inhibit caspases and are able to counteract with Smac/
DIABLO in anti-apoptotic manner
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8.3.7.1 X-Linked Inhibitor of Apoptosis Protein (XIAP)
A well-studied IAP family member is the X-linked IAP (XIAP) that is able to
directly inhibit caspases-3, -7 and -9 (Deveraux et al. 1997, 1998). It is
characterized by three baculoviral IAP repeat (BIR1–3) modules, an ubiquitin
associated (UBA) domain and a C-terminal RING domain. Structural investigations
on XIAP binding to caspase-3, -7 and -9 unraveled two different binding and
inhibition mechanisms, which are mainly related to binding of linker regions near
the BIR2 and BIR3 domains, respectively (Chai et al. 2001a; Riedl et al. 2001b;
Shiozaki et al. 2003). In addition, XIAP can simultaneously bind and inhibit both,
initiator caspase-9 and executioner caspase-3 (Bratton et al. 2002) at a tightly
packed “holo-apoptosome” that not only recruits pro-caspase-9 but also binds
active caspase-3 (Yuan et al. 2011).
Crystal structures of caspase-3 and -7 have been reported with a truncated XIAP
containing a short N-terminal linker peptide and the BIR2 domain (Fig. 8.6a).
Remarkably, both homologue caspases showed the same principle of inhibition:
The XIAP residues involved in binding interactions are located in the peptide
linker, which lies inside the substrate-binding cleft of the enzyme in opposite
direction when compared to the observed natural binding of substrate (Riedl
et al. 2001b). Furthermore, the S4 pocket is occupied by Asp-148 of XIAP whereas
upstream residues sterically block the access to the S1 and S10 subsites and thus
competitively inhibit the enzyme.
The complex of caspase-9 with the XIAP-BIR3 domain revealed a completely
different inhibition mechanism: The BIR3 domain binds at the caspase-9 dimer
interface of the catalytic domain and consequently traps caspase-9 in an inactive,
monomeric form thus preventing active site formation (Shiozaki et al. 2003)
(Fig. 8.6b). This interaction is further provoked by the N-terminal peptide of the
small subunit of caspase-9, which interacts with BIR3 at the so-called Smac pocket
(Shiozaki et al. 2003).
As other IAPs, XIAP can regulate the apoptotic pathway via its C-terminal
RING domain. Ubiquitination of caspase-3 mediates proteosomal degradation
(Suzuki et al. 2001) while RING domain truncations of XIAP lead to elevated
caspase-3 activity (Schile et al. 2008). In contrast, ubiquitination of AIF is
nondegradative but also attenuates its death-inducing activity (Lewis et al. 2011).
8.3.7.2 c-FLIP: A Structural Homologue of Caspase-8
The family of FLICE-inhibitory proteins (FLIPs) has been discovered in viral
genomes (termed vFLIPs) and supports viral infections by down regulation of
cellular death responses (Thome et al. 1997). In humans, numerous splice variants
of cellular FLIPs (c-FLIPs) have been reported whereas three isoforms are
expressed (Krueger et al. 2001; Golks et al. 2005; Safa 2012). The two known
short forms, c-FLIPS and c-FLIPR, consist of two DEDs that can be recruited to the
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DISC where they block binding of caspase-8 and thus prevent a death-receptor
mediated apoptosis (Krueger et al. 2001; Golks et al. 2005).
A longer isoform c-FLIPL is structurally similar to caspase-8 and comprises two
DED and a C-terminal caspase-like domain lacking enzymatic activity
(Yu et al. 2009). Its regulation of the extrinsic-apoptotic pathway is more adaptive
and concentration dependent compared to its short isoforms. On one hand, FLIPL is
recruited to the DISC where it can form heterodimers with catalytic domains of
caspase-8 at physiological conditions and thus mediates its activation (Chang
et al. 2002). In contrast, a high expression level of FLIPL induces partial autocatalytic
processing of caspase-8 (Krueger et al. 2001), which then remains at the DISC-
platform, cleaves local substrates like RIP1 and prevents apoptosis (Micheau
et al. 2002; Kavuri et al. 2011). Furthermore, c-FLIPL is also known as a limiting
factor of kinase-dependent necrosis (reviewedbyGreen et al. 2011;Oberst et al. 2011).
The highly variable signal transduction from death receptors to caspase-8 and
c-FLIPL strongly emphasizes the critical interplay of these proteins in regulation of
pro- or anti-apoptotic responses.
8.3.7.3 Non-natural Inhibition: Designed Ankyrin Repeat Proteins
(DARPins)
Gene knockouts or artificial inhibition of a specific protein are general methods used
in cell biology to target its distinct role in diverse cellular processes. These methods
have also been applied to unravel the known functions of the caspase family
members, which have been broadly studied in cells derived from gene knockout
mice. However, the production of a knockout mouse is a time-consuming process,
not always successful or occasionally inaccurate, as shown for the caspase-1 deficient
strain 129 that also harbors a deficient caspase-11 (Kayagaki et al. 2011).
A protein knock-out by specific inhibition is a second approach to study the role of
a specific protein in cellular processes. In the case of caspases this is rather difficult to
achieve due to the high structural homology of these enzymes. The commercially
available substrate-based inhibitors target the conserved active site and are thus not
very specific (McStay et al. 2008). In contrast, selected binding proteins like anti-
and nanobodies or designed ankyrin repeat proteins (DARPins) bind via an increased
protein-protein interaction surface that may enhance the specificity. Furthermore,
the binding may induce functional modification of the target protein, as shown in
several examples like a Fas receptor agonistic antibody (Chodorge et al. 2012) or an
ABC transporter modulating DARPin (Seeger et al. 2012).
Highly specific inhibition of caspase-2 and -3 has been achieved with two
different DARPins (Schweizer et al. 2007; Schroeder et al. 2013). These binding
proteins were designed based on the ankyrin protein scaffold and usually contain
two or three internal repeats that are sandwiched between a N- and C-terminal
capping repeat (Binz et al. 2004). Each internal repeat obtains six randomized
positions that are potentially involved in interactions, forming a diverse library
with at least 1010 different molecules that can be selected by phage- or ribosome
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display (Hanes and Plu¨ckthun 1997; Steiner et al. 2008). Selected DARPins com-
bine the advantages of high affinity and stability with high purity and expression
yields in a cysteine less framework.
Fig. 8.6 Specific inhibition. (a) XIAP inhibition of caspase-3 and -7. Crystal structures of XIAP-
BIR2 domain in complex with either caspase-3 (1I3O) or caspase-7 (1I51) revealed a competitive
inhibition mechanism by direct binding into the substrate-binding groove. The BIR2 domain was
crystallized in both complexes, although no electron density for the domain could be observed in
the complex with caspase-7. (b) The crystal structure of XIAP-BIR3 domain in complex with
caspase-9 (1NW9) unraveled a different inhibition mechanism: BIR3 interacts with residues in the
dimer interface and thus prevents a dimerization of caspase-9. (c) Complex structure of caspase-
2 with DARPin F8 (2P2C) showed a binding of the DARPin to loop-4. This binding stabilizes the
loop in a distinct conformation compared to substrate bound caspase-2 and thus inhibits the
enzyme allosteric. (d) DARPin D3.4 binds to caspase-3 (2XZD) at the substrate-binding cleft
and inhibits the enzyme in a linear competitive mechanism
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The caspase-2 specific DARPin (AR_F8) binds and inhibits the enzyme with a
tight binding mixed-type inhibition mechanism (Schweizer et al. 2007). AR_F8
binding to caspase-2 occurs primarily at the binding groove forming loop-4 and
stabilizes a distinct conformation of this loop compared to substrate analogue
bound caspase-2 (Fig. 8.6c). Additional structural rearrangements have been
observed N-terminal at the small subunit of the adjacent catalytic domain that finally
results in a displacement of the catalytic residue Cys-285. Altogether, the structural
and kinetic analysis of this DARPin clearly revealed an allosteric inhibition of
caspase-2 with high specificity.
Another selected DARPin (D3.4) has been reported to specifically target
caspase-3 (Schroeder et al. 2013). This binder inhibits the protease in a tight
binding and purely competitive mechanism (Fig. 8.6d). Structural data uncovered
a complex formation of D3.4 and caspase-3 at the active site cleft leading to
obstructed binding pockets. D3.4 positions its residue Asp-45 inside the S4 pocket
mimicking a natural peptide binding. Further interactions of the second internal
repeat lock the caspase-3 residue Tyr-204 in a closed state that occupies the subsite
S2 as seen in the XIAP caspase-3 complex structure (Riedl et al. 2001b). Although
the structural mechanism of inhibition displays similarities to XIAP, the active site
occupying peptide is not in a reversal orientation. Furthermore, this binder is a
decent example for active site directed inhibition that is combined with an enlarged
target-inhibitor interaction surface to achieve high specificity.
8.4 Caspase-Related Diseases
The important roles that caspases mediate in cell death and differentiation pathways
are highly regulated and often include redundant mechanisms. However, their
importance in cellular processes also increases the susceptibility for severe diseases
in case of misregulation. For instance, alteration of the apoptotic pathway is related
to cancer, neurological and cardiovascular disorders as well as autoimmune
diseases (reviewed by Favaloro et al. 2012).
Cancer development and progression is highly connected to overexpression of
regulatory Bcl-2 proteins, down-regulation of apoptosome formingApaf-1 andmodu-
lation of death receptor pathways by reduced or increased expression of death
receptors or death ligands, respectively (Favaloro et al. 2012). Direct mutations of
the caspase genes can lead to a reduction or loss of enzymatic activity, while other
studies reported dominant negative caspase variants that prevent activation of the wild
type form (reviewed by Olsson and Zhivotovsky 2011). This results in a decrease of
apoptotic capacity that may favor cancer manifestation. However, there is little
evidence for tumorigenesis induced by an individual caspase-mutant that indeed
emphasizes a redundant network with tumor suppressor functionalities (Olsson and
Zhivotovsky 2011).
Caspases have been reported as major conductors in the development of
Alzheimer’s disease (reviewed by Rohn 2010). Two of the major pathological
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markers in Alzheimer’s disease are the formation of neurofibrillary tangles (NFTs),
consisting of hyperphosphorylated microtubule-associated protein tau and the extra-
cellular deposition of amyloid-β (Aβ) in plaques. Aβ is created after sequential
proteolysis of the amyloid precursor protein (APP) by β- and γ-secretases. However,
caspase involvement of APP cleavage has also been observed (Zhang et al. 2011).
In addition, it has been proposed that the presence of Aβ stimulates caspase
activation that leads to tau cleavage, predominantly mediated by caspase-3 and -6,
and a following tau hyperphosphorylation (Rohn 2010). Moreover, this hypothesis
of Aβ-linked tau cleavage has been verified using a transgenic mouse model that
overexpresses the antiapoptotic protein Bcl-2 (Rohn et al. 2008). Thus, the role of
caspases in Alzheimer’s disease lays assumably not only terminal in the execution
of neuronal cell death but also proximal in the initiation of the disease mechanism.
Caspase involvement has also been shown in Huntington’s disease, a neuronal
disorder that is caused by mutation of the huntingtin (htt) protein (reviewed by
Ehrnhoefer et al. 2011). Disease related htt mutations lead to an abnormal elonga-
tion of a polyglutamine stretch in the N-terminal region, which is supposed to
prevent aggregation in wildtype proteins by turnover regulation (Ehrnhoefer
et al. 2011). Both, either wildtype or mutant proteins can be processed by proteases,
including the caspase family.
N-terminal cleavage fragments of the htt mutant have been reported to increase
the apoptotic susceptibility in dependence of fragment and polyglutamine extension
length (Hackam et al. 1998). Removal of the five predicted caspase cleavage site in
htt could reduce its toxicity and furthermore unraveled a specific caspase-6 cleavage
site that is crucial in the development of Huntington’s disease symptoms
(Graham et al. 2006). Active caspase-6 has been proposed as an early disease marker
due to its activation before the manifestation of the first motor abnormalities
(Graham et al. 2010).
Activation of caspase-6 and downstream cleavage of this enzyme has been shown
to be a fundamental step in the development of neurodegenerative diseases and
highlights its potential as a novel therapeutic target (reviewed by Graham et al. 2011).
Alterations in the inflammasome formation mechanisms can lead to hyper-
activation of caspase-1 and extensive production of IL-1β and IL-18, which can
be related to autoimmune diseases (reviewed by Lamkanfi et al. 2011). For
instance, enhanced expression of caspase-1 and IL-18 has been found in patients
suffering from multiple sclerosis (Huang et al. 2004).
8.5 Concluding Remarks
Death pathways are fundamentalmechanisms ofmulticellular organisms to ensure the
correct development, tissue maintenance and homeostasis. The diverse processes
are tightly regulated to prevent accidental cellular demise but also to facilitate a
fast removal of cells upon cell death activation. Its redundant system of overlapping,
distinctive pathways secures the multicellular integrity upon various cytotoxic stimuli
in an exceptional manner.
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The particular death pathways of apoptosis and pyroptosis are primarily driven
by caspases. These enzymes are classified according to their activity related to
inflammation and apoptosis. Active caspases cleave specific substrates, which
results in either activation of demise effectors or deactivation of survival proteins
that both accelerate cell destruction. Thus, a precise regulation is indispensable and
occurs at numerous steps. Although this highly specific and minimal error-prone
regulatory system has been evolved with redundancy, imbalances result in severe
diseases including cancer and neurodegenerative disorders.
In conclusion, modern research unraveled a broad contribution of caspases not
only in cell death mechanism but also in inflammatory responses and tissue
protection by anti-inflammatory activity during apoptosis. Thus, researchers
began to reconsider the general classification of inflammatory and apoptotic
caspases. Martin et al. (2012) recently suggested a new classification of positive
and negative regulators of inflammation: Besides the pro-inflammatory caspases-1,
-4 and -5, the nowadays known apoptotic caspases are categorized as anti-
inflammatory proteases. Overall, it further underlines the remarkable role of this
protease family in numerous distinctive cellular processes besides death pathways.
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1.2	  Designed	  Ankyrin	  Repeat	  Proteins	   	  
1.2.1	  Development	  and	  scaffold	  design	  In	   2003,	   Binz	   et	  al.	   reported	   a	   novel	   scaffold	   for	   potential	   binding	   proteins	   that	  were	  later	   named	   Designed	   Ankyrin	   Repeat	   Proteins	   (DARPins).1,3	   The	   intended	   design	   of	  those	   proteins	   was	   based	   on	   a	   repetitive	   module	   that	   has	   been	   observed	   in	   ankyrin	  proteins.	  Such	  ankyrin	  repeat	  motives	  consist	  of	  a	  β-­‐turn	  and	  two	  antiparallel	  α-­‐helices	  and	   their	   involvement	   has	   been	   observed	   in	   various	   protein-­‐protein	   interactions.4	  Sequence	  alignments	  of	  various	  ankyrin	  repeat	  proteins	  revealed	  a	  consensus	  sequence	  for	   the	   designed	   molecule:	   Invariant,	   conserved	   resides	   were	   defined	   as	   framework	  residues	   whereas	   non-­‐conserved	   residues	   were	   subjected	   to	   randomization.	  Randomized	  positions	  were	  chosen	  primarily	  in	  the	  β-­‐turn	  of	  the	  module	  (figure	  1a)	  to	  ensure	  the	  overall	  stability	  of	   the	  module.	   In	  addition,	  N-­‐	  and	  C-­‐terminal	  repeats	  were	  developed	   to	   increase	   the	   proteins’	   thermodynamic	   stability	   by	   covering	   the	  hydrophobic	   core	   of	   the	   repeat	  modules	  with	   a	   hydrophilic	   protein	   surface.	   Thus,	   the	  resulting	  DARPin	  scaffold	  consists	  in	  general	  of	  2	  -­‐	  3	  internal	  repeats	  flanked	  by	  a	  N-­‐	  and	  C-­‐terminal	  capping	  module	  usually	  referred	  to	  NI2C	  and	  NI3C	  DARPins	  (figure	  1b).	  	  	  Six	   randomized	  positions	  were	   intended	   to	   be	   any	   of	   the	   natural	   amino	   acids	   (except	  cysteine,	  glycine	  and	  proline)	  whereas	  one	  backbone	  residue	  (position	  z	   in	   figure	   1a)	  
Figure 1: Designed Ankyrin Repeat Proteins 
a) Consensus sequence of the capping and internal repeats. b) Internal repeat with randomized position shown 
as red sticks. c) Three internal repeats flanked by capping repeats form a NI3C DARPin (pdb: 1MJ0)  
d). Surface representation visualizes the DARPin binding interface. 
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was	  subjected	  to	  be	  asparagine,	  histidine	  or	  tyrosine.3	  Assembly	  into	  a	  library	  leads	  to	  a	  theoretical	  diversity	  of	  about	  5.2·1015	  and	  3.8·1023	  molecules	  in	  case	  of	  a	  NI2C	  and	  NI3C	  library,	   respectively.3	   However,	   the	   practical	   diversity	   is	   typically	   estimated	   to	   be	  between	  109	  and	  1012	  depending	  on	  the	  amount	  of	  DNA	  recovered	  in	  the	  last	  assembly	  step.	  	  The	  first	  structure	  determination	  of	  an	  unselected	  DARPin	  (E3_5)	   in	  combination	  with	  unfolding	  measurements	  unraveled	  a	  highly	  stable	  protein	  with	  a	  slight	  curvature	  and	  a	  protein	   surface	   that	   can	   be	   randomized	   to	   provoke	   interactions	  with	   a	   desired	   target	  protein	  (figure	  1c,d).5	  Furthermore,	  these	  proteins	  could	  be	  expressed	  in	  large	  amounts	  and	   purification	   with	   immobilized	   metal	   affinity	   chromatography	   (Ni2+-­‐NTA)	   yielded	  highly	   pure	   proteins.1,	   3	   Overall	   the	   first	   initial	   studies	   on	   this	   novel	   scaffold	   already	  emphasized	  the	  today	  well-­‐known	  benefits	  of	  the	  DARPins:	  A	  highly	  stable	  protein	  with	  binding	  properties	   to	   a	   selected	   target,	  which	   can	  be	   expressed	   in	   large	   amounts	   and	  easily	  be	  purified.	  	  	  Recently,	   a	   thorough	   analysis	   of	   DARPin-­‐protein	   interfaces	   solved	   by	   X-­‐ray	  crystallography	   resulted	   in	   a	   second	   generation	   DARPin	   library	   with	   reduced	  hydrophobicity	  (see	  also	  chapter	  5).6	  This	  newly	  generated	  library	  is	  based	  on	  the	  very	  same	  scaffold	  although	  it	  includes	  a	  different	  randomization	  strategy	  and	  a	  modified	  C-­‐terminal	  capping	  repeat.	  Since	  the	  initial	  design	  of	  this	  terminal	  repeat	  has	  been	  shown	  to	   be	   the	   least	   stable	  module,	   an	   improved	   version	   has	   been	   developed	   that	   is	  more	  tightly	  packed	  to	  the	  adjacent	  internal	  repeat.7,	  8	  
	  
1.2.2	  Selection	  and	  target	  prerequisites	  Assembled	  DARPin	  libraries	  can	  be	  applied	  for	  in-­‐vitro	  selection	  of	  specific	  binders	  using	  either	   phage-­‐9	   or	   ribosome	   display.10	   Both	   selection	   techniques	   require	   a	   highly	   pure	  target	  protein	  to	  prevent	  selection	  against	  impurities.	  In	  addition,	  the	  protein	  has	  to	  be	  stable	  over	  the	  time	  of	  selection	  to	  exclude	  the	  enrichment	  of	  DARPins	  that	  will	  interact	  with	  degradation	  products.	  Immobilization	  of	  the	  target	  protein	  is	  a	  crucial	  step	  for	  in-­‐
vitro	  selection	  and	  is	  generally	  performed	  using	  neutravidine	  coated	  beads	  or	  surfaces.11	  For	   that	   purpose,	   the	   target	   protein	   needs	   to	   be	   biotinylated,	   either	   chemically	   or	  enzymatically.	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Since	  the	  DARPin	  scaffold	  has	  been	  successfully	  applied	  many	  times	  in	  ribosome	  display	  selections,3,	   12-­‐20	   we	   have	   chosen	   to	   use	   this	   technique	   for	   the	   selection	   of	   caspase	  specific	   DARPins	   (see	   chapter	   2	  -­‐	  4).	   However,	   high	   affinity	   binders	   have	   also	   been	  reported	   using	   a	   modified	   variant	   of	   phage	   display	   that	   is	   designed	   for	   the	   signal	  recognition	  particle	  secretion	  system.21,	  22	  	  	  The	   fundamental	   principal	   of	   a	   selection	   round	   by	   ribosome	   display	   is	   depicted	   in	  
figure	  2:	  A	  DARPin	   library	   is	   transcribed	  into	  mRNA	  (a)	  and	  translated	  to	  the	  nascent	  protein	   (b).	   Due	   to	   a	   missing	   stop	   codon,	   the	   genetic	   information	   on	   the	   mRNA	   is	  coupled	   via	   the	   ribosome	   to	   the	   translated	   polypeptide	   chain	   (c).	   These	   ternary	  complexes	  are	  then	  applied	  to	  immobilized	  target	  proteins	  (d)	  and	  after	  a	  washing	  step	  
(e),	   specific	   binders	   will	   be	   retained	   (f).	   An	   elution	   step	   (g)	   followed	   by	   reverse	  transcription	   of	   the	   mRNA	  
(h)	   leads	   to	   an	   enriched	  DARPin	   library	   for	   a	  particular	   target	   protein	   (i).	  High	   affine	   DARPins	   can	   be	  obtained	  by	  performing	  these	  procedure	   3	   to	   4	   times.	  Furthermore,	   adding	   a	   pre-­‐panning	   step	   with	  homologous	   proteins	   can	  increase	   the	   specificity	   of	   a	  selected	  DARPin	  for	  a	  protein	  with	   closely	   related	   family	  members.	   This	   has	   been	  successfully	   applied	   in	   case	   of	  caspase-­‐specific	   DARPins	   (see	  also	  chapter	  2	  -­‐	  4).14,	  23	  
1.2.3	  Selected	  DARPins	  and	  their	  application	  The	   DARPin	   scaffold	   has	   been	   used	   several	   times	   to	   obtain	   high	   affine	   binders	   for	  proteins	   of	   interest.	   Besides	   their	   application	   as	   crystallization	   aids18,	   24,	   25,	   selected	  DARPins	   were	   utilized	   as	   modulators	   of	   active	   proteins	   such	   as	   drug	   transporters25,	  
Figure 2: Ribosome display selection procedure 
Schematic representation adapted from Ref 2. See main text for 
further explanations.  
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kinases26	   and	   proteases.14,	   23	   Furthermore,	   these	   binding	   proteins	   were	   successfully	  used	   as	   entry	   inhibitors	   of	   HIV16,	   27	   as	   well	   as	   for	   tumor	   diagnostics28	   and	   tumor	  targeting.17,	  29-­‐31	   Recently,	   DARPins	   have	   also	   been	   suggested	   as	   potential	   anti-­‐allergic	  drugs,	   since	   a	   DARPin	   demonstrated	   an	   accelerated	   disassembly	   of	   an	   IgE-­‐receptor	  complex.32	  The	   cysteine-­‐free	   framework	  of	   these	  binders	   is	   beneficial	   for	   intracellular	  applications	   rendering	   these	   binders	   to	   be	   attractive	  molecules	   for	   fluorescent-­‐based	  biosensors.33,	  34	  Besides	  that,	  the	  combination	  of	  high	  stability,	  high	  expression	  rates	  and	  simple	  purification	   emerges	  DARPins	   as	  potential	   candidates	   in	   clinical	   studies	  where	  first	  promising	  results	  have	  been	  achieved.35	  For	  further	  information	  about	  therapeutic	  strategies,	  the	  reader	  is	  referred	  to	  a	  recently	  published	  review.36	  	  
1.2.4	  Concluding	  remarks	  A	   decade	   ago,	   DARPins	   have	   been	   developed	   based	   on	   natural	   occurring	   ankyrin	  proteins	   using	   a	   consensus	   approach.	   The	   designed	   scaffold	   has	   been	   extensively	  studied	   leading	   to	   improved	   thermodynamic	   stability.	   Besides	   that,	   selections	   against	  numerous	  different	   target	  proteins	  have	  verified	   the	   intended	  scaffold	   in	  shaping	  high	  quality	   binding	   molecules.	   DARPins	   with	   high	   affinity	   and	   high	   specificity	   are	   now	  widely	   used	   to	   answer	   various	   scientific	   questions	   while	   a	   first	   clinical	   trial	   is	  approaching	  phase	  3	  thereby	  forecasting	  a	  promising	  future	  of	  those	  proteins.	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Specific targeting of human caspases using 
designed ankyrin repeat proteins
Abstract: Caspases play important roles in cell death, dif-
ferentiation, and proliferation. Due to their high homology, 
especially of the active site, specific targeting of a partic-
ular caspase using substrate analogues is very difficult. 
Although commercially available small molecules based 
on peptides are lacking high specificity due to overlapping 
cleavage motives between different caspases, they are often 
used as specific tools. We have selected designed ankyrin 
repeat proteins (DARPins) against human caspases 1–9 and 
identified high-affinity binders for the targeted caspases, 
except for caspase 4. Besides previously reported caspase-
specific DARPins, we generated novel DARPins (D1.73, 
D5.15, D6.11, D8.1, D8.4, and D9.2) and confirmed specificity 
for caspases 1, 5, 6, and 8 using a subset of caspase fam-
ily members. In addition, we solved the crystal structure of 
caspase 8 in complex with DARPin D8.4. This binder inter-
acts with non-conserved residues on the large subunit, 
thereby explaining its specificity. Structural analysis of this 
and other previously published crystal structures of cas-
pase/DARPin complexes depicts two general binding areas 
either involving active site forming loops or a surface area 
laterally at the large subunit of the enzyme. Both surface 
areas involve non-conserved surface residues of caspases.
Keywords: apoptosis; cell death; DARPins; specific 
caspase targeting; X-ray crystallography.
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Introduction
A well-ordered removal of aberrant cells is important in 
multicellular animals to ensure the organism’s cellular 
integrity. Thus, a variety of cell death pathways exist of 
which apoptosis is presumably one of the best-studied 
mechanisms, removing cells in an non-inflammatory 
manner thereby preventing a severe immune response in 
the organism (Taylor et al., 2008). Further, apoptosis plays 
a crucial role in embryonic development and tissue home-
ostasis. Although it is a highly controlled mechanism, its 
misregulation has been associated with severe diseases 
such as cancer or Alzheimer’s disease (Rohn, 2010; Faval-
oro et al., 2012).
Proteases of the caspase family have been identified 
to be the major contributors of apoptosis. Caspases either 
induce (caspases 2, 8, 9, and 10) or execute (caspases 3, 6, 
and 7) the apoptotic signaling (Grütter, 2000). Furthermore, 
caspases 1, 4, 5, and 12 have been related to inflammatory 
pathways. Because all caspases share a high sequence and 
structural homology, specific targeting of one particular 
family member is limited with the contemporary available 
tools. The small peptide substrates or inhibitors lack speci-
ficity due to targeting of the highly conserved active site 
(McStay et al., 2008). Another more promising approach is 
the development of small molecule compounds that bind 
and inhibit caspases 3 and 7 outside the active site pocket, 
although the identified binding site for these compounds 
is conserved between both caspases (Hardy et al., 2004).
To increase a compound’s specificity for a particu-
lar caspase, we used engineered binding proteins that 
provide larger binding interfaces and potentially also 
involve nonconserved residues. For our studies, we 
selected binders using a designed ankyrin repeat protein 
(DARPin) library. DARPins were designed based on repeat 
modules occurring in natural ankyrin proteins and consist 
of an N-terminal capping repeat (N-cap) followed by two 
( = NI2C) or three ( = NI3C) internal and a C-terminal repeat 
(C-cap) (Binz et  al., 2004). Each internal repeat of a 
DARPin harbors six randomized positions resulting in a 
theoretical diversity of 1023 different molecules in assem-
bled DARPin libraries (Binz et al., 2004). These libraries 
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are generally used for binder selections against various 
different targets using ribosome display, an in vitro selec-
tion technique (Hanes and Plückthun, 1997). In addition, 
DARPins have also been successfully selected using phage 
display (Steiner et al., 2008).
Numerous DARPin selections yielding high affinity 
binders for particular target proteins have been reported 
(Amstutz et  al., 2005; Sennhauser et  al., 2007; Stefan 
et al., 2011). In the past, we used DARPin libraries to select 
highly specific inhibitors for caspase 2 (Schweizer et al., 
2007) and caspase 3 (Schroeder et  al., 2013) as well as 
binders for pro- and active caspase 7 that prevent procas-
pase 7 activation (Flütsch et al., 2014).
Here, we describe the general procedure for the selec-
tion of DARPin binders in parallel against the panel of 
human caspase 1–9. The selection led to high-affinity 
binders with the exception of caspase 4. Besides the 
previously reported specific DARPins for caspase 2 (Sch-
weizer et al., 2007), caspase 3 (Schroeder et al., 2013), and 
caspase 7 (Flütsch et  al., 2014), we report novel binders 
for caspases 1, 5, 6, 8, and 9. The binder’s target speci-
ficity for caspases 1, 5, 6, and 8 was evaluated using a 
subset of caspase family members. In addition, we solved 
the first crystal structure of caspase 8 in complex with 
DARPin D8.4 and provide a comparison and analysis of 
the binding interface with the other three previously pub-
lished caspases 2, 3, and 7/DARPin complex interfaces.
Results
Caspase purification
Because the targeted protein’s purity and stability is 
crucial to prevent selection against impurities or degrada-
tion products, we have established purification protocols 
with high reproducibility for caspase 1–9 (Roschitzki-
Voser et al., 2012). The kinetic characterization in combi-
nation with analysis of the oligomeric state determined 
by size exclusion chromatography (SEC) and the purity by 
SDS page ensured that the targeted caspases were prop-
erly folded and active enzymes.
Selection and characterization of 
 caspase-targeted DARPins
DARPin selection was performed using ribosome display 
against caspases 1–9. We modified the selection protocol 
to achieve specificity and introduced pre-panning steps 
against the closest homologues of the targeted caspases 
in the first and third selection rounds (Supplementary 
Figure 1). Furthermore, additional washing has been per-
formed to obtain a slow off rate using an excess of non-
biotinylated targeted caspase after the panning step in the 
second and fourth rounds (Supplementary Figure 1). After 
four rounds of selection, the enriched caspase-targeted 
DARPin libraries have been used to analyze individual 
clones by crude extract ELISA. In general, binders that 
exhibited strong signal to the targeted caspases compared 
with the maltose-binding protein (MBP) control obtained a 
unique identifier (DX.Y), with X indicating the targeted cas-
pases and Y the sequence of discovery. Obtained DARPins 
were sequenced (Supplementary Figure 2), purified, and 
analyzed for complex formation with the targeted caspase 
in solution using SEC (Figure 1A and Supplementary 
Figure 3). Notably, binding of the DARPins can occur to the 
monomeric as well as to the dimeric form of the targeted 
caspase. In addition, SEC traces suggest that binding of 
D1.73 and D8.4 may alter the oligomeric state of the tar-
geted caspase. While first results using ultracentrifugation 
and D8.4 support these findings (data not shown), further 
experiments will be necessary to fully confirm an induced 
change of the oligomeric state upon DARPin binding.
Affinity of binders that displayed unambiguous 
sequencing results and a stable complex on SEC were 
analyzed using surface plasmon resonance (SPR) (e.g., 
caspase 8/D8.4 in Figure 1B). Following this approach, 
we were able to identify DARPins with affinities in the 
low nanomolar range to caspases 1–9 with the exception 
of caspase 4. Measured SPR data for these binders are 
summarized in Figure 1C, where we included the previ-
ously reported values of DARPins with high specificity for 
caspase 2 (Schweizer et  al., 2007), caspase 3 (Schroeder 
et al., 2013), and pro- and active caspase 7 (Flütsch et al., 
2014). Kinetic data have been obtained by fitting the meas-
ured data with the heterogeneous ligand model (Bravman 
et  al., 2006), with exception of D9.2, which exhibited 
a very low signal. Different values of Kd1 and Kd2 can be 
explained by altered accessibility of the two binding 
epitopes most probably originating from the direct coating 
of the caspase molecules via biotin on the sensor chip. 
However, we cannot fully exclude a cooperative binding 
mechanism in case of the caspase 3 binders that exhibit a 
large difference between these two values.
In case of D8.4, the Langmuir model was used to fit 
the data (Figure 1B) obtaining a Kd of 5.2 nm. With the 
exception of D1.73, D8.1, and D8.4, which exhibited high 
χ2 values while curve fitting, binding constants were 
determined by equilibrium analysis. DARPins that were 
selected against caspase 4 exhibited binding in the low 
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millimolar range, three orders of magnitude higher than 
the best binders we have found against the other cas-
pases. An explanation for that observation could be that 
caspase 4 is less stable under selection conditions. Protein 
sequence and biophysical properties of the DARPins listed 
in Figure 1C can be found in Supplementary Table 1.
Caspase specificity of the selected DARPins was deter-
mined using SPR analysis against a representative set of 
caspases (caspases 1, 4, 5, 6, 7, and 8) including members 
of all different pre-panning groups (see Supplementary 
Figure 1). Caspase 3 was excluded due to its lower sta-
bility when coated on the SPR chip, whereas caspases 2 
and 9 were represented by the panning group member 
caspase 8. Although not all caspases were tested in par-
ticular, the chosen array of different caspases is well suit-
able to elucidate the binder’s specificity. It confirms that 
pre-panning during selection leads to not only specificity 
within a panning group (e.g., caspases 1, 4, and 5) but 
also across panning groups with more distantly related 
caspases (e.g., caspases 1, 7, and 8).
With the exception of D9.2, we tested and con-
firmed the binders’ specificity for the targeted caspases. 
Caspase  8 binding specificity was tested using DARPin 
D8.1, which shares a very similar sequence with D8.4 
with only two point mutations (Q26R and V139A, see 
Supplementary Figure 5) suggesting the same binding 
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a1(M-1s-1) k d1(s-1) Kd1(M) k a2(M-1s-1) k d2(s-1) Kd2(M) Kd(M)
D1.73 Casp-1 1.03E+05 4.70E-04 4.54E-09 1.20E+06 1.88E-03 5.87E-09 –
AR_F8 Casp-2 – – 4.10E-09 – – – –
D3.4S76R Casp-3 1.74E+05 4.20E-03 2.42E-08 1.62E+06 7.45E-04 4.61E-10 6.00E-09
D3.8 Casp-3 1.77E+05 2.49E-03 1.41E-08 2.44E+06 1.11E-04 4.57E-11 3.40E-09
D5.15 Casp-5 1.05E+06 1.01E-02 1.00E-08 2.85E+05 5.97E-04 2.10E-09 1.10E-08
D6.11 Casp-6 6.05E+05 1.05E-02 2.13E-08 1.55E+05 9.66E-04 6.23E-09 3.37E-08
D7.18 Casp-7 1.73E+05 1.31E-02 7.60E-08 1.08E+04 2.11E-04 1.96E-08 1.44E-07
D7.43 Casp-7 4.44E+04 9.97E-04 2.30E-08 6.65E+05 1.77E-02 2.70E-08 2.47E-08
D8.1 Casp-8 6.00E+04 1.96E-03 3.27E-08 – – – –
D8.4 Casp-8 1.80E+05 9.31E-04 5.20E-09 – – – –
D9.2 Casp-9
(1)
(2)
(2)
(3)
(3)
– – – – – – 1.80E-08
Kinetic data
Figure 1 Binding characterization of selected DARPins.
(A) Selected DARPins were analyzed on SEC for the formation of a stable complex in solution (see also Supplementary Figure 3). Caspase 8 
exhibits a monomer-dimer equilibrium [marked with (m) and (d), respectively]. D8.4 binds to both the monomer and the dimeric forms 
of caspase 8 and elutes at earlier retention volume as a protein complex (solid lines, complex peak marked with (C) and (Dp) for DARPin 
excess). Calibration curve (right ordinate) was made using aldolase (158 kDa), conalbumin (75 kDa), ovalbumin (43 kDa), carbonic 
anhydrase (29 kDa), ribonuclease A (13.7 kDa), and aprotinin (6.5 kDa). Furthermore, (B) binding affinities were determined using SPR. 
(C) Binding affinities and kinetic constants of selected DARPins. Binders with two indicated kinetic constants were determined using the 
heterogeneous ligand model (Bravman et al., 2006). D8.1 and D8.4 kinetic data were determined using the Langmuir model. The equilib-
rium KD determination for D1.73, D8.1, and D8.4 resulted in high χ2 values and are therefore excluded. Previously reported DARPins are 
indicated with a gray background, and references are given with numbers: (1) Schweizer et al. (2007), (2) Schroeder et al. (2013), (3) Flütsch 
et al. (2014).
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interaction. Binding specificities for AR_F2, D3.4S76R, 
D3.8, D7.18, and D7.43 were reported previously (Schweizer 
et al., 2007; Schroeder et al., 2013; Flütsch et al., 2014).
Crystal structure of caspase 8 in complex 
with D8.4
To obtain a better understanding of the binding interac-
tions between a selected DARPin and the targeted caspase, 
we have crystallized caspase 8 in complex with DARPin 
D8.4 and determined the structure at 1.8 Å resolution. 
Structure determination details and refinement statistics 
are listed in Supplementary Table 2. Crystals grew under 
acidic conditions at pH 4.9, indicating that the protein inter-
action remains intact even at low pH. This was also tested 
in ELISA format (data not shown) and showed that binding 
still occurs at acidic pH values, although a lower signal 
compared with neutral pH suggests a weakened binding 
affinity. The asymmetric unit contains a caspase 8 dimer 
consisting of two small and two large subunits, two bound 
inhibitor molecules Ac-IETD-CHO, and two bound DARPins 
(Figure 2A). The binding epitope is localized on the side of 
the large subunit of the enzyme and primarily involves resi-
dues of α-helix α2 as well as β-strand β2 (Figure 2B).
In total, 25 caspase 8 residues are involved in 
binding to 31 residues of the DARPin spanning a binding 
interface of 938 Å2. Sixteen hydrogen bonds and 7 salt 
bridges surround a hydrophobic core, which is formed 
by amino acids Phe-56, Leu-86, Leu-89, Phe-90, and 
Phe-123 of the DARPin and Gln-291, Ile-295, and Ile-298 
of caspase 8 (Figure 2B). Remarkably, besides the 16 
non-randomized residues that are involved in binding, 
D8.4 possesses two unintended framework mutations 
(Arg-26 and Arg-85, see Supplementary Figure 5), which 
play a role in hydrogen bonding to caspase 8 (marked in 
Figure 2B, left).
As intended, the specificity of D8.4 for caspase 8 is 
achieved by targeting of non-conserved residues. Espe-
cially the hydrophobic interaction provided by Ile-298 
180 °
N-cap
Caspase-8
1st
2nd
3rd
C-cap
Ac-IETD-CHO
Ac-IETD-CHO
C-cap
A
B
C-cap
α2
β2
2nd repeat3rd repeat 1st repeat N-cap C-cap3rd repeat2nd repeat1st repeat
Arg-85
Arg-26
Phe-56 Phe-90 Phe-123
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Ile-295 Gln-291
Ile-298
Figure 2 Caspase 8 in complex with DARPin D8.4.
(A) Standard view of caspase 8 (small subunit in light gray, large subunit in dark gray, Ac-IETD-CHO inhibitor in orange) in complex with 
DARPin D8.4 (N- and C-cap in dark blue, internal repeats are light blue). The DARPin binds lateral at the large subunit of the enzyme. (B) 
Close-up view of the caspase 8/DARPin D8.4 binding interface displaying the major interactions between the DARPin and α-helix α2 of 
caspase 8 (left) and the interactions of D8.4 with β-strand β2 of caspase 8 (right). Important residues are labeled in blue (DARPin) and gray 
(caspase 8). See also Supplementary Figure 5 for a list of interacting residues.
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(Figure 2B, right) is not conserved among the apoptotic 
caspases, which harbor a larger and more hydrophilic 
residue at this position (Supplementary Figure 5). Besides 
that, only Thr-288 at the beginning of α-helix α1 was iden-
tified as highly conserved. Therefore, our crystal structure 
not only provides insights into the binding interface but 
also elucidates the specificity of the selected DARPin. In 
addition, it confirms our chosen selection procedure with 
the additional pre-panning steps against homologues cas-
pases. A structural alignment of our caspase 8/DARPin-8.4 
structure with the high-resolution structure of the same 
enzyme (1QTN; Watt et al., 1999) results in a very low root 
mean square deviation of about 0.7 Å, indicating no or 
only minor differences between the two structures. While 
they show no structural differences in the overall fold and 
the active site, several side chains in the caspase/DARPin 
interface adopt different conformations (e.g., Glu-290, Glu-
294, Ile-298) due to the presence of the DARPin D8.4.
DARPin binding interfaces on human 
caspases
With the previously described crystal structures of cas-
pases in complex with specific DARPins (Schweizer et al., 
2007; Schroeder et al., 2013; Flütsch et al., 2014), we were 
able to compare the different DARPin epitopes for each 
particular caspase (Figure 3).
Based on the caspase standard view, where the five 
main parallel β-strands (β1–β5) of a caspase protomer are 
aligned with their C-termini pointing upwards, caspase 
2-specific DARPin AR_F8 (Figure 3A; Schweizer et  al., 
2007) binds apical at the backside of loop 4 (also known 
as loop 381; Fuentes-Prior and Salvesen, 2004), which is 
involved in the formation of the active site cleft. Because 
this loop is not highly conserved among other caspases, 
it explains the high specificity of DARPin AR_F8 for 
caspase 2. The binding area of 799 Å2 includes a hydropho-
bic core, six hydrogen bonds, and nine salt bridges. AR_F8 
binding at the backside of loop 4 leads to a loop shift of 1 Å 
and opens the active site cleft (Schweizer et al., 2007). This 
finally results in a displacement of the active site cysteine 
(Cys-155) and structurally elucidates the allosteric mode of 
inhibition.
Although DARPin D3.4S76R binds in a similar way 
apical to caspase 3 (Figure 3B; Schroeder et  al., 2013) at 
the active site forming loops, the epitope is only partially 
overlapping with that of caspases 2 and AR_F8. D3.4S76R 
binds directly into the active site pocket of caspases 3 and 
only interacts with the tip of loop 4. Its high specificity is 
achieved by the formation of a salt bridge between Lys-56 
and the Asp-253 of caspase 3. Interestingly, the interact-
ing DARPin residue Asp-45 occupies the S4 pocket of the 
enzyme, as it can be observed in binding of peptide sub-
strates. In addition, Ile-78 of the DARPin keeps Tyr-204 of 
caspase 3 in a conformation that blocks the S2 binding 
pocket. Overall, the binding of D3.4S76R to caspase 3 pre-
vents substrate entrance to the active site pocket and mimics 
an interaction seen for caspase 3 with its natural inhibitor 
XIAP (Schroeder et al., 2013). Enzyme kinetic analysis has 
classified D3.4S76R as a purely competitive inhibitor.
Besides the apical binding sites of AR_F8 and 
D3.4S76R, another favored caspase/DARPin epitope could 
be identified laterally at the large subunit of the peptidase. 
In addition to the above-described DARPin D8.4 that binds 
sideways at the large subunit (p20) primarily to residues 
of α-helix α2 (Figure 3D), DARPins that have been selected 
against caspase 7 bind at a similar epitope (Flütsch et al., 
2014). For instance, the crystal structure of caspase 7 
in complex with DARPin D7.18 (Figure 3C) unraveled a 
binding interface of 672 Å2 that is predominantly formed by 
residues located on β-strand β2. In particular, two DARPin 
tryptophans (Trp-46 and Trp-78) are deeply buried in a 
hydrophobic pocket shaped by non-conserved residues of 
caspase 7. Because this hydrophobic pocket is obstructed 
in other homologues, these two tryptophans are the major 
contributors for the high specificity of DARPin D7.18. 
Although there is another caspase 7/DARPin complex 
structure available (pdb: 4JB8; Seeger et  al., 2013) with 
DARPin C7_16 binding laterally at the large subunit of cas-
pases 7, we excluded this protein complex in our structural 
analysis. This DARPin has been selected without addi-
tional pre-panning steps and thus may lack specificity.
More interestingly, D7.43 and D7.18 also bind to pro 
caspase 7, thus preventing a successful activation (Flütsch 
et al., 2014). D8.4 with a lateral but different binding epitope 
would suggest a potential effect on the activation mecha-
nism in analogy to the caspase 7 DARPins. However, the 
activation mechanism of caspase 8 is different compared 
with the caspase-mediated cleavage of procaspase  7. It 
occurs via autocatalytic processing after proximity-induced 
oligomerization (Salvesen and Dixit, 1999) and therefore is 
dependent on the oligomeric state of caspase 8. Complex 
formation on SEC (Figure 1A) and first ultracentrifugation 
experiments (data not shown) demonstrate that D8.4 can 
bind to the monomer as well as to the dimer of caspase 8 
in vitro. Whether binding in a cellular environment to the 
full procaspase 8 with its two N-terminal death effector 
domains occurs and modulates caspase 8 activation has 
not been further analyzed and remains unknown.
All the complex structures display binding of one 
selected DARPin to one caspase protomer; thus, every 
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Figure 3 Caspase-specific DARPins: complex structure overview.
Currently available caspase structures in complex with specific DARPins are shown in standard view and rotated (90° around the y-axes). 
Interacting residues on the caspase surface are colored according to the color of the binding DARPin. (A) AR_F8 binds caspase 2 from the 
backside of loop 4. (B) D3.4S76R blocks the active site cleft of caspase 3. (C) D7.18 binds at the large subunit (p20) of caspase 7. (D) A 
similar epitope can be observed for caspase 8-specific DARPin D8.4. (E) Superposition of all DARPins on caspase 8 visualizes the different 
epitopes. See also Supplementary Figure 6 for a sequence alignment of all caspases and the interacting caspase residues.
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caspase dimer has two DARPins bound. A superposition of 
all DARPins on caspase 8 shows the particular difference 
between the binding interfaces and emphasizes similari-
ties (Figure 3E). While the apical epitope of DARPin AR_F8 
is located at the backside of loop 4, D3.4S76R binds inside 
the active site cleft and completely blocks an entrance of 
substrate. The lateral binding at the large subunit is less 
distinct. DARPin D7.18 and D8.4 share a similar binding 
area on the caspase surface, but their position is slightly 
tilted by an angle of 30°. Notably, the N-terminus of 
all DARPins is oriented to the backside in the standard 
caspase representation resulting in a ‘dorsal to ventral’ 
DARPin orientation.
Comparison of these DARPin epitopes on the caspase 
surface suggests that binding in specific manner is more 
likely if it occurred at the outer rim of the enzyme rather 
than centrally located close to the dimer interface of two 
caspase protomers. However, we cannot exclude that this 
finding is experimentally influenced by the immobilization 
of the caspase molecule during the selection procedure. 
Random chemical biotinylation may orient the enzyme in 
a particular direction that binding to the outer rim is more 
likely. Besides that, it has been shown that the central cavity 
formed by two caspase protomers is conserved between 
caspases 3 and 7 (Hardy et  al., 2004), suggesting a less 
favored epitope for high caspase specificity in close prox-
imity to the cavity. In addition, exosite studies on caspase 7 
revealed that surface residues located at the large subunit 
influence the cleavage efficiency for particular substrates 
(Boucher et  al., 2012). For example, a caspase 7 mutant 
(K69L) exhibited reduced processing of the Hsp90 co-chap-
erone p23. More interestingly, Lys-69 is also involved in 
binding to DARPin D7.18, is not conserved in other caspases 
(see Supplementary Figure 6) and the caspase 8 homologue 
residue (Tyr-235) also contributes to DARPin D8.4 binding. 
Although very preliminary, this finding indicates that 
the non-conserved caspase residues involved in DARPin 
binding might also be of importance in providing specific 
binding interactions to certain caspase substrates.
Discussion
Using the here-described DARPin selection procedure 
including pre-panning steps against close homologues, we 
obtained new binders against five members of the human 
caspase family. We characterized these novel DARPins for 
caspases 1, 5, 6, 8, and 9 and included data of the previ-
ously reported specific binders for caspases 2, 3, and 
7 (Schweizer et  al., 2007; Schroeder et  al., 2013; Flütsch 
et al., 2014). Caspase specificity of the new DARPins D1.73, 
D5.15, D.6.11, and D8.1 was tested using a subset of caspase 
family members (caspases 1, 4, 5, 6, 7, and 8). Although 
our results suggest high target specificity, binding of the 
DARPins to caspases 2, 3, and 9 was not tested.
The crystal structure of caspase 8 in complex with 
DARPin D8.4 provides insights into the binding mode 
of this high affine binder. D8.4 binds lateral to the large 
p20 subunit of the enzyme and does not interfere with 
the active site of the enzyme. The binding interface of 
caspase  8 involves a hydrophobic patch consisting of 
several non-conserved caspase residues and thus explains 
its specificity. Although the previously reported DARPins 
for caspases 2, 3, and 7 are binders with inhibitory func-
tion (Schweizer et al., 2007; Schroeder et al., 2013; Flütsch 
et  al., 2014), the here newly reported DARPins do not 
prevent cleavage of small peptide substrates in vitro. If 
these binders can interact with the targeted procaspases 
and interfere with the activation process has not been 
tested and needs to be addressed in future experiments.
A structural comparison of all available caspase/
DARPin complexes reveals two distinct binding regions 
on the caspase surface. One is located apical close or at 
the active site. Here the DARPins interact with active site 
forming loops or with residues in the active site and thereby 
inhibit the enzyme either allosterically or competitively. 
The other favored region is found laterally at the large 
subunit of the peptidase and involves α-helix α1 and α2 as 
well as β-strand β2. With this study, we show that specific 
DARPins can be selected against a particular member of a 
highly homologous protein family sharing a high sequence 
identity. Thus, these DARPins provide a molecular toolbox 
for functional and structural investigations either in vitro or 
in cell-based assays using mammalian expression vectors.
Materials and methods
All reagents were bought from Sigma/Fluka if not stated otherwise. 
Sequencing was performed at Microsynth (Balgach, Switzerland).
Caspase purification and biotinylation
Caspase 1–9 have been purified as described previously (Roschitzki-
Voser et al., 2012). Ribosome display selection and ELISA experi-
ments were performed using chemically biotinylated caspases 
(EZ-Link Sulfo-NHS-LC-LC-Biotin, 21338; Pierce Biotechnology, 
Rockford, IL, USA). After purification, 1  ml of caspase (10 μm) in 
phosphate buffer saline (PBS), pH 7.3, or 50 mm HEPES, pH 7.5, 
containing 150 mm NaCl was incubated with a molar excess (7 × , 
70 μm) of biotin on ice for 30 min. The reaction was quenched by 
adding 5 m Tris pH 7.5 (10 μl). Biotinylated proteins were purified by 
SEC using a Superdex 200 10/300 GL (GE Healthcare, Piscataway, 
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NJ, USA) equilibrated in PBS at 4°C. Fractions containing bioti-
nylated caspases were pooled, frozen in liquid nitrogen after add-
ing sucrose (10%), and stored at -80°C in small aliquots.
DARPin selection by ribosome display
Cloning and amplification of a DARPin library has been described 
previously (Binz et  al., 2003) and a library containing NI3C and 
NI2C DARPins was used for selections by ribosome display (Hanes 
and Plückthun, 1997; Zahnd et  al., 2007). The selection procedure 
was slightly modified with focus on specificity and low koff rates 
(see Supplementary Figure 1). To prevent unspecific binding to ran-
dom proteins, each round included a pre-panning step for MBP 
(coated 22 nm). In addition, two of the most homologues caspases 
were included in pre-panning steps (coated 22 nm) in rounds 1 and 3. 
koff maturation was done by adding a 100- and 500-fold excess of unbioti-
nylated caspase for 5 or 10 min in rounds 2 and 4, respectively. Unbound 
DARPin/ribosome complexes were washed after each round with 
increasing stringency (Supplementary Figure 1). The enriched library 
was cloned after 4 selection rounds into a pQE30 vector and transfected 
to XL1-Blue Escherichia coli cells (Stratagene, La Jolla, CA, USA).
Crude extract ELISA
Single E. coli colonies, each expressing one selected DARPins, were 
picked and inoculated in 900 μl auto-inducing media (Studier, 2005) 
using 96-well plates (Abgene by Fisher Scientific, Wohlen, Switzer-
land). Cells grew over night at 37°C; 200 μl of each well were then 
transferred to a 96-well plate (Nunc by Thermo Fisher Scientific, 
Waltham, MA, USA) for plasmid preparation, and 700 μl were har-
vested by centrifugation. Cells were lysed using B-PER II (50 μl, 78260; 
Pierce Biotechnology, Rockford, IL, USA) per well (30 min, shaking at 
room temperature). Lysis buffer was neutralized with PBS (950 μl) 
and cell debris was removed by centrifugation (20 min, 4500 rpm at 
4°C). A 20-μl supernatant were transferred to 384 well ELISA plates 
(Nunc by Thermo Fisher Scientific, Waltham, MA, USA), which were 
prepared in advance with either immobilized MBP or targeted cas-
pase. For immobilization, plates were coated using NeutrAvidin solu-
tion (20 μl at 22 nm, 31000; Pierce Biotechnology, Rockford, IL, USA), 
followed by incubation of biotinylated proteins and extensive wash-
ing. Cell lysate supernatants containing the expressed DARPin were 
incubated for 1  h at room temperature. After three washing cycles 
(PBS), each well was incubated with mouse anti-RGS-H4 antibody 
(1:2000 in PBS+1% bovine serum albumin, 34650; Qiagen, Boston, 
MA, USA). After washing, the secondary antibody (goat α-mouse IgG 
alkaline phosphatase conjugate from Sigma; A3562) was incubated. 
After four washing cycles, the substrate (3 mm di-sodium 4-nitro-
phenyl phosphate in 50 mm NaHCO3, 50 mm MgCl2) was added and 
OD405 nm was measured using a multiwell plate reader (Tecan Infinity 
M1000, Tecan, Männedorf, Switzerland). DARPins exhibited strong 
signals ( > 5-fold vs. MBP control) were sequenced.
Expression and purification of DARPins
DARPins were expressed in auto-inducing media (Studier, 2005) 
overnight or in 2YT (3 h at 37°C) after the induction with isopropyl 
β-d-1-thiogalactopyranoside (0.5 mm, IPTG) at an OD600 nm between 0.6 
and 1. Cells were harvested (6000 rpm, 5 min, 4°C; Biofuge primo R, 
Heraeus, Hanau, Germany) and lysed by ultrasonification. DARPin 
purification was performed by immobilized metal-affinity chroma-
tography (gravity columns, 0.5  ml Ni2+-NTA agarose beads, 30210; 
Qiagen, Boston, MA, USA). DARPins were eluted in PBS, 200  mm 
imidazole, pH 7.4. Imidazole was removed using a PD-10 desalting 
column (17-0435-01; GE Healthcare, Piscataway, NJ, USA). For storage 
at 4°C, 0.05% sodium azide (NaN3) was added, whereas 20% glycerol 
was used for storage at -20°C.
Complex formation on SEC
Purified caspases were incubated with a 2-fold molar excess of 
selected DARPins. Protein solutions were applied on SEC using a 
Superdex 200 5/150 GL column (GE Healthcare, Piscataway, NJ, 
USA) equilibrated in 50 mm Tris, 150 mm NaCl, pH 7.5. Absorption at 
280  nm was recorded and analyzed in Prism (Version 5, GraphPad 
Software, La Jolla, CA, USA).
SPR analysis
SPR experiments were performed using a Proteon XPR36 (Bio-Rad Lab-
oratories, Hercules, CA, USA) and an NLC sensor chip. Sterile filtered 
PBS, pH 7.3, 0.005% Tween 20, was the standard buffer for all coating and 
kinetic measurements. Approximately 1000 RU of biotinylated caspases 
(5 nm) were coated on the chip at 30 μl/min. Dilution series of DARPin 
analytes were prepared prior to the experiment in 96-well plates and 
sealed to prevent evaporation or contamination. At least eight differ-
ent concentrations (0–500 nm) starting with the lowest concentration 
were measured at 20°C. Due to the heterogeneity of the system, the 
chip surface was not regenerated between different analyte concen-
tration but dissociation time could be prolonged up to 30 min. In 
general, experiments were performed at flow rates of 100 μl/min with 
5-min association phases and 20 min dissociation phases. Recorded 
data were processed and evaluated using ProteOn Manager 2.1.1 (Bio-
Rad Laboratories, Hercules, CA, USA). Binding kinetics and affinities 
were determined by equilibrium analysis or curve fitting (Bravman 
et al., 2006).
Crystallization of caspase 8 in complex with DARPin 
D8.4
Caspase 8 was incubated with a 2-fold molar excess of DARPin D8.4 
(10 min on ice). The formed complex was separated using a Superdex 
200 10/300 GL column (GE Healthcare, Piscataway, NJ, USA), 20 mm 
Tris, pH 7.5 (4°C), 20 mm NaCl. Fractions containing the dimeric cas-
pase 8/D8.4 complex were pooled and concentrated (15–21 mg/ml) 
using an Amicon Ultra centrifugation device (10 kDa MWCO, EMD Mil-
ipore, Darmstadt, Germany). Prior to crystallization, the protein solu-
tion was incubated with a peptide aldehyde inhibitor Ac-IETD-CHO 
(two inhibitors per active site). Crystals were grown at room tempera-
ture using sitting-drop vapor-diffusion method (100 mm citric acid, 
pH 4.9, 200 mm Li2SO4, and 22.4% PEG 4000). For cryoprotection, the 
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crystals were equilibrated in reservoir buffer containing ethylene gly-
col (10%–15%) and flash frozen in a nitrogen stream at -170°C.
X-ray diffraction, data collection, and structure  
determination
Diffraction data were collected at the Swiss Light Source (SLS, X06SA 
beamline) on a Pilatus 6M fast readout pixel detector. XDS (Kabsch, 
2010) was used for data processing. The crystal structure was solved 
by molecular replacement using PHASER (McCoy et  al., 2007) and 
the structure of caspase 8 (1QDU) (Blanchard et  al., 1999) and a 
NI3C-DARPin (2QYJ) (Merz et  al., 2008) as search model. Structure 
refinement was performed with REFMAC 5.5.01.09 (Murshudov et al., 
1997) and binding interface analysis was done using the EPPIC server 
(Duarte et al., 2012) (www.eppic-web.org). Structure figures were pre-
pared in PyMOL (http://www.pymol.org).
Accession numbers
Atomic coordinates and structure factors of caspase 8/D8.4 were 
deposited in the Protein Data Bank (2Y1L).
Competing financial interests
T.S. is partner at Nextech Invest Ltd. and R.A. is employed 
at Cilag AG. The other authors declare no competing 
financial interest.
Acknowledgments: Financial support of this work was 
provided by the Swiss National Science Foundation grant 
310030-122342 to M.G.G. We thank Beat Blattmann and 
Céline Stutz-Ducommun from the NCCR crystallization 
facility for crystal screening and the staff of the X06SA 
beamline at the Swiss Light Source of the Paul Scherrer 
Institute (PSI) for their support during data collection. Dr. 
Christopher Weinert is acknowledged for his calibration 
data of the size exclusion column.
References
Amstutz, P., Binz, H.K., Parizek, P., Stumpp, M.T., Kohl, A., Grütter, 
M.G., Forrer, P., and Plückthun, A. (2005). Intracellular kinase 
inhibitors selected from combinatorial libraries of designed 
ankyrin repeat proteins. J. Biol. Chem. 280, 24715–24722.
Binz, H.K., Stumpp, M.T., Forrer, P., Amstutz, P., and Plückthun, A. 
(2003). Designing repeat proteins: well-expressed, soluble 
and stable proteins from combinatorial libraries of consensus 
ankyrin repeat proteins. J. Mol. Biol. 332, 489–503.
Binz, H.K., Amstutz, P., Kohl, A., Stumpp, M.T., Briand, C., Forrer, P., 
Grütter, M.G., and Plückthun, A. (2004). High-affinity binders 
selected from designed ankyrin repeat protein libraries. Nat. 
Biotechnol. 22, 575–582.
Blanchard, H., Kodandapani, L., Mittl, P.R., Marco, S.D., Krebs, J.F., 
Wu, J.C., Tomaselli, K.J., and Grütter, M.G. (1999). The three-
dimensional structure of caspase-8: an initiator enzyme in 
apoptosis. Structure 7, 1125–1133.
Boucher, D., Blais, V., and Denault, J.B. (2012). Caspase-7 uses an 
exosite to promote poly(ADP ribose) polymerase 1 proteolysis. 
Proc. Natl. Acad. Sci. USA 109, 5669–5674.
Bravman, T., Bronner, V., Lavie, K., Notcovich, A., Papalia, G.A., and 
Myszka, D.G. (2006). Exploring “one-shot” kinetics and small 
molecule analysis using the ProteOn XPR36 array biosensor. 
Anal. Biochem. 358, 281–288.
Duarte, J.M., Srebniak, A., Schärer, M.A., and Capitani, G. (2012). 
Protein interface classification by evolutionary analysis. BMC 
Bioinform. 13, 334.
Favaloro, B., Allocati, N., Graziano, V., Di Ilio, C., and De Laurenzi, V. 
(2012). Role of apoptosis in disease. Aging 4, 330–349.
Flütsch, A., Ackermann, R., Schroeder, T., Lukarska, M., Hausam-
mann, G.J., Weinert, C., Briand, C., and Grütter, M.G. (2014). 
Combined inhibition of caspase 3 and caspase 7 by two highly 
selective DARPins slows down cellular demise. Biochem. J. 461, 
279–290.
Fuentes-Prior, P. and Salvesen, G.S. (2004). The protein structures 
that shape caspase activity, specificity, activation and inhibi-
tion. Biochem. J. 384, 201–232.
Grütter, M.G. (2000). Caspases: key players in programmed cell 
death. Curr. Opin. Struct. Biol. 10, 649–655.
Hanes, J. and Plückthun, A. (1997). In vitro selection and evolution 
of functional proteins by using ribosome display. Proc. Natl. 
Acad. Sci. USA 94, 4937–4942.
Hardy, J.A., Lam, J., Nguyen, J.T., O’Brien, T., and Wells, J.A. (2004). 
Discovery of an allosteric site in the caspases. Proc. Natl. Acad. 
Sci. USA 101, 12461–12466.
Kabsch, W. (2010). Integration, scaling, space-group assignment 
and post-refinement. Acta Crystallogr. D Biol. Crystallogr. 66, 
133–144.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., 
Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic 
software. J. Appl. Crystallogr. 40, 658–674.
McStay, G.P., Salvesen, G.S., and Green, D.R. (2008). Overlapping 
cleavage motif selectivity of caspases: implications for analy-
sis of apoptotic pathways. Cell Death Differ. 15, 322–331.
Merz, T., Wetzel, S.K., Firbank, S., Plückthun, A., Grütter, M.G., and 
Mittl, P.R. (2008). Stabilizing ionic interactions in a full-consen-
sus ankyrin repeat protein. J. Mol. Biol. 376, 232–240.
Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement 
of macromolecular structures by the maximum-likelihood 
method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255.
Rohn, T.T. (2010). The role of caspases in Alzheimer’s disease; 
potential novel therapeutic opportunities. Apoptosis 15, 
1403–1409.
Roschitzki-Voser, H., Schroeder, T., Lenherr, E.D., Frölich, F., 
Schweizer, A., Donepudi, M., Ganesan, R., Mittl, P.R., Baici, A., 
and Grütter, M.G. (2012). Human caspases in vitro: expression, 
purification and kinetic characterization. Protein Expr. Purif. 
84, 236–246.
Salvesen, G.S. and Dixit, V.M. (1999). Caspase activation: the 
induced-proximity model. Proc. Natl. Acad. Sci. USA 96, 
10964–10967.
Brought to you by | University of California
Authenticated | 10.248.254.158
Download Date | 9/5/14 5:56 PM
A. Flütsch et al.: Caspase-specific DARPins
56 Biol. Chem. 2014; 395(10): 1243-1252
1252      A. Flütsch et al.: Caspase-specific DARPins
Schroeder, T., Barandun, J., Flütsch, A., Briand, C., Mittl, P.R., and 
Grütter, M.G. (2013). Specific inhibition of caspase-3 by a 
competitive DARPin: molecular mimicry between native and 
designed inhibitors. Structure 21, 277–289.
Schweizer, A., Roschitzki-Voser, H., Amstutz, P., Briand, C., Gulotti-
Georgieva, M., Prenosil, E., Binz, H.K., Capitani, G., Baici, 
A., Plückthun, A., et al. (2007). Inhibition of caspase-2 by a 
designed ankyrin repeat protein: specificity, structure, and 
inhibition mechanism. Structure 15, 625–636.
Seeger, M.A., Zbinden, R., Flütsch, A., Gutte, P.G., Engeler, S., 
Roschitzki-Voser, H., and Grütter, M.G. (2013). Design, con-
struction, and characterization of a second-generation DARPin 
library with reduced hydrophobicity. Protein Sci. 22, 1239–1257.
Sennhauser, G., Amstutz, P., Briand, C., Storchenegger, O., and 
Grütter, M.G. (2007). Drug export pathway of multidrug 
exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 5, e7.
Stefan, N., Martin-Killias, P., Wyss-Stoeckle, S., Honegger, A., 
Zangemeister-Wittke, U., and Plückthun, A. (2011). DARPins 
recognizing the tumor-associated antigen EpCAM selected by 
phage and ribosome display and engineered for multivalency. 
J. Mol. Biol. 413, 826–843.
Steiner, D., Forrer, P., and Plückthun, A. (2008). Efficient selection 
of DARPins with sub-nanomolar affinities using SRP phage 
display. J. Mol. Biol. 382, 1211–1227.
Studier, F.W. (2005). Protein production by auto-induction in  
high density shaking cultures. Protein Expr. Purif. 41,  
207–234.
Taylor, R.C., Cullen, S.P., and Martin, S.J. (2008). Apoptosis: con-
trolled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 
9, 231–241.
Watt, W., Koeplinger, K.A., Mildner, A.M., Heinrikson, R.L., Tomas-
selli, A.G., and Watenpaugh, K.D. (1999). The atomic-resolution 
structure of human caspase-8, a key activator of apoptosis. 
Structure 7, 1135–1143.
Zahnd, C., Amstutz, P., and Plückthun, A. (2007). Ribosome display: 
selecting and evolving proteins in vitro that specifically bind to 
a target. Nat. Methods 4, 269–279.
Supplemental Material: The online version of this article (DOI: 
10.1515/hsz-2014-0173) offers supplementary material, available to 
authorized users.
Brought to you by | University of California
Authenticated | 10.248.254.158
Download Date | 9/5/14 5:56 PM
Publication: Caspase-Specific DARPins
DOI: 10.1515/hsz-2014-0173, c©2014 De Gruyter 57
	   1	  
Supplementary material for 
 
Specific targeting of human caspases  
using designed ankyrin repeat proteins 
 
Andreas Flütsch1,2,#, Thilo Schroeder1,3,#, Jonas Barandun1,4,#, Rafael Ackermann1, Martin 
Bühlmann1, Markus G. Grütter1,* 
 
 
1Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, 
Switzerland 
 
2present address:  University of California, San Diego,  
9500 Gilman Drive, La Jolla, CA 92093-0629, USA 
3present address:  Nextech Invest Ltd., Scheuchzerstrasse 35, 8006 Zurich, Switzerland 
4present address:  The Rockefeller University, Laboratory of Protein and Nucleic Acid 
Chemistry, 1230 York Avenue, New York, NY 10065, USA 
 
#These authors contributed equally to this work  
 
 
MGG: Tel. +41-44-6355580, Fax. +41-44-6356834, E-mail. gruetter@bioc.uzh.ch 
 
 
 
  
A. Flütsch et al.: Caspase-specific DARPins
58 Biol. Chem. 2014; 395(10): 1243-1252
	   2	  
Supplementary Figure 1 
 
 
 
 
Supplementary Figure 1: Ribosome display selection strategy 
To increase the binders specificity for a single caspase family member, additional pre-panning 
steps in round no°1 and no°3 with the closest homologues of the targeted caspase was 
introduced. In addition, round n°2 and n°4 was extended with koff maturation steps with a final 
washing step containing an excess of targeted caspase. 
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Supplementary Figure 2 
 
 
Supplementary Figure 2: Caspase-targeted DARPin sequences 
The DARPin consensus sequence is shown on top in black with randomized residues in red (X = All 
amino acids except Cys, Gly and Pro; Z = N, H or Y). Unintended framework mutations are depicted 
in green. Interacting residues were determined by the EPPIC server (1) (http://www.eppicweb.org) and 
are marked bold and underlined. 
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Supplementary Table 1 
 
 
 
 
Supplementary Table 1: Biophysical parameters of selected DARPins 
Molecular weight, extinction coefficient and theoretical isoelectric point were calculated using the 
ProtParam Tool provided on expasy.ch (http://web.expasy.org/protparam/). Eight of eleven binders are 
N3C DARPins and five DARPins have reported inhibitory effects on the targeted caspase (2-4). All 
other selected DARPins did not show an inhibitory effect using peptide substrates. However, 
procaspase binding and interference with caspase activation as reported for caspase-7 DARPins (4) 
was not tested and thus can not be excluded. 
 
  
DARPin Target Type No# of AA 
Molecular 
weight 
Extinction 
coefficient 
Theoretical 
isoelectric 
point 
Comments Ref. 
D1.73 Casp-1 N3C 169 18358 9970 5.34 No inhibition of small substrates  
AR_F8 Casp-2 N3C 169 18417 18450 5.28 Allosteric inhibitor (2) 
D3.4S76R Casp-3 N2C 136 14786 6690 5.56 Competitive Inhibitor (3) 
D3.8 Casp-3 N3C 168 17964 8480 5.51 Competitive Inhibitor (3) 
D5.15 Casp-5 N3C 169 18324 19480 4.99 No inhibition of small substrates  
D6.11 Casp-6 N3C 169 18300 9970 5.46 No inhibition of small substrates  
D7.18 Casp-7 N3C 169 18273 15470 4.74 Zymogen activation inhibitor (4) 
D7.43 Casp-7 N2C 136 14812 6990 5.68 Zymogen activation inhibitor (4) 
D8.1 Casp-8 N3C 169 18157 5500 5.28 No inhibition of small substrates  
D8.4 Casp-8 N3C 169 18190 5500 5.30 No inhibition of small substrates  
D9.2 Casp-9 N3C 169 18112 12490 5.01 No inhibition of small substrates  
Publication: Caspase-Specific DARPins
DOI: 10.1515/hsz-2014-0173, c©2014 De Gruyter 61
	   5	  
Supplementary Figure 3 
 
  
A. Flütsch et al.: Caspase-specific DARPins
62 Biol. Chem. 2014; 395(10): 1243-1252
	   6	  
Supplementary Figure 3: Caspase-DARPin complex formation in solution 
The reported DARPins form stable protein complexes with the targeted caspase in solution and 
can be separated on size exclusion chromatography. Without a present DARPin, Caspases-1, -5 
and -9 run as monomers (dotted line, peak marked with dotted arrow and (m) for monomer), 
whereas caspases-2, -3, -6 and -7 run as dimers (peak marked with dotted arrow and (d) for 
dimer). Caspase-8 shows a monomer-dimer equilibrium (marked with (m) and (d) respectively). 
In presence of a selected DARPin, all caspases elute at earlier retention volumes (solid lines, 
complex peak marked with (C), for complex and (Dp) for DARPin excess). Caspase-5 and -6 
were used directly after NiNTA purification (5) displaying an elution peak at 2.6 ml originating 
from imidazole. Calibration curve (right ordinate) was made using aldolase (158 kDa), 
conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), ribonuclease A 
(13.7 kDa) and aprotinin (6.5 kDa).   
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Supplementary Table 2: Data collection and refinement statistics 
  
Data	  collection	   	  Space	  group	   P212121	  Cell	  dimensions	   	  
a,	  b,	  c	  (Å)	   61.0,	  81.60,	  163.20	  α,	  β,	  γ	  (°)	   90.0,	  90.0,	  90.0	  Resolution	  (Å)	   48.86	  –	  1.8	  Wavelength	  (Å)	   1.0	  Rsym	  (%)	   9.8	  (51.5)	  Completeness	  (%)	   99.4	  (98.9)	  I/σ(I)	   13.29	  (3.76)	  
Refinement	   	  Resolution	  [Å]	   1.8	  
Rwork/Rfree	   18.0	  /	  21.8	  No.	  atoms	   	  Protein	   6246	  Water	   685	  Ligands	   3	  ⋅ SO42-­‐,	  5	  ⋅	  C2H6O2	  
B-­‐factors	   	  Protein	   22.9	  Water	   33.9	  rmsd	   	  Bond	  length	  [Å]	   0.009	  Bond	  angle	  [°]	   1.2	  Ramachandran	   	  Preferred	  [%]	   97.0	  Allowed	  [%]	   3.0	  Outliers	  [%]	   0	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Supplementary Figure 4 
a) 
 
 
b) 
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c) 
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Supplementary Figure 4 
d) 
 
 
Supplementary Figure 4: Caspase specificity of selected DARPins  
Caspase specificity of (a) D1.73, (b) D5.15, (c) D6.11 and (d) D8.1 was measured by surface plasmon 
resonance on a Proteon XPR36 (Bio-Rad Laboratories, Inc) machine using a NLC sensor chip. Six 
ligand channels were coated with biotinylated caspases-1, -4, -5, -6, -7 and -8 and binding of the 
DARPins was simultaneously observed at six different concentrations (0 nM to 128 nM). Caspase 
specificity of AR_F8 for caspase-2, D3.4S76R for caspase-3 and D7.18 as well as D7.43 for caspase-7 
is reported elsewhere (2-4). D9.2 was not tested against other caspase family members. 
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Supplementary Figure 5: DARPin D8.4/Caspase-8 interacting residues 
(a) DARPin sequence D8.1 and D8.4 are aligned with the DARPin consensus sequence displaying two 
unintended framework mutations: H85R and V139A in D8.1; Q26R and H85R in D8.4 (marked in 
green). Interacting residues determined by the EPPIC server (1) (http://www.eppicweb.org) are 
marked in bold/underlined. In total, 18 framework and 13 randomized residues are involved in a 
binding interface of overall 938 Å2. Notably, the D8.1 sequence is almost identical and besides Arg-26, 
all interacting residues of D8.4 are present in D8.1 suggesting the same interaction. 
(b) Comparison of caspase-8 residues involved in D8.4 binding by sequence alignment (ClustalW2, 
http://www.ebi.ac.uk/Tools/msa/clustalw2/) with other human caspases. Amino acids are classified 
and colored in five groups. Caspase sequence accession numbers are indicated in supplementary 
figure 6. 
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Supplementary Figure 6 
A. Flütsch et al.: Caspase-specific DARPins
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Supplementary Figure 5: Caspase sequence alignment and interacting residues 
(a) Caspase topology map with active site residues (His-237 and Cys-285) indicated with green dots. 
Active-site forming loops are marked with loop-1 to loop-4. They are also known as 179-loop 
(=loop-1), 240-loop (=loop-2), 341-loop (=loop-3) and 381-loop (=loop-4) (6). 
(b) Sequence alignment (ClustalW2, http://www.ebi.ac.uk/Tools/msa/clustalw2) of all human caspase 
family members with sequence accession numbers as indicated in the figure. DARPin interacting 
residues were determined using the EPPIC server (1)  (http://www.eppicweb.org) and are marked in 
red. Primary structure elements are indicated below the sequence and labeled according the caspase 
topology map depicted in panel (a). Consensus symbols are depicted below the sequence with (*) 
indicating fully conserved residues and conservation of strongly (:) and weakly (.) similar properties. 
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SUMMARY
Dysregulation of apoptosis is associatedwith several
human diseases. The main apoptotic mediators are
caspases, which propagate death signals to down-
stream targets. Executioner caspase-3 is respon-
sible for the majority of cleavage events and its
therapeutic potential is of high interest with to date
several available active site peptide inhibitors. These
molecules inhibit caspase-3, but also homologous
caspases. Here, we describe caspase-3 specific
inhibitors D3.4 and D3.8, which have been selected
from a library of designed ankyrin repeat proteins
(DARPins). The crystal structures of D3.4 and
mutants thereof show how high specificity and inhi-
bition is achieved. They also show similarities in the
binding mode with that of the natural caspase inhib-
itor XIAP (X-linked inhibitor of apoptosis). The kinetic
data reveal a competitive inhibition mechanism. D3.4
is specific for caspase-3 and does not bind the highly
homologous caspase-7. D3.4 therefore is an excel-
lent tool to define the precise role of caspase-3 in
the various apoptotic pathways.
INTRODUCTION
Apoptosis is a central process for the development and tissue
homeostasis of multicellular organisms. It is characterized
by morphological changes such as nuclear fragmentation,
membrane blebbing, or the formation of apoptotic bodies (Wyllie
et al., 1980). In multicellular organisms including humans,
improper regulation of apoptosis leads to a variety of pathologies
such as cancer, autoimmune diseases, and neurodegenerative
disorders (Riedl and Shi, 2004). Apoptosis is triggered by various
internal and external stimuli, which are propagated by different
pathways. Common to all apoptotic pathways are caspases
(Fuentes-Prior and Salvesen, 2004; Gru¨tter, 2000; Riedl and
Shi, 2004). These proteins are synthesized as inactive pro-
enzymes and activated upon triggering of the cell death
machinery: The activation of initiator caspases occurs through
dimerization (induced proximity model; Boatright et al., 2003;
Muzio et al., 1998), followed by autoproteolytic cleavage of the
prodomain and the linker between the two subdomains. Execu-
tioner caspases exist as dimeric zymogens and are activated by
proteolytic cleavage of the N-terminal pro-peptide and the
intersubunit linker (Fuentes-Prior and Salvesen, 2004). Active
caspases are dimers of two catalytic domains with a small p10
and a large p20 chain.
Of the 11 known human caspases, caspase-3 plays a promi-
nent role in the apoptotic cascade. Caspase-3 is activated by
intrinsic and/or extrinsic death signals and it executes cell death
by the cleavage of downstream key mediators of apoptosis
(Timmer and Salvesen, 2007). Because apoptosis is a dangerous
process for the cell, caspase activation is strictly controlled and
all apoptotic signaling pathways are tightly regulated. All
caspases recognize tetrapeptide sequences, which are charac-
terized by an aspartic acid at the C terminus (P1 position) and
either tryptophan, aspartic acid or leucine residues at the
N terminus (P4 position) conferring selectivity for caspase-1, -3,
and -8, respectively. The P4 selectivity has been attributed to
different interactions with residues in loops flanking the P4
binding pocket (Mittl et al., 1997; Rotonda et al., 1996). However,
the selectivity of short peptidic substrates remains controversial.
It has been reported that the in vitro selectivity of caspase-3 for
a substrate harboring a P4 aspartic acid is at least 100-fold
higher than that for a glutamate or an asparagine (Stennicke
et al., 2000). Despite this finding, commercially available peptide
substrates failed to exhibit the expected caspase selectivity
(McStay et al., 2008). Caspase-3 is the most unrestrained and
efficient caspase and it is often more active in cleaving short
peptide substrates than the caspase for which the peptide
substrate was designed for (McStay et al., 2008). This analysis
raised doubt regarding the use of short peptides to dissect
signaling cascades leading to apoptosis. The observation that
naturally occurring caspase inhibitors, such as X-linked inhibitor
of apoptosis (XIAP), are highly specific for caspase-3 and -7
(Deveraux et al., 1997; Roy et al., 1997) suggests that specificity
can be gained by extending the size of the inhibitor. Caspases
are attractive drug targets because they are implicated in various
diseases. Therefore, selective and potent caspase-specific
inhibitors are highly desirable.
To develop a caspase-3 specific inhibitor, we used the
Designed Ankyrin Repeat Protein (DARPin) technology (Binz
et al., 2003). From a highly diverse library of DARPin molecules,
binders that recognize the target molecule can be selected by
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either ribosome- or phage display (Steiner et al., 2006; Zahnd
et al., 2007). DARPins consist of N- and C-terminal capping
repeats and two or three internal repeats. These internal repeats
recognize the target molecule by means of specific amino acids
that are randomized in the DARPin library. DARPins possess
several beneficial properties that make them attractive for bio-
technological applications. They are thermodynamically stable,
easily produced, and do not contain cysteine residues allowing
intracellular applications (Binz et al., 2005). Highly selective
DARPins have been successfully selected and described for
a variety of different target proteins such as caspase-2 (Schwe-
izer et al., 2007) or kinase inhibitors (Amstutz et al., 2005), crys-
tallization chaperones (Sennhauser et al., 2007), HIV inhibitors
(Schweizer et al., 2008), and tumor-targeting binding molecules
(Zahnd et al., 2010).
Here, we report the selection and characterization of
DARPins that bind to active caspase-3. Kinetic and binding
experiments revealed that DARPins D3.4 and D3.8 are compet-
itive caspase-3 inhibitors that do not recognize other members
of the caspase family at all (D3.4) or only extremely weakly
caspase-7 (D3.8). The structure of the caspase-3/D3.4 complex
reveals the critical interactions leading to high specificity and
tight binding and analogies to XIAP inhibition.
RESULTS
Selection of Caspase-3-Specific DARPin Binders
A DNA library containing NI2C and NI3C DARPins was used
to select caspase-3 binders by ribosome display (Zahnd
et al., 2007). After four selection rounds, 768 putative binders
were screened by crude cell extract ELISA yielding 29 clones
that possessed submicromolar affinities for caspase-3. These
high affinity binders were individually expressed, purified, and
their binding affinities for caspase-3 were determined by surface
plasmon resonance (SPR) analysis. Four of the selected
DARPins showed affinities below 10 nM (Figure S1 available
online). Their sequences were aligned and are shown in Figure 1.
Although DARPins D3.4 and D3.8 contain 2 and 3 internal
repeats, respectively, they possess the highest sequence simi-
larity. Of the 14 randomized positions of the internal repeats
seven residues are identical. When comparing the sequences
of DARPin D3.6 and D3.13 only four residues in a total of 21
randomized positions are identical. Despite the different
numbers of internal repeats all four DARPins possess very
high affinities for caspase-3. SPR analysis revealed that
D3.4, D3.6, D3.8 and D3.13 bind caspase-3 with KD values of
9.6 ± 1.1 nM, 8.8 ± 2.0 nM, 3.4 ± 0.4 nM, and 7.7 ± 0.4 nM,
respectively (Table 1). These KD values were determined based
on equilibrium analyses of the SPR signal. We used the hetero-
geneous ligand model to determine the kinetic values (Table 1),
which suggests two epitopes with substantially different binding
affinities (Morton et al., 1995).
Inhibition of Caspase-3 by DARPins D3.4 and D3.8
The inhibitory properties of the purified DARPins were analyzed
using two different approaches. Initially the ability of the
DARPins to inhibit the hydrolysis of the short chromogenic
caspase-3 substrate Ac-DEVD-AMC was measured. These
initial tests revealed that D3.4 and D3.8 inhibit the hydrolysis
of the standard caspase-3 substrate with Ki values of 16.8 ±
0.3 nM and 6.7 ± 0.2 nM, respectively, whereas D3.6 and
D3.13 showed no detectable inhibitory activities (Table 1). To
characterize the mode of inhibition (competitive versus uncom-
petitive), specific velocity plot (Figure S2; Baici, 1981) analysis
was performed, which yields the ratio between competitive
and uncompetitive inhibitor constants (a) and the turnover
rate of free enzyme to inhibited enzyme (b). For both DARPins
we determined equal values of a =N and b = 0, demonstrating
that D3.4 and D3.8 are purely competitive inhibitors of caspase-
3 (Table 1).
In the past, short peptide substrates have been extensively
used for the characterization of proteases, because the
Figure 1. Sequence Alignment of Caspase-3-Specific DARPin Binders
The general DARPin sequence is shown with the consensus sequence in black and the randomized amino acid positions in red (X, any of the 20 natural amino
acids except cysteine, glycine, or proline; Z, any of the amino acids asparagine, histidine, or tyrosine). Four DARPin sequences are aligned to the consensus
sequence with identical residues represented as a dot. Amino acids involved in the interaction with caspase-3 are colored in orange. Differences among the D3.4
and D3.8 sequences are highlighted in green. The D3.4_S76Rmutation is marked by a red box. The sequence number is based on D3.4, a N2C DARPin that lacks
the first internal repeat.
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determination of rate constants is straightforward in those exper-
iments. On the other hand, short peptide substrates represent
a rather artificial situation because these substrates utilize
a very limited number of binding interactions. Natural protease
substrates are significantly larger and consequently their binding
is guided by a broader set of interactions. Therefore, we tested
whether the selected DARPins also inhibit the processing of
PARP-1, one of the best-characterized caspase-3 substrates.
The 116-kDa PARP-1 is specifically cleaved by caspases-3
and -7 on the C-terminal side of Asp216 into an 85-kDa and
a 31-kDa fragment (Lazebnik et al., 1994). The addition of 10-
fold molar excess of D3.4 or D3.8 over caspase-3 inhibited the
cleavage of PARP-1 by 90%, whereas the addition of E3_5,
a DARPin that does not bind caspase-3, showed no effect on
the cleavage of PARP-1 (Figure 2). In addition, a 50-fold molar
excess of the caspase-3 DARPin inhibitors completely abolishes
PARP-1 cleavage (Figure 2).
Specificity of DARPins D3.4 and D3.8
All commercially available caspase inhibitors are capable of
inhibiting both caspases-3 and -7 equally well (McStay et al.,
2008). We investigated the caspase selectivity of D3.4 and
D3.8 by measuring the binding affinity and inhibitory activity
against caspase-7 (56% sequence identity with caspase-3)
and the more distantly related caspase-6 (41% sequence iden-
tity). SPR analysis did not show any detectable binding of the
caspase-3 directed DARPins D3.4 and D3.8 to caspases-6
or -7 (Figure S3), suggesting that both DARPins are highly
specific for caspase-3. These results are consistent with
the activity measurements where D3.4 and D3.8 were also
unable to inhibit PARP-1 cleavage by caspase-7 (Figure 2).
Probing the ability of D3.4 and D3.8 to inhibit the hydrolysis of
chromogenic tetrapeptide substrates by caspases-1, -2, -4, -5,
-6, -7, -8, and -9 revealed that D3.4 is highly specific for cas-
pase-3 and cannot inhibit any other tested caspase, whereas
D3.8 has a moderate inhibitory activity against caspase-7
(Figures 3 and S4). A 1,000-fold excess of D3.8 decreases the
activity of caspase-7 to approximately 40%.
Crystal Structure Analysis of the Caspase-3/DARPin
D3.4 Complex
To understand the structural basis for the inhibition mechanism
of caspase-3 by DARPins the crystal structure of the caspase-
3/D3.4 complex was determined at 2.1 A˚ resolution. The details
of the structure determination (data collection and refinement)
are listed in Table 2. In the crystal structure the asymmetric
unit contains one (p12, p17)2 caspase-3 heterotetramer and
two D3.4 molecules (Figure 4A). In the complex every DARPin
buries a surface area of 876 A˚2. A surface complementarity index
of 0.74 indicates a good fit between D3.4 and caspase-3
(Table 1). The interface involves residues from the N-terminal
capping repeat and the two internal repeats of the DARPin,
which form specific hydrogen bonds and hydrophobic interac-
tions with the caspase (Figure 4A). The crystal structure reveals
first of all that D3.4 binds in the active site pocket of caspase-3
and prevents substrate molecules from accessing the catalytic
residues (Figure 4A). The b-turns of D3.4 point toward the
b strand of caspase-3 that is responsible for the recognition of
the substrate by main chain hydrogen bonds (residues 205 to
207). This observation agrees very well with the kinetic analysis
of the inhibition mechanism, where no uncompetitive contribu-
tion was observed (a = N). Therefore, structural and kinetic
analyses consistently classify D3.4 as a purely competitive
caspase-3 inhibitor (Figure S2).
When comparing the caspase-3/D3.4 complex with previously
published caspase/protein complexes, such as the caspase-2/
AR_F8 (Schweizer et al., 2007) or the natural caspase-3/XIAP
complexes (Riedl et al., 2001), the following features can be high-
lighted: (1) DARPins AR_F8 and D3.4 both bind to loop-4 (also
termed 381-loop). However, AR_F8 binds from the backside
and inhibits caspase-2 by an allosteric mechanism (Figure 4B).
(2) D3.4 and XIAP are competitive caspase-3 inhibitors, but the
main chains of D3.4 and the N-terminal extension loop of XIAP
run in opposite directions (Figure 4C).
The binding mode of D3.4 shows similarities to the binding of
natural substrates (based on inhibitor structures) and the natural
inhibitor XIAP. Asp45 of D3.4 is located in the b-turn that
Table 1. Kinetic Constants and Characteristics of the Interaction
DARPin
Kinetic
kon1(M
1s1) koff1(s
1) KD1(M) kon2(M
1s1) koff2(s
1) KD2(M)
D3.4 2.85 3 105 8.81 3 103 3.09 3 108 1.12 3 106 1.13 3 103 1.01 3 109
D3.4_S76R 1.74 3 105 4.20 3 103 2.42 3 108 1.62 3 106 7.45 3 104 4.61 3 1010
D3.6 1.48 3 105 1.13 3 103 7.63 3 109 1.46 3 106 1.00 3 102 6.88 3 109
D3.8 1.77 3 105 2.49 3 103 1.41 3 108 2.44 3 106 1.11 3 104 4.57 3 1011
D3.13 2.74 3 105 1.24 3 103 4.51 3 109 2.31 3 106 7.86 3 103 3.41 3 109
DARPin
Equlibrium Inhibition Interaction
KD(nM) KI(nM) a b SC A˚
2 DiG kcal/mol
D3.4 9.6 ± 1.1 16.8 N 0 0.740 875.95 6.1
D3.4_S76R 6.0 ± 0.5 3.5 N 0 0.725 907.55 7.1
D3.6 8.8 ± 2.0 – – – – – –
D3.8 3.4 ± 0.4 6.7 N 0 nd nd nd
D3.13 7.7 ± 0.4 – – – – – –
See also Figures S1 and S2. nd, not determined.
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connects the N-terminal capping repeat and the first internal
repeat of D3.4, and its side chain occupies the S4 pocket of
caspase-3 (Figure 5A). It forms a direct hydrogen bond with
Asn208-ND2 and two water-mediated hydrogen bonds with
Trp214-NE1 and Phe250-N (Figures 5A and S5). The main chain
carbonyl oxygen of Asp45 forms another water-mediated
(Wat10) hydrogen bond with Arg207-N of caspase-3. In other
caspase-3 structures Arg207-N participates in an antiparallel
b sheet with the substrate main chain. A water molecule (water
10) forms a third hydrogen bond with the hydroxyl group of-
Tyr204. As a consequence, Thr166 moves toward the active
site pocket and forms hydrogen bonds with Trp79-NE1 and
Lys111-NZ from D3.4 (Figures 5A and 6A).
The tip of loop-4 of caspase-3 is recognized by the concave
surface of D3.4 (Figures 5B and 5C). The side chain of Asp44
of D3.4 is buried in the interface and forms two hydrogen bonds
with Ser251-OG and Phe252-N. In contrast, the side chains of
Lys56 and Arg81 of D3.4 are solvent exposed and form salt
bridges with the Asp253 side chain of caspase-3. Hydrophobic
interactions seem to play equally important roles. The side chain
of Phe256 of caspase-3 fits into a pocket that is formed by Ala46,
Val48, Ile78, and Trp79 of D3.4. The benzyl ring of Phe256 of cas-
pase-3 forms T-stacking interactions with the indole ring of D3.4
Figure 2. Inhibition of Caspase-3-Dependent PARP-1 Cleavage by
DARPin Inhibitors
The cleavage of PARP-1 by caspase-3 (40 nM) and -7 (150 nM) was analyzed
by SDS-PAGE (upper panel). Full length and cleaved PARP-1 (cPARP-1) were
detected by a specific antibody that recognizes both forms. None of the
selected DARPins cleave PARP-1 themselves. DARPins were added at 10-,
50-, and 100-fold molar excess per active site (lower panel).
Figure 3. Specificity and Inhibition of Selected DARPins for
Caspase-3, -6, and -7
(A–C) The relative enzymatic activity of caspase-3 is shown in the presence
of D3.4, D3.4_S76R, D3.8, and E3_5 (control DARPin). Each DARPin was
added at three different concentrations: 10- (black), 100- (light gray), and
1,000-fold molar excess (gray). All DARPins inhibit the activity of caspase-3
with the exception of E3_5. Shown are the relative enzymatic activities of
caspase-6 (B) and 7 (C) in presence of four DARPins as described above.
The 1000-fold molar excess of DARPin was not measured for caspase-6
because no inhibition was observed at 100-fold molar excess. D3.8
shows a moderate inhibition of caspase-7; all other DARPins are specific for
caspase-3. Error bars represent the standard deviation of three independent
experiments.
See also Figures S3 and S4.
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Trp79 (Figure 5C). Although the Phe256 binding pocket is mainly
hydrophobic, the side chain of Asp77 is located at the bottom of
this pocket and forms an intramolecular salt bridge with Arg81
and a hydrogen bond with Wat26 (Figure 5C).
Comparison of the Caspase-3/D3.4 Structure
with Caspase-3 in Complex with XIAP and DEVD
The overall structure of caspase-3 is identical to several other
caspase structures. Superposition of the caspase-3/D3.4 struc-
ture with the caspase-3/z-DEVD-cmk (2DKO; Ganesan et al.,
2006) and the caspase-3/XIAP complex structures (1I3O; Riedl
et al., 2001) reveals rmsd values of 0.39 A˚ and 0.35 A˚, respec-
tively. Differences between caspase-3/D3.4 and the caspase-
3/z-DEVD-cmk structures are observed in the active site pocket.
In the caspase-3/D3.4 structure loop-4 of caspase-3 has moved
approximately 1 A˚ out of the active site, whereas Thr166 has
moved into the active site compared to the caspase-3/
z-DEVD-cmk structure (Figure 6A). The movement of Thr166 is
a consequence of the 120 rotation of the Tyr204 side chain. In
the caspase-3/z-DEVD-cmk structure Tyr204 points toward
Thr166, whereas in the caspase-3/D3.4 complex the Tyr204
side chain occupies the S2 pocket (Figure 6A).
The conformations of Tyr204 and loop-4 in the caspase-3/
D3.4 complex structure resemble the conformations seen in
the caspase-3/XIAP structure (1I3O) (Figure 6B). In both
complexes, Tyr204 occupies the S2 pocket (Riedl et al., 2001).
Furthermore, Tyr204 rests against a hydrophobic patch of the
inhibitor, which is formed by Leu141 and Val146 in XIAP and
by Ala46 and Ile78 in D3.4 (Figure 6B).
Modeling the Caspase-3/D3.8 Complex Structure
Based on the sequence alignment and the competitive inhibition
we assume that D3.4 and D3.8 bind to the same epitope
with similar interactions. We were not able to crystallize the
caspase-3/D3.8 complex and thus calculated a homologymodel
of D3.8 based on a N3C DARPin E3_5 structure (1MJ0; Kohl
et al., 2003). This homology model was superimposed on D3.4
in the caspase-3/D3.4 crystal structure (Figure 6C). The N2C
DARPin D3.4 lacks the first internal repeat so that the N-cap
of D3.4 superimposes on the first internal repeat of the N3C
DARPin D3.8 (Figure 6C). Furthermore, D3.8 has two critical
mutations compared to D3.4. Mutations Lys56Ser and Ser76Arg
are located in the caspase/DARPin interface, whereas all
other amino acid changes between D3.4 and D3.8 are located
more than 4 A˚ away from caspase-3. The homology model
showed that the salt bridge between Lys56 and Asp253 is
absent in the D3.8/caspase-3 complex (Figure 6D). In D3.8 the
corresponding Ser56 is unable to form a salt bridge as observed
in the caspase-3/D3.4 structure. Furthermore, the positive
charge of Lys56 in D3.4 could cause repulsive interactions with
His255 at the top of loop-4 of caspase-7 (Figure 6D). These
repulsive interactions could explain why D3.4 does not show
any affinity for caspase-7, whereas D3.8 possesses weak affinity
for caspase-7 due to the Lys56Ser mutation.
D3.4 Mutant Ser76Arg
D3.8 binds caspase-3 with higher affinity and has a lower inhibi-
tion constant (Ki = 6.7 nM) compared to D3.4 (Table 1). Residue
Ser76 in D3.4 is located in proximity to the interface but does not
interact with caspase-3. The caspase-3/D3.8 model suggests
that a bulkier side chain, such as arginine, could participate in
an extended DARPin/caspase-3 interface. To test this hypoth-
esis we generated the D3.4 Ser76Arg mutant (D3.4_S76R)
and characterized its functional and structural properties.
D3.4_S76R revealed dissociation and inhibitory constants of
KD
S76R = 6.0 ± 0.5 nM and Ki
S76R = 3.49 ± 0.03 nM, respectively.
Thus, D3.4_S76R shows an equally low inhibitory constant for
caspase-3 compared to D3.8 (Table 1).
The 2.1 A˚ resolution crystal structure of the caspase-3/
D3.4_S76R complex revealed that although the overall structure
is identical to the caspase-3/D3.4 structure (rmsd of 0.198 A˚), the
C-terminal capping repeat has shifted by approximately 2 A˚ (Fig-
ure 6E). The side chain of the newly introduced Arg76 forms two
intramolecular hydrogen bonds with Gly80-O and Gln109-O of
the C-terminal capping repeat and an intermolecular hydrogen
bond with Gly60-O of caspase-3 (Figure 6E). In addition, the
weak hydrogen bond between Lys111 and Thr166 as it is seen
in the parent structure is broken and the Lys111 side chain points
into the active site forming a water-mediated hydrogen bond
with Gly165-O of caspase-3 and an intramolecular hydrogen
bond with Ile78-O from the preceding DARPin repeat. The medi-
ating water molecule is located in direct vicinity of the active site
Cys163 (Figure 6E).
DISCUSSION
The development of specific caspase inhibitors has remained
a challenging task due to the similarity between the active sites
of caspases. Although the selectivity of caspases for short
Table 2. X-Ray Data Collection and Model Refinement Statistics
Caspase-3/
D3.4 (2XZD)
Caspase-3/
D3.4_S76R (2Y0B)
Data Collection
Frame width () 0.25 0.2
Space group P3121 P3121
Unit cell parameter a = 98 A˚ a = 98 A˚
b = 98.0 A˚ b = 98.0 A˚
c = 193.6 A˚ c = 192.9 A˚
a = b = 90.0
g = 120.0
a = b = 90.0
g = 120.0
Resolution (A˚) 49.0–2.1 49.0–2.1
Wavelength (A˚) 1.000 0.92
Rsym (%) 4.2 (60.4) 4.9 (60.9)
Completeness (%) 99.3 (99.5) 99.2 (99.5)
I/s(I) 15.59 (1.92) 12.94 (1.96)
Refinement
Resolution (A˚) 2.1 2.1
RF/Rfree (%) 18.5/21.8 19.1/21.7
No. of protein atoms 5,616 5,622
No. of water atoms 247 345
Average B-factor (A˚2) 35.3 35.8
Root Mean Square Deviations
Bond length (A˚) 0.011 0.006
Bond angles () 1.192 0.941
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Figure 4. Structures of Caspase-3 in
Complex with Different Inhibitors
(A) Stereo view of the caspase-3/D3.4 complex
structure as a ribbon cartoon. The two chains of
caspase-3 are colored in dark (p17) and light gray
(p12). The active site L1, L2, and L4 loops and the
catalytic residues are highlighted in red and green,
respectively. D3.4 consists of N- and C-terminal
capping repeats (dark blue) and two internal
repeats (light blue). D3.4 binds in the active site
and interacts mainly with loop-4 of caspase-3.
(B) The superposition of the caspase-2 specific
DARPin AR_F8 (green, 2P2C) on the caspase-3/
D3.4 structure is shown in two different views.
Caspases are shown as a gray surface. Darpins
D3.4 (blue) and AR_F8 (green) recognize the active
site loop-4 (red), albeit from different sides.
(C) The caspase-3/XIAP structure (yellow, 1I3O)
was superimposed on the caspase-3/D3.4 struc-
ture. The C-terminal BIR2 domain of XIAP binds
outside the active side cleft and inhibits the
enzyme with the N-terminal tail.
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peptide inhibitors that differ in the P4 positions is well estab-
lished (Thornberry et al., 1997), their selectivity is often insuffi-
cient considering the different amounts of active caspases in
cells undergoing apoptosis (Berger et al., 2006). In 2007, Schwe-
izer et al. published the first truly specific caspase inhibitor
(AR_F8) that inhibits caspase-2 with an allosteric mechanism
by interacting with loop-4 (Schweizer et al., 2007).
Using the same technology (Binz et al., 2003), we identified
four caspase-3 DARPins, two of which specifically inhibited the
enzyme. Kinetic analysis characterized D3.4 and D3.8 as purely
competitive inhibitors, which is in agreement with the structural
data. In the caspase-3/D3.4 structure, the DARPin occupies
the active site pocket and recognizes loop-4 of caspase-3. The
caspase-2-directed DARPin AR_F8 also recognizes loop-4,
Figure 5. Binding Interface of Caspase-3 with D3.4
Close-up views of the caspase-3/D3.4 interaction in stereo. D3.4 (blue) interacts with caspase-3 (p17, dark gray; p12, light gray) via hydrogen bonds (dotted lines)
and hydrophobic interactions. Amino acids from the DARPin are labeled by an additional ‘. The active site cysteine is shown in green.
(A) Active site standard view: Asp45’ forms several hydrogen bonds in the S4 pocket of caspase-3. Thr166, which is located close to the active site Cys163, forms
two hydrogen bonds with the second repeat of D3.4.
(B and C) View from the backside of loop-4: The concave site of D3.4 recognizes the tip of loop-4 by several hydrogen bonds (B). The hydrophobic interactions in
the interface between caspase-3 and D3.4. Phe256 from caspase-3 binds into a hydrophobic pocket of D3.4 and forms T-stacking interactions with Trp79’ (C).
See also Figure S5.
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Figure 6. Structural Comparison of Caspase-3 Inhibitors
With the exception of caspase-3, the labels of all amino acids contain unique identifiers: D3.4 (’), DEVD (), XIAP (*), D3.4_S76R (^), D3.8 (D), and caspase-7 (#).
(A) Superposition of caspase-3/z-DEVD-fmk (light green andgray, 2DKO) on the caspase-3/D3.4 structure (dark gray andblue). Tyr204 is rotated by approximately
120 in the DARPin bound structure. As a consequence of this rotation Thr166 is shifted away from the active site. Movements are indicated by black arrows.
(B) Superposition of caspase-3/XIAP (gray and yellow, 1I3O) on the caspase-3/D3.4 structure (dark gray and blue) indicating a similar orientation of Tyr204 in
a subsite S2-blocking position.
(C) The D3.8 model (dark red and salmon represent the capping and internal repeats, respectively) superimposed on D3.4 (dark and light blue) with numbered
a helices in repeat 2 (D3.8) and 1 (D3.4), respectively. Caspase-3 is shown as a gray surface with loop-4 highlighted in red.
(D) Close-up view of the modeled interaction between either D3.4 (blue) or D3.8 (salmon) and either caspase-3 (gray) or caspase-7 (green). Shown are the
a helices 1 of the first internal repeat of D3.4 and the second internal repeat of the D3.8 model. In the caspase-3/D3.4 complex Lys56’ forms a salt bridge with
Asp253. In caspase-7, this position is occupied by His255#. In D3.8 Ser56D cannot form the salt bridge with caspase-3 and does not exert repulsive interactions
with His255# in caspase-7.
(E) Superposition of the caspase-3/D3.4 on the caspase-3/D3.4_S76R structure. Caspase-3 is shown as a gray surface with loop-4 colored in red, whereas D3.4
and D3.4_S76R are shown as dark blue and green Ca-traces. Interacting side chains are highlighted. Hydrogen bonds are indicated as gray dotted lines. In the
caspase-3/D3.4_S76R structure the side chain of Arg76^, Ile78^, and Lys111^ form hydrogen bonds that are not seen in the parent structure (Table 3) and cause
a shift of the C-cap.
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however from a different direction than the caspase-3-directed
DARPin D3.4. Its kinetic characterization using the specific
velocity plot demonstrated a mixed type inhibition with a signifi-
cant part of uncompetitive inhibition. The different inhibition
modes of D3.4 and AR_F8 can be explained by the different
epitopes on the caspases. AR_F8 recognizes caspase-2 from
the backside of loop-4 and stabilizes a distinct conformation,
which is not able to bind the substrate, whereas D3.4 binds
straight into the active site of caspase-3. Our analysis further
showed that D3.4 prevents substrates from accessing the cata-
lytic Cys163 and leaves the conformation of loop-4 almost undis-
turbed when compared to the caspase-3 inhibitor structure.
Another finding is the superior inhibition of caspase-3 by the
closely related D3.8, which inhibits caspase-3 even better than
D3.4. DARPin molecules D3.6 and D3.13 bind caspase-3 but
do not inhibit hydrolysis and were thus not further analyzed.
D3.4 does not inhibit the closely related caspase-7 but from
the data given in Figure 2 the IC50 value for the inhibition of cas-
pase-7 by D3.8 can be estimated to be in the lower micro-molar
range. This residual activity is probably resulting from the
replacement of Lys56 in D3.4 to Ser56 in D3.8. Lys56 in D3.4
forms a salt bridge with Asp253 from caspase-3 and at the
same time could enforce a repulsive effect to His255 from cas-
pase-7 to ensure specificity for caspase-3. The model of the
less specific D3.8 does not show this repulsion at caspase-7,
which could explain the slight binding ability of D3.8 for
caspase-7. Thus, even inhibitors with significantly extended
interaction surfaces compared to tetrapeptide inhibitors can
recognize closely related caspases, albeit with affinity constants
that differ by at least three orders of magnitude.
Our inhibition studies using PARP-1 as a caspase substrate
revealed that the selected DARPins (D3.4, D3.4_S76R and
D3.8) inhibit PARP-1-cleavage by caspase-3 completely using
a 50-fold molar excess. In contrast, caspase-7 cleavage is not
influenced even with a 100-fold excess of D3.4, D3.4_S76R, or
D3.8, respectively.
Our data suggest that D3.4 and D3.8 bind to the same
caspase-3 epitope because residues that seem to be crucial
for the recognition of this epitope, such as Asp45, Ala46,
Val48, Ile78, Trp79, and Arg81, are conserved in both molecules.
The crystal structure revealed that D3.4 recognizes caspase-3
by a set of specific hydrogen bonds, salt bridges and hydro-
phobic contacts (Table 3). Particularly interesting are the interac-
tions formed by Asp45, which occupies the S4 pocket. So far all
structurally characterized caspase-3 specific peptide inhibitors
harbor an aspartic acid that occupies this pocket (Figure 7).
Although the hydrogen bonding networks are different in the
structures of caspase-3 in complex with D3.4, z-DEVD-cmk or
XIAP, the positive electrostatic potential explains the preference
for a small and negatively charged hydrogen bonding partner like
aspartate. Further similarities between the complex structures of
caspase-3 with D3.4 and XIAP are seen for Tyr204 (Figure 7). In
both structures the Tyr204 side chain points toward Arg341,
placing the phenyl ring at van der Waals distance to Cys163-
Sg. On the opposite side the Tyr204 phenyl ring rests against
a hydrophobic core, which is composed of caspase-3 residues
Leu168 and Phe256 and the side chains of Ala46 and Ile78
from D3.4 or Leu141 and Val146 from XIAP. D3.4 and XIAP are
Table 3. Hydrogen Bonds in the Caspase-3/D3.4 Interface
DARPin Distance Caspase-3
D:ARG 23 [NH1] 3.19 C:PHE 252 [O]a
D:ASP 44 [OD2] 2.69 C:SER 251 [OG]a
D:ASP 44 [OD2] 2.97 C:PHE 252 [N]a
D:ASP 45 [OD1] 3.1 C:ASN 208 [ND2]b
D:ASP 45 [O] 2.5/2.8 C:Wat 10 - TYR 204 [OH]b
D:ASP 45 [OD2] 2.6/2.7 C:Wat 12 - PHE 250 [N]a
D:ASP 45 [OD2] 2.6/2.9 C:Wat 11 - TRP 214 [NE1]b
D:LYS 56 [NZ] 3.38 C:ASP 253 [OD1]a
D:LYS 56 [NZ] – C:ASP 253 [OD2]a
D:TRP 79 [NE1] 2.87 C:THR 166 [O]a
D:ARG 81 [NH2] 2.79 C:ASP 253 [OD2]a
D:LYS 111 [NZ] 3.75 C:GLU 167 [OE2]a
D:LYS 111 [NZ]c 2.68 C:THR 166 [OG1]a
D3.4_S76R
D:ARG 76 [NE] 3.3 C:GLY 60 [O]a
D:LYS 111 [NZ] 2.7/3.2 C:Wat - GLY 165 [O]a
aCaspase residues, not involved in subsite formation.
bCaspase residues, forming substrate binding pockets S4–S1.
cNot present in D3.4_S76R.
Figure 7. Schematic Caspase-3 Inhibition
(A) The peptide inhibitor Ac-DEVD-fmk occupies four substrate binding
pockets of caspase-3 (S1–S4).
(B) The BIR2 domain of XIAP occupies the S4 pocket of caspase-3 with
Asp146 and Val146 keeps Tyr204 at a position, which blocks the S2 pocket. S1
is filled with water molecules. Compared to Ac-DEVD-fmk the XIAPmain chain
runs in the opposite direction.
(C) D3.4 uses a caspase-3 inhibition mechanism that shares features of XIAP
and Ac-DEVD-fmk. The S4 pocket is also occupied (Asp45), Ile78 keeps
Tyr204 in a locked conformation and the S1 pocket is filled with water, but the
D3.4 main chain runs in the same direction like in Ac-DEVD-fmk.
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both lacking an aspartic acid that could occupy the S1 pocket of
caspase-3, which consequently is filled by water molecules. The
same conformation of Tyr204 is also seen in several other
structures of caspase-3 in complex with low molecular weight
inhibitors that are lacking a P1 aspartate (Agniswamy et al.,
2009; Ganesan et al., 2011) as well as in unliganded caspase-3
(Ni et al., 2003). Conversely, this conformation is different
from structures with classical tetrapeptide inhibitors, where the
Tyr204 side chain rests against the side chain of Thr166 (Gane-
san et al., 2006).
The main chains of the small peptide inhibitor z-DEVD.cmk
and D3.4 run antiparallel to caspase-3 residues 204–208. The
S4 pocket of caspase-3 is occupied by Asp1 and Asp45 of
z-DEVD.cmk and D3.4, respectively. In contrast to that the
main chain of XIAP runs parallel to caspase-3 with Val146 and
Asp148 binding into the S2- and the S4 pocket, respectively.
Although the main chains of D3.4 and XIAP run in opposite
directions, both inhibitors use very similar interactions to inhibit
caspase-3 (Figure 7). Thus, the comparison of the caspase-3/
D3.4 crystal structure with the caspase-3/XIAP crystal structure
provides an interesting example for the molecular mimicry of
natural and designed caspase-3 inhibitors.
In summary, our study presents the selection and character-
ization of caspase-3-directed DARPin inhibitors with implica-
tions for specificity and inhibition mechanism. The selected
DARPins D3.4 and D3.8 are pure competitive inhibitors. D3.4
and the improved variant D3.4_S76R are the first truly specific
caspase-3 inhibitors and do not bind caspase-7, a close
caspase-3 paralog, or any other human caspase. Such highly
specific binders/inhibitors are a prerequisite for the analysis
of the function of any enzyme involved in signaling pathways.
In the particular case of caspase-3 and its role in apoptotic
signaling, D3.4_S76R is the best molecule for such an analysis.
Remarkably D3.4 inhibits caspase-3 with a similar mechanism
compared to XIAP, the natural caspase-3 inhibitor that also
inhibits caspase-7. It has previously been postulated that spec-
ificity is achieved by two key factors, allosteric regulation and
scanning of large volumes of conformational space (Salvesen
andRiedl, 2007).While the second aspect holds true, we demon-
strate here that specificity can be achieved even when the
conserved substrate binding pockets are targeted, provided
this is combined with specific surface recognition of non-subsite
residues, which are unique to the targeted protein.
EXPERIMENTAL PROCEDURES
DARPin Selection with Ribosome Display
We performed four rounds of ribosome display to enrich caspase-3 specific
binders based on a NI3C and NI2C library as described before (Binz et al.,
2004; Zahnd et al., 2007). Prior to each selection the DARPin-ribosome-
mRNA complex was incubated with the closest homologous of caspase-3
(caspase-6 and -7) and streptavidin for 30 min at 4C to avoid selection of
unspecific DARPins. Biotinylated caspase-3 was immobilized on magnetic
particles (Dynabeads, Invitrogen) for solution panning. DARPin selection was
performed in the absence of a caspase-3 inhibitor. The DARPin-ribosome-
mRNA complex was incubated with 20 ml of beads for 30 min at 4C in
a tube that was previously blocked with TBST-BSA (50 mM Tris-HCl pH 7.4,
150 mM sodium chloride, 0.05% Tween-20, 0.1% BSA). The incubation was
followed by four washing cycles in 50mMTris-acetate pH 7.4, 150mMsodium
chloride, 50 mM magnesium acetate, and 0.05% Tween-20. The RNA was
eluted in 50 mM Tris-acetate pH 7.4, 150 mM sodium chloride, and 25 mM
EDTA and transcribed into DNA for amplification. In rounds three and four,
we added a 1000-fold excess of unbiotinylated caspase-3 for 10 min during
the selection to favor the enrichment of DARPins with slow koff rates. After
four rounds of selection, we cloned the DARPin library in a pQE30 vector (-
QIAGEN), transformed competent XL1 blue cells (Stratagene), and continued
with crude cell extract ELISA.
Crude Cell Extract ELISA
Single colonies each containing one DARPin clone of the selected library were
picked and inoculated in 0.9 ml auto-inducing media 5052 (Studier, 2005) con-
taining deep 96-well plates (Abgene, UK). The cells were grown over night at
37C while shaking at 300 rpm in a shaker (TH15, Edmund Bu¨hler GmbH).
Then 200 ml of each well were transferred into a sterile 96-well plate
(449824, Nunc) as a backup for further protein expression and plasmid
preparation. The remaining 700 ml of cell-suspension was harvested by centri-
fugation and the cell pellet was lysed with 50 ml B-PER II (Pierce, 78260) per
well for 30 min shaking at room temperature. The lysed cells were resus-
pended by adding 950 ml PBS, pH 7.3, and cell debris were removed by centri-
fugation (20 min, 4500 rpm at 4C) in a tabletop centrifuge (Eppendorf). We
now took 20 ml of the supernatant of four 96 well plates and transferred it to
one 384-well ELISA plate (Nunc, 464718). This plate was previously coated
with 20 ml of a 22 nM neutravidin solution (Pierce, 31000) and biotinylated
caspase-3, followed by extensive washing. After 1 hr of incubation at room
temperature and three washing cycles, the plate was incubated with mouse
anti-RGS-H4 antibody (QIAGEN, 34650) at a dilution of 1:2000 in PBS 1%
BSA. After adding the secondary antibody (goat-a-mouse IgG alkaline phos-
phatase conjugate, Sigma, A3562) and four washing steps the amount of
bound DARPin was quantified by adding the substrate buffer (3 mM di-sodium
4-nitrophenyl phosphate, 50 mM sodium bicarbonate, 50 mM magnesium
chloride). The optical density (OD) was measured at 405 nm using a multiwell
plate reader (Infinite M1000, Tecan).
Expression, Purification, and Biotinylation of Proteins
All DARPins were expressed in auto-inducing media (Studier, 2005) or
lysogeny broth media (Binz et al., 2003). The expressed DARPin was purified
by IMAC using a self-made gravity column (Supelco, 57024) containing
0.5 ml bead volume of Ni2+-NTA agarose (QIAGEN, 30210). The DARPins
were eluted in PBS complemented with 200 mM imidazole. The imidazole
was removed with a PD-10 desalting column (GE Helthcare, 17-0435-01).
We added sodium azide to a final concentration of 0.03% to prevent growth
of bacteria and fungi. The DARPin solutions were stored at 4C. Caspase-1
to caspase-9 were expressed and purified as described elsewhere
(Roschitzki-Voser et al., 2012). Expression plasmids for caspase-6, -7, and -9
have been obtained from Dr. Guy Salvesen, the Burnham Institute, La Jolla,
CA, USA (Denault and Salvesen, 2003).
For chemical biotinylation of caspases, we used the linker EZ-Link Sulfo-
NHS-LC-LC-Biotin (Pierce, 21338), containing a reactive group, a 3.05-nm
long linker, and a biotin moiety. After purification, 1 ml of 10 mM caspase in
PBS, pH 7.3 was incubated with a 7-fold molar excess (1 ml of a 70 mM solu-
tion) of biotin on ice for 30 min. The reaction was quenched by adding 10 ml of
5 M Tris-HCl, pH 7.5. The biotinylated protein was purified by size exclusion
chromatography, using a Superdex 200 10/300 GL (GE Healthcare) in PBS
at 4C. Fractions containing biotinylated caspase were pooled and frozen in
liquid nitrogen after adding sucrose to a final concentration of 10%.
Crystallization
The caspase/DARPin complexes were formed by incubating caspase-3 with
a 2-fold molar excess of each DARPin for 10min on ice. The complex was puri-
fied by size exclusion chromatography (Superdex 200 HR 10/30, Amersham
Pharmacia, Sweden) in 50 mM Tris-HCl, pH 8.0 (4C), 50 mM sodium chloride.
Fractions containing caspase/DARPin were concentrated to 5 mg/ml and
10 mg/ml for D3.4 and D3.4_S76R, respectively, using an ultrafiltration device
with a molecular weight limit of 15 kDa (Amicon Ultra, Millipore).
Crystals were grown at room temperature using the vapor-diffusion method.
Two microliters of concentrated protein solution were mixed with 1 ml of reser-
voir solution containing 100 mM HEPES, pH 7.3, 70% (v/v) 2-methyl-2,4-
pentanediol. Crystallization plates were stored at 20C. Crystals appeared
within 24 hr.
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Data Collection, Structure Determination, and Refinement
For X-ray diffraction analysis, crystals were flash-frozen in liquid nitrogen and
data were collected (100 K) at beamline X06SA (Swiss Light Source, Villigen,
Switzerland). No cryoprotectant was necessary for data collection. The
beamline was equipped with a Pilatus 6M fast readout pixel detector (Dectris,
Switzerland). The program XDS was used for data processing and data were
scaled with XSCALE (Kabsch, 2010; Potterton et al., 2003). Both complexes
crystallized in space group P3121. Unit cell dimensions are listed in Table 2.
The structures were solved by molecular replacement with the program
PHASER (McCoy et al., 2007) using a high-resolution structure of caspase-3
(2DKO; Ganesan et al., 2006) and a model of the N2C DARPin, which was
generated by homology modeling (MODELER 9v8; Eswar et al., 2007) using
the N3C DARPin E3_5 (1MJ0; Kohl et al., 2003) as a template. The crystals
have a solvent content of 59% (Matthews coefficient of 3.0 A˚3/Da) (Collabora-
tive Computational Project, Number 4, 1994) with one (p12, p17, D3.4)2
complex in the asymmetric unit. Alternating rounds of manual model building
using COOT (Emsley et al., 2010) and restrained refinement using REFMAC
version 5.5.01.09 (Murshudov et al., 1997) yielded RF/Rfree values of 0.185/
0.217 for the caspase-3/D3.4 and 0.174/0.214 for the caspase-3/D3.4_S76R
complex. Data collection and structure refinement statistics are listed in
Table 2. Structures were superimposed using COOT (Emsley et al., 2010)
and figures were prepared using PyMOL (Schrodinger, 2010).
Site-Directed Mutagenesis
We used the QuikChange Site Directed Mutageneis Kit (Stratagene) to incor-
porate mutations in the DARPin sequence. The following primers were used
to introduce the Ser76Arg mutation in D3.4: 50-GGT GCT GAC GTT AAC
GCT CGT GAC ATT TGG GGT CGT ACT-30 (fwd) and 50-AGT ACG ACC
CCA AAT GTC ACG AGC GTT AAC GTC AGC ACC-30 (rev). The underlined
codons indicate the mutation.
Surface Plasmon Resonance Analysis
For SPR experiments we used the Proteon XPR36TM (Biorad Laboratories)
and a NLC sensor chip (Biorad Laboratories). Sterile filtered PBS, pH 7.3,
and 0.005% Tween-20 were used as the standard buffer for all coating and
kinetic analysis steps. A 5-nM solution of biotinylated, fully processed caspase
was coated in the absence of caspase inhibitors on the sensor chip at a
flow rate of 30 ml per minute. The coating procedure was stopped when
1000 relative units were immobilized on the chip. Dilution series of DARPins
were pipetted in 96-deep well plates (Biorad, 176-6023), which were sealed
to prevent evaporation and contamination with dust particles. Starting with
the lowest concentration we measured the binding of DARPins at 0, 0.176,
0.52, 1.58, 4.47, 14.2, 42.6, and 128 nM concentrations. All experiments
were performed at 20C. Flow rates of 100 ml per minute, association times
of 3 min and dissociation times of 20 min were used. Data were recorded
and kinetic binding data were determined with the ProteOn Manager 2.1.1
software (Biorad) using the heterogeneous ligand model (Bravman et al.,
2006).
Caspase Activity Measurements
Specific inhibition of caspase-1 to caspase-9 was measured using peptide
substrates from Peptide Institute (Osaka, Japan). We used Ac-DEVD-amc
for caspase-3, -6, -7, and -8; Ac-WEHD-amc for caspase-1, -4, and -5;
Ac-VDVAD-amc for caspase-2; and Ac-LEHD-amc for caspase-9. Enzyme
and substrate concentrations in the assay were as follows: caspase-1
(10 nM enzyme; 150 mM substrate), caspase-2 (25 nM; 150 mM), caspase-3
(0.5 nM; 150 mM), caspase-4 (200 nM; 600 mM), caspase-5 (10 nM; 150 mM),
caspase-6 (10 nM; 600 mM), caspase-7 (2 nM, 400 mM), caspase-8 (10 nM;
150 mM), and caspase-9 (25 nM, 600 mM) considering all caspases as hetero-
tetramers. DARPins were added assuming that one DARPin binds to every
caspase active site. The following assay buffers were used: caspase-2,
100 mM MES, pH 6.5, 10% PEG600 (w/v), 0.1% CHAPS (w/v), 10 mM DTT;
caspase-9, 50 mM Tris-HCl, pH 7.5, 10% sucrose (w/v), 1.3 M sodium
citrate; all other caspases, 20 mM PIPES, pH 6.5, 10% sucrose (w/v), 0.1%
CHAPS (w/v), 10 mM DTT, 150 mM sodium chloride, and 1 mM EDTA. AMC
release was monitored by measuring the fluorescent excitation and emission
wavelengths of 360 nm and 465 nm, respectively, using an Infinite M-1000
spectrofluorometer (Tecan).
Specific Velocity Plot
Inhibition mechanism and Ki values of DARPins D3.4, D3.8, and D3.4_S76R
have been determined using the specific velocity plot (Baici, 1981). The
concentration of caspase-3 was determined by active site titration as
described previously (Stennicke et al., 2000). The caspases inhibitor Ac-
DEVD-cmk (0 to 7.6 nM), caspase-3 (0.5 nM), and the substrate Ac-DEVD-
amc (100 mM) were prepared in activity buffer containing no DTT (20 mM
PIPES, pH 6.5, 10% sucrose [w/v], 0.1% CHAPS [w/v], 150 mM sodium chlo-
ride, 1 mM EDTA). Concentrations of DARPins were determined using amino
acid analysis at the Functional Genomic Center (Zu¨rich, Switzerland). The
initial velocities of substrate hydrolysis with 0.5 nM caspase-3 have been
measured at different DARPin concentrations (D3.4, 8–32 nM; D3.4_S76R,
4–10 nM; D3.8, 2–8 nM) and substrate concentration between 0.2 and 0.8
times Km (Km = 24.7 ± 1.8 mM). Graphical analysis of the velocity plot was
done with Prism5 (GraphPad Software). The inhibitor titration has been per-
formed using 0.5 nM caspase-3, different DARPin concentrations (D3.4,
0–1,000 nM; D3.4_S76R, 0–1,000 nM; D3.8, 0–100 nM), and 24 mM substrate.
To determine Ki values of DARPins initial velocities were fitted to the tight
binding inhibition equation as described previously (Szedlacsek et al., 1988).
PARP-1 Inhibition and Western Blot Analysis
A 0.18-mM solution of PARP-1 in 50 mM Tris-HCl, pH 7.5, 150 mM sodium
chloride was mixed with either 40 nM caspase-3 or 150 nM caspase-7 and
the corresponding DARPin (10- to 100-fold excess per active site) as indicated
in Figure 2. The mixture was incubated for 20 min at room temperature in
50 mM Tris-HCl pH 7.5, 150 mM sodium chloride, and 0.5 mM DTT, and
stopped by adding SDS sample buffer (95C for 5min). The samples were sub-
jected to 12% SDS-PAGE under reducing conditions and transferred to a
nitrocellulose membrane (iBlot, Invitrogen). The membrane was blocked in
high-TBS (50 mM Tris-HCl, pH 7.5, 500 mM sodium chloride) containing 5%
(w/v) nonfat dry milk for 1 hr at room temperature. The primary PARP antibody
(Cell Signaling, 9542) was incubated with the membrane at a dilution of 1:1000
in high-TBS-T (50 mM Tris-HCl, pH 7.5, 500 mM sodium chloride, 0.1%
Tween-20) at 4C overnight. After intensive washing in high-TBS-T, we incu-
bated themembrane with anti-rabbit HRP conjugated antibody (Cell Signaling,
7074) for 1 hr at room temperature in TBS (50 mM Tris-HCl, pH 7.5, 150 mM
sodium chloride). Protein bands were visualized by chemiluminescence using
the SuperSignal West Pico Chemiluminescent Substrate (Pierce) in combina-
tion with a Fuji Las 3000 camera.
Modeling of D3.8
Based on the kinetic data and sequence alignments, we hypothesized that
D3.8 binds to the same epitope as D3.4. Therefore, we generated a model
of D3.8 in complex with caspase-3. The N3C DARPin E3_5 (1MJ0; Kohl
et al., 2003) was used as a template to calculate a homology model of D3.8
using the program MODELER 9v8 (Eswar et al., 2007). The model of D3.8
was then superimposed on D3.4 in the complex structure according to the
sequence alignment shown in Figure 1.
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Combined inhibition of caspase 3 and caspase 7 by two highly selective
DARPins slows down cellular demise
Andreas FLU¨TSCH*1, Rafael ACKERMANN*2, Thilo SCHROEDER*2,3, Maria LUKARSKA*4, Georg J. HAUSAMMANN*,
Christopher WEINERT*, Christophe BRIAND*5 and Markus G. GRU¨TTER*6
*Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
Caspases play important roles during apoptosis, inflammation
and proliferation. The high homology among family members
makes selective targeting of individual caspases difficult, which is
necessary to precisely define the role of these enzymes. We have
selected caspase-7-specific binders from a library of DARPins
(designed ankyrin repeat proteins). The DARPins D7.18 and
D7.43 bind specifically to procaspase 7 and active caspase 7,
but not to other members of the family. Binding of the DARPins
does not affect the active enzyme, but interferes with its activation
by other caspases. The crystal structure of the caspase 7–D7.18
complex elucidates the high selectivity and the mode of inhibition.
Combining these caspase-7-specific DARPins with the previously
reported caspase-3-inhibitory DARPin D3.4S76R reduces the
activity of caspase 3 and 7 in double-transfected HeLa cells during
apoptosis. In addition, these cells showed less susceptibility
to TRAIL (tumour-necrosis-factor-related apoptosis-inducing
ligand)-induced apoptosis in living cell experiments. D7.18 and
D7.43 are therefore novel tools for in vitro studies on procaspase
7 activation as well as for clarifying the role of its activation
in different cellular processes. If applied in combination with
D3.4S76R, they represent an excellent instrument to increase our
understanding of these enzymes during various cellular processes.
Key words: caspase inhibition, caspase targeting, designed
ankyrin repeat protein (DARPin), procaspase 7 activa-
tion, tumour-necrosis-factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis.
INTRODUCTION
To ensure the correct development of a multicellular organism,
a variety of distinctive death pathways have evolved. These
processes guarantee an accurate tissue maintenance and
homoeostasis by the removal of aberrant cells. One of the
well-studied cellular death pathways is termed apoptosis, which
is primarily executed by proteolytic enzymes of the caspase
family and triggered by either intra- or extra-cellular stimuli
[1–3]. Once initiated, apoptosis leads to distinct morphological
changes (e.g. rapid cell shrinkage, nuclear fragmentation or
membrane blebbing) and non-inflammatory elimination of the cell
by the recruitment of macrophages [4–6]. To prevent accidental
apoptosis, various redundant regulatory systems have evolved.
However, down- or up-regulation is related to severe pathological
diseases such as tumour development, Parkinson’s disease or
Alzheimer’s disease [2,7].
A crucial regulatory mechanism of apoptosis is the expression
of caspases as inactive zymogens, which are activated upon
certain death stimuli. The activation of initiator caspases requires
dimerization at recruitment platforms followed by autoproteolytic
cleavage of the prodomain and intersubunit linkers. The zymogens
of the executioner procaspases are expressed as stable dimeric
proteins and activated by partial proteolysis at the N-terminal
propeptide and between the two subunits either by initiating
or executing family members. After successful activation, all
caspases consist of two catalytic domains, each formed by
a large (p20) and a small (p10) subunit. Once initiated, the
caspase cascade leads to numerous proteolytic cleavage events
at downstream proteins, mainly performed by the executioner
caspases, i.e. caspases 3, 6 and 7. Although these enzymes share
a very high sequence identity of up to 50%, their executing role
during apoptosis has been proposed as similar, but non-redundant
[8,9].
Targeting a well-conserved active site as observed in the caspase
family is a challenging task. For example, the commercially
available specific caspase substrates lack specificity owing to
overlapping sequence recognition and cleavage by other caspases
[10]. Besides targeting the active site, the selection of binding
proteins with larger protein–protein interaction surfaces seems to
be more promising. Such binding interfaces may involve non-
conserved residues that would increase the binding specificity for
the targeted enzyme. We therefore decided to screen for caspase-
specific binders using a library of DARPins (designed ankyrin
repeat proteins).
The intended DARPin design is based on the scaffold of
ankyrin proteins [11]: located between a N- and C-terminal
capping repeat, DARPins contain two (= NI2C) or three
(= NI3C) internal repeats that each harbour six randomized
positions. This results in a library with a theoretical diversity
Abbreviations: Ac, acetyl; cmk, chloromethylketone; DARPin, designed ankyrin repeat protein; DMEM, Dulbecco’s modified Eagle’s medium; IMAC,
immobilized metal-ion-affinity chromatography; NA, numerical aperture; PARP-1, poly(ADP-ribose) polymerase 1; SEC, size-exclusion chromatography;
SPR, surface plasmon resonance; TRAIL, tumour-necrosis-factor-related apoptosis-inducing ligand; Z, benzyloxycarbonyl.
1 Present address: University of California, San Diego, 9500 Gilman Drive; M/C 0322, La Jolla, CA 92093, U.S.A.
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3 Present address: Nextech Invest Ltd, Scheuchzerstrasse 35, 8006 Zurich, Switzerland.
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Structure factors and co-ordinates of the caspase 7–DARPin D7.18 complex were deposited in the PDB under code 4LSZ.
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of up to 1023 different molecules, which can be used in
phage or ribosome display selection procedures [12,13]. Besides
their straightforward purification, these molecules combine
high thermodynamic stability with a cysteine-free framework,
rendering them highly attractive for intracellular applications.
Successful DARPin selections have been reported for numerous
target proteins [14–17]. We highlight the caspase-2-specific
[18] and the recently reported caspase-3-specific [19] inhibitory
DARPins that are of importance to the present study. Whereas
the caspase-2-targeted DARPin AR_F8 inhibits the enzyme in
a highly specific and allosteric manner, the caspase-3-selected
DARPin D3.4S76R is a highly specific competitive inhibitor.
To increase the availability of such caspase-specific and
potentially inhibitory DARPins, we have performed DARPin
selection to target human caspase 7. The DARPins D7.18 and
D7.43, reported in the present paper, share an overlapping epitope
and are highly selective binders for the active and the zymogenic
form of caspase 7. Although both DARPins do not affect the
function of the active enzyme, their binding to the zymogen
interferes with its proteolytic activation. A crystal structure of
the caspase 7–D7.18 complex unravels a potential mechanism
of caspase 7 inhibition, which has been tested in vitro as well as
in transfected HeLa cells.
MATERIALS AND METHODS
Reagents
All chemicals and growth media (including additives) were
purchased from Sigma/Fluka if not mentioned otherwise.
Primers were obtained from Microsynth, restriction enzymes and
polymerases were from New England Biolabs (NEB) and T4 DNA
ligase was purchased from Thermo Scientific. DARPin E3_5 is
an unselected non-binding DARPin, widely used as a control and
is described elsewhere [20].
DARPin selection by ribosome display and crude extract ELISA
Caspase-7-specific DARPin selection was performed as described
in [19] using a library containing NI3C and NI2C DARPins
[11,21]. Notably, before the caspase-7-panning step, the in vitro
translation ribosomal complex was incubated with the closest
homologues, caspases 3 and 6, for 30 min at 4 ◦C avoiding the
selection of cross-specific binders. In addition, off-rate maturation
was performed in rounds 3 and 4 by adding a 1000-fold
excess of unbiotinylated caspase 7 for 10 min. The full selection
was performed in the absence of caspase active-site inhibitors.
Selected DARPins were then probed against caspase 7 using crude
extract ELISA as described in [19], and DARPins surpassing a
signal over control of 5 were sequenced by Microsynth.
Protein expression and purification
Expression and purification of caspases 3, 6, 7 and 8 was
performed as described previously [22]. Purified enzymes were
frozen in liquid nitrogen and stored at −80 ◦C.
DARPin D7.18 and D7.43 were expressed in Escherichia coli
XL-1-Blue cells inoculated in 2YT medium (Bacto tryptone and
Bacto yeast extract from Becton Dickinson). Expression time
varied from 4–6 h up to overnight expression for crystallization
trials. After cell lysis, DARPins were purified by IMAC
(immobilized metal-ion-affinity chromatography) using Ni-NTA
(Ni2+-nitrilotriacetate) resins in gravity columns. Standard IMAC
wash and elution buffers were 50 mM Tris/HCl (pH 7.5), 400 mM
NaCl and 20 mM or 200 mM imidazole respectively. These
buffers were adapted according to the intended use of the proteins,
which are mentioned below. Eluted DARPins were stored at 4 ◦C
after the addition of sodium azide to a final concentration of
0.05%.
Production of procaspase 7
Procaspase 7 was obtained by mutagenesis of the active-
site cysteine residue (C186A) [23,24] using a QuikChange®
site-directed mutagenesis kit (Stratagene) and the pri-
mers 5′-CATTCAGGCTGCCCGAGGGACC-3′ and 5′-GGT-
CCCTCGGGCAGCCTGAATG-3′.
Expression and purification of procaspase 7 was performed
using the procedure for active caspase 7 [22].
Biotinylation of procaspase 7 and active caspase 7
Before chemical biotinylation, caspase 7 and its zymogenic form
were subjected to buffer exchange on a Superdex 200 10/300 GL
column (GE Healthcare), equilibrated in PBS (pH 7.4) containing
10% (w/v) sucrose. Protein-containing fractions were pooled and
subsequently used for chemical biotinylation using a 4-fold molar
excess of EZ-Link sulfo-NHS-LC-LC-biotin [sulfosuccinimidyl-
6′-(biotinamido)-6-hexanamido hexanoate] (Pierce). Coupling
mixtures of 700 μl of procaspase 7 (95 μM) or 700 μl of caspase
7 (62 μM) plus the calculated amount of biotin were incubated
for 15 min on ice. The reaction was then quenched by the addition
of Tris/HCl to a final concentration of 2.8 mM. Free biotin was
removed with an additional SEC (size-exclusion chromatography)
step using the same column and buffer as mentioned above.
Chemically biotinylated enzymes were frozen in liquid nitrogen
and stored in aliquots of 100 μl at −80 ◦C.
SPR (surface plasmon resonance) analysis
Binding affinities of DARPin D7.18 and D7.43 to caspase 7
and procaspase 7 were determined by SPR analysis using a
NeutrAvidin-coated NLC sensorchip with a ProteOnTM XPR36
machine (Bio-Rad Laboratories). Approximately 1000 RU
(response units) of biotinylated enzymes (80 nM in SPR buffer:
PBS and 0.005% Tween 20, filtered through a 0.22 μm pore-
size filter) were immobilized on the chip at a flow rate of
30 μl/min. Analyte solutions of a DARPin 2-fold dilution series,
from 512 nM to 8 nM, were injected beginning with the lowest
concentration. Each measurement was performed at 20 ◦C using
a flow rate of 60 μl/min with a contact time of 400 s and a
dissociation time of 1800 s. Obtained sensorgrams were processed
and analysed with the ProteOn Manager Software (version 3.1.0.6,
Bio-Rad Laboratories). Binding affinities were determined by
equilibrium analysis and kinetic data was obtained by curve-fitting
using the heterogeneous ligand model [25].
In vitro procaspase 7 cleavage assay
The caspase 7 zymogen processing in presence of DARPins
D7.18, D7.43 and E3_5 was monitored by incubation of
chemically biotinylated procaspase 7 (2.5 μM) with the
corresponding DARPins in a 10-fold excess. The reaction was
started by the addition of the cleaving enzymes caspases 3,
7 or 8 (all 500 nM) or caspase 9 (5 μM) and was performed
in PBS (pH 7.4) on ice for 48 h. Reactions with the cleaving
enzyme caspase 9 were incubated on ice for 62 h. Enzymatic
reactions were stopped by adding reducing SDS sample buffer
and subsequent boiling at 95 ◦C for 5 min. Reaction mixtures were
applied to SDS/PAGE (15%) and blotted on to nitrocellulose
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membranes using the Mini Trans-Blot® system (Bio-Rad
Laboratories). Membranes were blocked in PBS containing 5%
(w/v) non-fat dried skimmed milk powder for 60 min at room
temperature or overnight at 4 ◦C. After extensive washes with
PBS, streptavidin-conjugated horseradish peroxidase (Pierce,
1:2000 dilution in PBS) was incubated for 60 min at room
temperature. Protein bands were finally digitized at different
exposure times on a Fuji Las 4000 system using the SuperSignal
Pico Chemiluminescent Substrate (Pierce).
Crystallization of caspase 7 in complex with DARPin D7.18
Protein purification protocols were slightly modified for
crystallization: caspase 7 and DARPin D7.18 were both purified
by IMAC using 50 mM Hepes (pH 7.5), 400 mM NaCl and
20 mM or 200 mM imidazole for wash and elution respectively.
Then, complex formation was initiated by incubation of caspase
7 with DARPin D7.18 at a molar ratio of 1:5 for 10 min at
4 ◦C. The protein complex was separated from DARPin excess by
SEC using a Superdex 200 10/300 GL column (GE Healthcare)
equilibrated in 50 mM Hepes (pH 7.5) and 150 mM NaCl.
Fractions corresponding to the caspase–DARPin complex were
pooled, concentrated to ∼16 mg/ml and applied to crystallization
using the sitting-drop vapour-diffusion method.
Initial crystal hits appeared in 100 mM Tris/HCl (pH 7.5),
200 mM Li2SO4 and 25% PEG 2000 monomethyl ether, and
could be improved by additive screens to the final conditions
of 100 mM Tris/HCl (pH 7.6), 0.8 M sodium formate and 13%
PEG 4000. Crystals were stored in liquid nitrogen after addition
of 20% ethylene glycol for cryoprotection until data collection.
Data collection, structure determination and refinement
Data collection was performed at the synchrotron beamline
X06SA (Swiss Light Source, Villigen, Switzerland), and data
processing and scaling were carried out using XDS and XSCALE
[26]. To solve the complex structure, the PDB codes 3IBC [27]
for caspase 7 and 2P2C [18] for DARPin were applied for
molecular replacement using Phaser [28]. Final model building
was performed manually in Coot [29] with alternating refinement
steps by PHENIX [30] including TLS (Translation–Libration–
Screw-rotation) refinement [31]. For caspase–DARPin interface
analysis, the EPPIC server [32] (http://www.eppic-web.org)
was used and structure Figures were made using PyMOL
(http://www.pymol.org).
Modelling of the procaspase 7 interdomain linker
For better visualization of the flexible interdomain linker of
procaspase 7, a model was generated using the program
MODELLER 9.12 [33]. Co-ordinates of chain A of the procaspase
7 structure (PDB code 1K88) [23] were used as a template to
calculate 20 different models containing the interdomain linker.
A crystal structure of caspase 8 (PDB code 1QTN) [34] was
aligned with its substrate-binding cleft to the linker cleavage
site. For that purpose, the caspase-8-bound peptide inhibitor (Ac-
IETD-aldehyde, where Ac is acetyl) was mutated to the caspase 7
cleavage sequence (IQAD) using PyMOL’s mutagenesis wizard.
Cloning of DARPin constructs for mammalian expression
The production of fluorescent DARPins for mammalian
expression was performed in two cloning steps. First, DARPins
D7.18, D7.43 and E3_5 were amplified by PCR using Vent
polymerase and the primers 5′-TTCCTCCATGGGTATGAGA-
GGATCGCATCACCATCACCATCACGGATCCGACCTGGG-
3′ and 5′-CCCAAGCTTCTGCAGGATTTCAGCCAG-3′. PCR
products were purified by (1%, w/v) agarose gel electrophoresis,
digested using BamHI and HindIII for 2 h at 37 ◦C, and ligated
into a custom-made pQe vector containing the fluorescent
proteins, which was double digested by BamHI and HindIII
as well as dephosphorylated by rAPid alkaline phosphatase
(Roche). Ligation with T4 ligase led to a fusion protein of the
DARPin with a C-terminal eGFP or mCherry and a C-terminal
Myc tag.
In the second cloning step, the fusion proteins were transferred
by FX-cloning [35] into a FX-ready mammalian expression vector
based on the pcDNA5 vector (Invitrogen) using the primers 5′-
ATATATGCTCTTCTAGTAGAGGATCGCATCACCATCACC-
ATCAC-3′ and 5′-TATATAGCTCTTCATGCTCATTATTCATT-
CAAGTCCTCTTCAGA-3′. DNA for mammalian expression
was purified using a PureYieldTM Plasmid Midiprep System
(Promega) and sequenced by Microsynth (Supplementary Figure
S1a at http://www.biochemj.org/bj/461/bj4610279add.htm).
Cell culturing and transfection of HeLa cells
HeLa cells were cultured in a humidified incubator with a 5%
CO2 atmosphere using DMEM (Dulbecco’s modified Eagle’s
medium high glucose; Sigma #6429). Medium was supplemented
with 10% (v/v) FBS, 100 units/ml penicillin and 100 μg/ml
streptomycin.
For transient expression of fluorescent DARPins, HeLa cells
were seeded on to six-well plates and grown to 80% confluence.
For transfection, the medium was replaced by 1.2 ml of
fresh DMEM containing 2% (v/v) FCS and antibiotics. Each
transfection mixture consisted of a total amount of 3.4 μg of
DARPin–DNA and 5.1 μg of branched PEI (polyethyleneimine)
(25 kDa) mixed in 500 μl of DMEM without FCS and
antibiotics. In the case of double transfections, the molar ratio
of each construct was 1:1. After 20 min of incubation at room
temperature, the transfection mixture was added dropwise to
the cells. Successful transfection was determined 24 h after
transfection using a Nikon Eclipse TE300 inverted microscope
equipped with a xenon lamp and a Plan Fluor × 10/0.30 NA
(numerical aperture) objective (Nikon) (Supplementary Figure S2
at http://www.biochemj.org/bj/461/bj4610279add.htm). Transfer
to either 96-well plates (six wells per experiment) or chambered
coverglass (Nunc® Lab-Tek® II) was performed by trypsinization
with 0.1% trypsin/EDTA solution and a splitting rate of 1:5. The
cells were then grown in Phenol Red-free and Hepes-buffered
(25 mM) DMEM (high glucose from Gibco) supplemented with
10% (v/v) FBS and antibiotics.
Caspase activity measurements
The activity of caspase 3 and 7 was measured using the Caspase
Glo® 3/7 assay (Promega) according to the manufacturer’s
protocol with minor modifications. The medium of transfected
cells grown on 96-well plates was exchanged to fresh Phenol Red-
free DMEM (see above) containing one of the following well-
known apoptosis inducers [36–41]: TRAIL (tumour-necrosis-
factor-related apoptosis-inducing ligand) (100 ng/ml; Gibco),
etoposide (100 μM) and cisplatin (100 μM). Half of the cells per
experiment (i.e. three wells) were grown in apoptosis-inducer-free
medium and served as a control. Treated cells were incubated
for 3 h (TRAIL) or 24 h (etoposide and cisplatin) at 37 ◦C.
Then, 100 μM caspase inhibitor Z-DEVD-cmk (where Z is
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Table 1 DARPin affinities and kinetic constants
(a) Kinetic data
Target DARPin k a 1 (M−1 · s−1) k d 1 (s−1) K d 1 (nM) k a 2 (M−1 · s−1) k d 2 (s−1) K d 2 (nM) χ 2 of Rmax (%)
Caspase 7 D7.18 1.73 × 105 1.31 × 10−2 76 1.08 × 104 2.11 × 10−4 19.60 3.7
D7.43 4.44 × 104 9.97 × 10−4 23 6.65 × 105 1.77 × 10−2 27 7.2
Procaspase 7 D7.18 1.01 × 105 1.44 × 10−2 142 9.07 × 103 1.75 × 10−4 19 3.0
D7.43 2.99 × 104 1.41 × 10−3 47 4.73 × 105 2.39 × 10−2 51 4.9
(b) Equilibrium
Target DARPin K d (nM)
Caspase 7 D7.18 144.0 +− 35.7
D7.43 24.7 +− 4.9
Procaspase 7 D7.18 295.0 +− 84.3
D7.43 32.2 +− 7.0
benzyloxycarbonyl and cmk is chloromethylketone) (Bachem)
was added to non-transfected control cells and incubated for
10 min at room temperature. Caspase Glo® 3/7 reagent was
added to cells and mixed gently by pipetting. After incubation
for 40 min at room temperature, 50 μl of reaction mixture was
transferred to white 96-well plates (half area, Corning) to measure
the luminescence of each reaction on a multi-well plate reader
(Tecan Infinity M1000). The signal-to-noise ratio was calculated
using eqn (1) and statistical comparisons between the inhibitory
DARPin-expressing cells (D7.43/D3.4S76R, D7.43/E3_5 and
D3.4S76R/E3_5) were performed by one-way ANOVA and
Tukey’s post-hoc test in GraphPad Prism version 5.
Signal-to-noise ratio = signal − background average
S.D. of background
(1)
Live-cell imaging
Fluorescent time-lapse experiments were performed using a
confocal laser-scanning microscope (Leica SP5) equipped with
a resonant scanner (8000 Hz) for fast imaging, two sensitive
HyD detectors and an environmental chamber. Images (512
pixels × 512 pixels, 12 bits) were taken using a HCX PL APO CS
× 40/1.25 NA oil-immersion objective with a 3-fold line-average
and a minimal zoom of 1.7. Each experiment was observed at 25
positions every 1 min with autofocusing every 15 min.
Before imaging, the culture medium of transfected cells grown
on chambered coverglass (Nunc® Lab-Tek® II) was replaced
with fresh medium (DMEM, Phenol Red-free, as above). Cells
were imaged for approximately 20 min at 37 ◦C until TRAIL
was added to a final concentration of 50 ng/ml to induce
apoptosis. A time-lapse experiment was then performed for
5.5 h. Image analysis was carried out using ImageJ (version
1.45s, http://rsbweb.nih.gov/ij/) using the included cell counting
plugin in a modified version for cell counting and manual
determination of apoptotic time points. Cells that were displaying
rapid shrinkage followed by membrane blebbing were considered
as apoptotic and the time point of this event was noted. Cells
were marked as survivors in the case of survival after incubation
for 5.5 h in TRAIL-containing medium. Statistical analysis was
performed using GraphPad Prism version 5.
RESULTS
Selection and characterization of caspase-7-specific DARPins
DARPin selection was performed by ribosome display as
described in [19] using a NI2C and NI3C DARPin library
[11]. A total of 288 individual clones were picked after the
fourth round of selection and screened for binding to targeted
caspase 7 by crude extract ELISA. A total of 43 binders with a
strong signal were purified and subjected to SPR analysis for
a preliminary binding-affinity evaluation (results not shown).
The DNA of 24 high-affinity binders with a Kd below 500 nM
exhibited unambiguous and unique sequencing results. Sequence
alignments did not show highly conserved motifs at randomized
positions as experienced previously in two different DARPin
selections against caspase 3 [19,42]. Although our experience
with conserved DARPin features [43] would suggest different
binding interactions of the selected DARPin to caspase 7, seven
of the highest affinity binders possess an overlapping epitope,
as determined by competition ELISA (Supplementary Figure
S3a at http://www.biochemj.org/bj/461/bj4610279add.htm, and
results not shown). The selected binders were analysed further
for caspase 7 inhibition as described previously [19]. None of the
binders showed a detectable inhibitory effect (results not shown).
DARPin D7.43 had the highest affinity for caspase 7, but only
DARPin D7.18 crystallized in complex with caspase 7.
Selected DARPins bind to procaspase 7 and active caspase 7
To test whether the selected DARPins bind to the caspase 7
zymogen, complex formation with procaspase 7 was tested. Both
DARPins D7.18 and D7.43 formed a stable complex with procas-
pase 7 in solution as detected by SEC (Supplementary Figure S4a
at http://www.biochemj.org/bj/461/bj4610279add.htm). Binding
affinities to procaspase 7 and active caspase 7 were determined
by SPR analysis. Equilibrium analysis of the measured data led
to Kd values of 144 +− 35.7 nM and 295 +− 84.3 nM in the case
of binding of DARPin D7.18 to caspase 7 and procaspase 7
respectively. In line with the preliminary SPR data measured
after the selection procedure, DARPin D7.43 showed a 5-fold
higher affinity for caspase 7 with a Kd of 25.7 +− 4.9 nM. Notably,
the affinity of D7.43 for procaspase 7 (Kd of 32.2 +− 7.0 nM) was
identical compared with that of the active enzyme, which is one
order of magnitude smaller than the Kd of the D7.18/procaspase 7
interaction. Binding curves (Supplementary Figures S4b and S4c)
were fitted using the heterogeneous ligand model [25] and kinetic
values are summarized in Table 1.
DARPin binding to procaspase 7 affects zymogen-processing
in vitro
To address the question of whether binding of caspase-7-specific
DARPins to the zymogenic form interferes with its processing,
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Figure 1 In vitro inhibition of procaspase 7 activation by specific DARPins
Processing of the zymogenic form of caspase 7 was monitored using chemically biotinylated procaspase 7 (2.5 μM), incubated with a 10-fold excess of either caspase-7-specific DARPins D7.18
and D7.43 or control DARPin E3_5, as well as without DARPin. Zymogen processing was performed using (a) caspase 3 (500 nM, 48 h), (b) caspase 7 (500 nM, 48 h), (c) caspase 8 (500 nM, 48 h)
or (d) caspase 9 (5 μM, 62 h) at 4◦C. All reactions are affected by caspase-7-specific DARPins and noticeably slow down the complete processing to p20. The small subunit p10 is not visible due
to a very low accessibility during biotinylation. (e) A control without cleaving enzyme showed only small degradation of procaspase 7 over time. All blots were exposed at different exposure times
ranging from 5 s to 5 min. The final blot picture was composed using different exposure times that displayed the best visibility. The particular exposure time is indicated in the different panels. Insets
with black borders show exposure time of 5 min for better visibility of the processed bands. The contrast of the inset for caspase 7 (b) was slightly adjusted for better visibility of the faint bands.
Possible cleavage products and corresponding molecular masses are depicted in (f).
cleavage of the interdomain linker was tested in the presence
of D7.18, D7.43 and a non-binding control DARPin E3_5.
Chemically biotinylated procaspase 7 was incubated with a 10-
fold molar excess of DARPins and a cleaving enzyme, namely
caspase 3, 7, 8 or 9. These caspase family members are well
known as procaspase-7-cleaving enzymes during apoptosis [44].
Interestingly, both of the selected DARPins had an effect on
zymogen processing: in the case of caspase 3 as the cleaving
enzyme, the activation process was stalled considerably compared
with the control reactions (Figure 1a). Cleavage by caspase 8 or
9 was abolished to approximately 90% (Figures 1c and 1d).
Whereas reactions with caspase 7 displayed no fully processed
large subunit p20, a semi-processed form appeared as a fragment
of approximately 25 kDa (Figure 1b). This would correspond to
a caspase 7 fragment containing the full propeptide, the large
subunit and the interdomain linker (Figure 1f). However, caspase
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Figure 2 Crystal structure of caspase 7 in complex with D7.18
(a) Standard view of caspase 7 with the large subunit (p20) coloured dark grey and the small subunit (p10) in light grey. Active-site residues are displayed as green sticks. The N- and C-termini
of p10 and p20 respectively are indicated; the right-hand protomer is labelled with an apostrophe (‘). DARPin D7.18 with capping repeats (dark blue) and internal repeats (light blue) binds
sideways at the p20 subunit. (b) Binding interface close-up view. Interacting residues (distance <4.5 A˚) are depicted in stick representation. The major contribution for binding relies on a hydrophobic
pocket shaped by caspase 7 residues (labelled #), which harbours two deeply buried DARPin tryptophan residues (labelled *). (c) Superimposition of caspase 3 (cyan) unravels the specificity of
DARPin D7.18 for caspase 7. The hydrophobic pocket shaped by caspase 7 (grey cartoon and surface representation) is shrunk on caspase 3 due to a large Arg86 (labelled “) residue (depicted in
stick representation).
7 was reported to primarily remove the N-terminal propeptide
leading to a fragment of approximately 33 kDa [44], which can
also be observed in our assay and which would prevent the
formation of such a 25-kDa fragment. Since a fragment of 25 kDa
also appeared in a control assay with no cleaving enzyme and
procaspase 7 possesses low catalytic activity [45], we considered
that this fragment originates from self-processing. Furthermore,
the formation of truncated bands at 25 kDa has been observed
in human brain tissues after experimental traumatic brain injury
[46], suggesting a natural occurring cleavage product.
Selected DARPins do not affect procaspase 3 activation by
caspases 3 and 8
Chemically biotinylated procaspase 3 incubated in the presence
of D7.18, D7.43 and E3_5 was processed by active caspases 3 and
8. Neither a 50-fold molar excess of caspase-7-specific DARPins
nor the control E3_5 had an effect on zymogen processing
(Supplementary Figure S3b). In case of caspase 9 as the cleaving
enzyme, we could not observe detectable activation of caspase 3
(Supplementary Figure S3b) even with extended incubation time
and higher enzyme concentration. This can be explained by the
caspase 9 monomer/dimer equilibrium and the enzyme’s lower
activity in buffers without kosmotropic salts [22,47].
D7.18 and D7.43 have no effect on caspase 7 activity
The inhibitory effect of caspase-7-specific DARPins was tested
during the initial DARPin screening procedure using the
chromogenic substrate Ac-DEVD-AMC (AMC is 7-amino-4-
methylcoumarin). No reduction of activity was observed (results
not shown). In addition, the influence of D7.43 on the cleavage
of a natural caspase 7 substrate was analysed. We used the 116-
kDa protein PARP-1 [poly(ADP-ribose) polymerase 1], which is
a well-known substrate for caspase 3 and 7 that is cleaved after a
canonical cleavage site (DEVD) at position 216 [48]. The resulting
fragments can be observed using a PARP-1-specific antibody as
described previously [19]. The cleavage assay was performed in
presence of a 50-fold molar excess of D7.43 or E3_5 with no
observable decrease in PARP-1 cleavage (Supplementary Figure
S3c).
The caspase 7–D7.18 complex structure
Despite extensive screening with the highest-affinity binder
D7.43, we were not able to obtain crystals of this DARPin
in complex with caspase 7. However, crystal screening with
D7.18 yielded a caspase 7–D7.18 complex structure determined at
2.26 Å (1 Å = 0.1 nm) resolution. The structure revealed a
DARPin-binding epitope located laterally on the large p20 subunit
of the enzyme (Figure 2a), which is substantially different from
the one reported for other caspase-inhibitory DARPins [18,19].
Details of the structure determination and refinement
statistics are summarized in Supplementary Table S1
(http://www.biochemj.org/bj/461/bj4610279add.htm). One cas-
pase 7 heterotetramer (p20, p10)2 and two binding DARPin
molecules form the asymmetric unit of the crystal. The binding
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interface comprises residues located at β-strand β2 and α-helix α2
of caspase 7 and randomized positions of D7.18 (Supplementary
Figure S1a). Five hydrogen bonds and five salt bridges in
combination with a hydrophobic core form a total binding
surface area of 672 Å2. A significant binding contribution can be
assigned to a deep hydrophobic pocket on the caspase 7 surface,
shaped by Lys69, Ile71, Ile109, Tyr111, Leu122 and Ala126 located
on β-strands β1 and β2 as well as on α-helix α2. The pocket
accommodates two deeply buried tryptophan residues (Figure 2b)
of the DARPin (Trp46 and Trp78). Both tryptophan residues are
stabilized further by hydrogen bonds with caspase 7 residues:
Trp46 forms a hydrogen bond with the backbone carbonyl oxygen
of Asp107, whereas Trp78 is hydrogen-bonded to Tyr111. This pocket
not only provides a large hydrophobic binding area, but also
explains the binding specificity of D7.18. Superimposition of
a high-resolution structure of the closest homologue, caspase
3 (PDB code 2DKO) [49], on the caspase 7–D7.18 complex
structure reveals that the Ile109 homologue on caspase 3 (Arg86)
fills the pocket to the extent that it prevents binding of D7.18 to
caspase 3 (Figure 2c). This was confirmed by a caspase 7 mutant
(I109R), which does not bind to D7.18 (Supplementary Figure
S5f at http://www.biochemj.org/bj/461/bj4610279add.htm). In
the case of caspase 6, the sequence homologue Lys86 shrinks the
pocket and blocks a possible interaction with D7.18 (results
not shown). Caspase sequence alignments show that Ile109 of
caspase 7 is not conserved (Supplementary Figure S6a at
http://www.biochemj.org/bj/461/bj4610279add.htm) and thus is,
to a large extent, responsible for the binder’s high specificity.
However, Ile109 is not the only determinant for specificity between
caspase 7 and D7.18, since the introduction of this isoleucine
residue in caspase 3 (R86I) does not confer binding of the DARPin
on caspase 3 (Supplementary Figure S5e). Clearly, other non-
conserved residues (Lys69, Phe98, Val110, Ala117, Lys118, Leu125
and Lys153) of caspase 7 also contribute to the binding interface
(Supplementary Figure S6).
Double transfection of D7.43 and D3.4S76R reduces caspase
activity in apoptotic cells
The intracellular effect of a procaspase 7 cleavage inhibitor was
tested in combination with the previously reported highly specific
caspase-3-inhibitory DARPin D3.4S76R [19]. We transiently
expressed D7.43 and D3.4S76R in HeLa cells and induced
apoptosis with three different and well-characterized apoptotic
stimuli [36–41]: TRAIL, etoposide and cisplatin. Co-transfected
cells will have expression of D7.43 to prevent caspase 7 activation
and D3.4S76R to inhibit activated caspase 3. After the induction
of apoptosis, caspase activity can be measured using the DEVD-
based Caspase Glo® 3/7 assay. It has to be noted that short peptide-
based caspase substrates are not highly selective for an individual
family member [10] and therefore measured values will represent
an average of all cleaving proteases. Nevertheless, we expected
an observable decrease in caspase activity in the case of caspase
3 and 7 inhibition, since these enzymes are known as highly
active executioner caspases during apoptosis [50]. Indeed, D7.43-
and D3.4S76R-co-expressing HeLa cells exhibited significantly
reduced caspase activity of approximately 70–80% after the
induction of apoptosis with three different inducers (Figure 3).
Control experiments were performed using double-transfected
cells expressing either D7.43 and E3_5 or D3.4S76R and E3_5.
Remarkably, caspase activity was reduced by approximately 30–
50% in cells expressing D3.4S76R/E3_5, whereas the expression
of D7.43/E3_5 had no effect on proteolytic activity. This indicates
that the additional 20–30% reduction in activity, which has
Figure 3 Caspase activity in co-transfected HeLa cells with D7.43 and
D3.4S76R
Caspase activity of HeLa cells untreated (grey bar) or treated with apoptotic stimuli (white
bar) measured using the Caspase Glo® 3/7 assay. Double-transfected cells expressing
caspase-7-specific DARPin D7.43 and caspase-3-inhibitory DARPin D3.4S76R show a
significantly reduced caspase activity after treatment with (a) TRAIL (100 ng/ml, 3 h), (b)
etoposide (100 μM, 24 h) or (c) cisplatin (100 μM, 24 h) compared with cells which are
expressing E3_5 and either D7.43 or D3.4S76R (*P6 0.05; **P6 0.01; ***P6 0.001).
Control with non-transfected cells and Z-DEVD-cmk display complete abolishment of caspase
activity. All values are signal-to-noise corrected means +− S.D. (n = 3).
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Figure 4 Time-lapse experiment following apoptosis of HeLa cells induced by TRAIL
HeLa cells were double transfected with D3.4S76R–eGFP and D7.43–mCherry leading to double-fluorescent cells in the case of successful co-transfection. (a) Cells expressing both DARPins
(left-hand scatter plot, green/red fluorescent cells) survive for longer than non-expressing cells (right-hand scatter plot). Black lines indicate the mean +− S.D. time until cells show rapid shrinkage
and membrane blebbing. Distributions of all counted cells, either double-fluorescent (b) or non-fluorescent (c), show a Gaussian distribution (bin width = 1000 s). Sample images at the beginning
of the time-lapse experiment (d) show healthy and a few double-transfected cells. After 3 h 24 min of incubation with TRAIL (50 ng/ml) (e), all non-fluorescent cells died, whereas DARPin-expressing
cells survived (indicated by white arrowheads) or just entered programmed cell death. The mean time for indication of cell death hallmarks of double-transfected cells was determined as 3 h 22 min
(Table 2). DIC, differential interference contrast. Scale bars, 25 μm. Additional information is provided in Supplementary Figure S7, Supplementary Table S2 and Supplementary Movie S1 at
http://www.biochemj.org/bj/461/bj4610279add.htm.
been observed for D7.43/D3.4S76R-expressing cells, derives
from a successful inhibition of procaspase 7 activation. It
underlines further the high processivity of caspase 3, which has
been determined as the major executioner caspase during the
demolition phase of apoptosis [9].
Live-cell imaging
Live-cell experiments were performed to directly monitor the
effect of caspase inhibitory DARPins on the progression of
apoptosis. The extrinsic apoptotic pathway of co-transfected HeLa
cells was initiated by supplementation of the growth medium
with TRAIL. After the addition of the death ligand (50 ng/ml),
cells were imaged for 5.5 h using a confocal microscope. Images
were analysed for observable hallmarks of apoptosis, such as
rapid cell shrinkage and membrane blebbing [4]. Time points
for such observations were determined for each individual cell
and analysed statistically (Figure 4 and Supplementary Figure
S7 at http://www.biochemj.org/bj/461/bj4610279add.htm). To
distinguish between successfully transfected and non-transfected
cells, expressed DARPins were fused to either eGFP or
mCherry. Non-transfected cells, E3_5 double-transfected cells
as well as D7.43 and D3.4S76R single-transfected cells dis-
played the first observable signs of apoptosis after
approximately 1.5 h (Table 2, and Supplementary Table S2 at
http://www.biochemj.org/bj/461/bj4610279add.htm). In contrast,
D7.43- and D3.4S76R-co-expressing cells were less susceptible
to TRAIL-induced apoptosis and entered apoptosis after
approximately 3.3 h (Figure 4d and Supplementary Movie S1
at http://www.biochemj.org/bj/461/bj4610279add.htm). Further-
more, 23.5% of all counted D7.43/D3.4S76R-expressing cells
survived for more than 5.5 h in TRAIL-containing medium.
DISCUSSION
Specific targeting of highly homologous proteins brings along
many challenges. The caspase family with a sequence identity of
up to ∼50% has been thoroughly analysed using either peptide-
based inhibitors or small substrates, which both target the highly
conserved active site of the enzyme. Although well established,
these short peptides are known for their lack of selectivity due
to their consensus caspase-recognition sequence [10]. A more
promising approach to target caspases more specifically has been
reported by using small molecules that are binding to a region
outside the active site [51–53]. These small compounds bind at
an allosteric site in the central cavity of caspase 3 and 7, thereby
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Table 2 Survival statistics of transfected HeLa cells after induction of apoptosis with TRAIL (50 ng/ml)
See also Supplementary Table S2 at http://www.biochemj.org/bj/461/bj4610279add.htm.
D3.4S76R + D7.43 double transfection Number of cells Number of survivors Survival (%) Mean +− S.D. time to cell death (h:min:s)
Green/red fluorescent 187 44 23.5 03:21:37 +− 00:53:09
Non-fluorescent 282 1 0.4 01:23:01 +− 00:31:47
Total 469 45 9.6
trapping the enzymes in a zymogenic and inactive form. Larger
molecules such as proteins may overcome the selectivity problem
by increasing the interaction surface involving non-conserved
residues. In the past, DARPins have been shown to be suitable
tools for specific caspase targeting. AR_F8 was reported as the
first truly specific allosteric caspase 2 inhibitor [18]. Recently,
caspase 3 was specifically inhibited in a competitive manner using
DARPin D3.4S76R [19].
We have selected caspase-7-specific DARPins using ribosome
display [21]. By using this method, we could achieve high
selectivity by introducing additional pre-panning steps, which
have been performed against the closest homologues of caspase
7, namely caspases 3 and 6. The DARPins D7.18 and D7.43,
reported in the present paper, share an overlapping epitope on
caspase 7. Furthermore, both DARPins exhibited binding to
procaspase 7, although the zymogenic form was not included
during the selection procedure. This suggests a binding area
apart from the active-site cleft, where no major structural
rearrangements occur during zymogen activation. Interestingly,
binding of D7.18 and D7.43 to procaspase 7 interferes with the
interdomain linker cleavage by other caspases during activation
processes. Cleavage of this linker is a prerequisite for the
formation of active and mature caspase 7 [23,24]. The in vitro
assay demonstrated that if D7.18 or D7.43 were incubated with
procaspase 7, the interdomain linker cleavage by caspase 3 is
significantly reduced, whereas cleavage by caspase 7, 8 or 9
is almost completely abolished. Furthermore, both DARPins do
not interfere with in vitro processing of procaspase 3 by active
caspase 3 and 8, emphasizing a high selectivity of these binders for
caspase 7.
The high specificity of the selected binders can be explained
by the large binding interface between the two molecules, which
involves not only conserved, but also non-conserved, caspase 7
residues. In the particular case of D7.18, the protein complex
structure illustrates that many non-conserved caspase 7 residues
interact with the DARPin D7.18 (Supplementary Figure S6).
A noteworthy binding interaction occurs between two DARPin
tryptophan residues that are deeply buried in a hydrophobic pocket
formed by α-helix α1 and β-strands β1 and β2 lateral on the large
subunit p20. Interestingly, one of the pocket-shaping residues
(Ile109) is not conserved among other caspases, which possess
bulkier residues at this position leading to a smaller shape of
the pocket. Thus the crystal structure provides good evidence
that the chosen selection procedure, which included pre-panning
steps with closely related caspases, resulted in highly specific
binders for caspase 7 by targeting of non-conserved amino acids.
Notably, this strategy has been successfully applied in the past for
a caspase-3-specific DARPin selection [19].
Although both DARPins share a similar epitope on caspase
7, the detailed molecular interactions between caspase 7 and
D7.43 are different as illustrated by the binding data of a mutant
caspase 7_I109R, which shows no binding to D7.18, but less
effect on binding to D7.43. This does not exclude an overlapping
epitope for both binders, and further mutational studies would
be necessary to narrow down the interacting residues of
caspase 7.
To elucidate how procaspase 7 activation is affected by
the DARPins, the superimposition of the procaspase 7 crystal
structure (PDB code 1K88) [23] with the caspase 7–DARPin
structure (Figure 5a) provides further insights. Although slight
rearrangements occur at the location of the interdomain linker, the
overall α/β topology of the enzyme is kept constant, resulting in a
non-altered DARPin epitope. Thus we assume that binding of the
DARPin itself does not induce conformational changes that cause
the observed inhibition of linker cleavage. The interdomain linker
is highly flexible and not resolved in the procaspase 7 structure.
For better visualization of its intrinsic flexibility, we modelled
20 interdomain linker structures and superimposed these models
with the caspase 7–DARPin structure (Figure 5b). A putative
cleaving complex with caspase 8 was modelled by alignment
of the cleavage site of the intersubunit linker with the peptide
inhibitor found in the caspase 8 structure (PDB code 1QTN) [34]
(Figure 5c). This Figure visualizes that the cleaving enzyme would
sterically clash with the DARPin leading to a reduced or abolished
cleavage. Conclusively, DARPin binding most probably reduces
the accessibility of the flexible linker for an activating caspase
(Figure 5d) rendering the selected DARPins D7.18 and D7.43
highly specific inhibitors.
Once activated, caspase 7 can cleave its natural substrate
PARP-1 even in presence of D7.43 (Supplementary Figure S3c),
suggesting that no steric hindrance occurs between a bound
DARPin and PARP-1, an example of a caspase 7 substrate. In
this particular case, it is presumably due to a highly accessible
cleavage site. However, this observation does not exclude the
possibility that processing of other natural substrates can be
affected. A caspase-7-bound DARPin could also either provide
steric hindrance or potentially mask an important exosite on the
surface of the enzyme.
To investigate the intracellular effect of the selected DARPins,
we produced DARPins fused to fluorescent proteins and expressed
them in HeLa cells. Furthermore, we included the highly specific
caspase-3-inhibitory DARPin D3.4S76R [19] and focused the
cellular studies on DARPin D7.43 because of its 10- and 5-fold
higher affinity for procaspase 7 and active caspase 7 respectively in
comparison with D7.18. D7.43 and D3.4S76R double-transfected
HeLa cells exhibited a strongly reduced caspase activity after
the induction of apoptosis by different stimuli. We were not
able to achieve a 100% reduction in caspase activity as shown
in a control assay using the peptide-based caspase inhibitor Z-
DEVD-cmk. There are two explanations for this. (i) The transient
expression of DARPins. Transfection efficiency was determined
to be approximately 80%, resulting in 20% non-transfected cells,
which would be responsible for the measured residual caspase
activity. (ii) Caspase activity was measured using the Caspase
Glo® 3/7 assay, which is based on the short peptide DEVD. This
peptide is not primarily specific for caspases 3 and 7, and is
also cleaved by other caspases [10]. Notably, D7.43/E3_5-double-
transfected cells showed no reduction in caspase activity, which
c© The Authors Journal compilation c© 2014 Biochemical Society
A. Flütsch et al.: Caspase-modulating DARPins
104 Biochem. J. (2014) 461, 279-290
288 A. Flu¨tsch and others
Figure 5 Superimposition of the procaspase 7 crystal structure and proposed inhibition mechanism
(a) The crystal structure of procaspase 7 (yellow, PDB code 1K88 [23]) is superimposed on the caspase 7–D7.18 complex structure (C7p20 is coloured dark grey, C7p10 is light grey; DARPin capping
repeats are dark blue, internal repeats are light blue) and shows only small structural differences far away from the binding interface of the DARPin mainly at the N- and C-termini of p20 and p10
respectively. (b) Twenty calculated models of the interdomain linker (ribbon representation) of procaspase 7 are shown for better visualization of the linker flexibility. (c) Alignment of the active-site
cleft of caspase 8 (green surface representation) with the linker cleavage site demonstrates how the cleaving enzyme would sterically clash with the caspase 7 DARPin. (d) Putative mechanism of
zymogen-processing inhibition by caspase-7-specific DARPins. Binding of the DARPin sideways at the large subunit (p20) leads to a steric hindrance during cleavage of the interdomain linker
performed by a cleaving caspase.
can be explained by the high efficiency of caspase 3 in cleavage
of small peptide substrates. Double-transfected cells expressing
D3.4S76R and E3_5 control DARPin showed a less prominent
reduction of caspase activity compared with D7.43/D3.4S76R-
transfected cells. This not only underlines the high processivity
of caspase 3, but also proves the inhibitory effect of D7.43 on
procaspase 7 activation.
Additional live-cell imaging experiments with D7.43- and
D3.4S76R-expressing HeLa cells highlight the importance of
both executioner caspases 3 and 7 during apoptosis and
illustrates the potential for intracellular applications using
these DARPins. D7.43/D3.4S76R-double-transfected HeLa cells
were less susceptible to TRAIL-induced apoptosis compared
with non-transfected cells. Furthermore, D7.43 or D3.4S76R
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single-transfected cells entered apoptosis on average at the
same time compared with non-transfected cells, emphasizing a
functional substitution and redundancy of these two enzymes.
In summary, the present study describes the selection of two
highly specific caspase 7 binders, D7.18 and D7.43, sharing
an overlapping epitope on the protease. The lateral binding of
DARPin D7.18 was revealed by its complex structure with caspase
7, illustrating that high specificity can be achieved by targeting a
surface with non-conserved residues. Both selected DARPins can
bind to the zymogen as well as to the active enzyme. In addition,
pro-form binding interferes with interdomain linker cleavage
in vitro. Thus DARPins D7.43 and D7.18 can be applied to study
the process of procaspase 7 activation and autoproteolysis in vitro.
In combination with the caspase-3-inhibitory DARPin 3.4S76R,
HeLa cells show reduced caspase activity upon apoptotic
stimuli and are able to escape apoptosis by surviving longer
in death-ligand-supplemented growth medium. In particular,
our findings demonstrate that the two DARPins, D7.43 and
D3.4S76R, can be excellent intracellular tools for caspase 3
and 7 targeting. On one hand, D7.43 can be used to study the
role of caspase 7 activation during various cellular processes. On
the other hand, the combination of D7.43 and D3.4S76R can be
used to shut down the activity of caspases 3 and 7 in a highly
selective manner. For example, a stable cell line with inducible
promoters for these binders will not only contribute to a better
understanding of the two executioner caspases during apoptosis,
but also open the door to study other remaining and less active
caspases. Furthermore, these DARPins provide tools to further
study bypass mechanisms of apoptosis. We believe that these
molecules could serve as prototypes to develop novel therapeutics
for degenerative diseases.
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Structure factors and co-ordinates of the caspase 7–DARPin D7.18 complex were deposited in the PDB under code 4LSZ.
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Figure S1 Caspase-7-specific DARPins and mammalian expression constructs
(a) Sequence alignment of caspase-7-specific DARPins D7.18 and D7.43. The consensus sequence is shown in black with randomized positions in red. D7.18 residues involved in caspase binding
were determined by the EPPIC server (http://www.eppic-web.org [1]) and are marked in bold and underlined. D7.18 is a NI3C DARPin with three internal repeats harbouring two unintended framework
mutations, which are not involved in the binding interface. D7.43 has two internal repeats (NI2C) and one framework mutation. (b) Size-exclusion chromatogram (Superdex 200 5/150, GE Healthcare)
and SDS/PAGE (15 %) analysis of D7.18 and D7.43. Both DARPins elute at the expected retention volume of a monomer and show high purity on SDS/PAGE after IMAC purification. (c) For expression
in mammalian cells, DARPins were C-terminally fused to either eGFP or mCherry with a C-terminal Myc tag for detection. Both additional features are separated by short and flexible linkers. Using
FX cloning [2], fused DARPins were transferred from a pQe into a pcDNA5 vector for mammalian expression (see the Materials and methods section of the main text).
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Figure S2 Expression levels of transfected HeLa cells 24 h after transfection
Expression levels of fluorescent DARPins were analysed using a Nikon Eclipse TE300 inverted microscope with a Plan Fluor ×10/0.30 NA objective. All co-transfection experiments showed a
successful expression of the applied DARPins: D3.4S76R–eGFP and D7.43–mCherry, E3_5–eGFP and D7.43–mCherry, D3.4S76R–eGFP and E3_5–mCherry, E3_5–eGFP and E3_5–mCherry.
Non-transfected cells appeared as non-fluorescent. All fluorescent images were exposed for 150 ms for comparison. The transfection efficiency was approximately 70–80 %, estimated from images
taken with longer exposure times (not shown), although co-transfection of E3_5 constructs seemed to be less efficient. Cells were afterwards used for Caspase Glo® 3/7 assay and live-cell imaging.
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Figure S3 Additional experiments
(a) Competition ELISA with either coated D7.18 (left-hand panel) or D7.43 (right-hand panel) using chemically biotinylated caspase 7 for detection by streptavidin-conjugated alkaline phosphatase.
Both DARPins bind to similar epitopes visualized by a loss of signal on D7.18-coated wells and D7.43 used as competitor. However, D7.18 was not able to compete with D7.43 indicating a lower
affinity. A short summary of the competition ELISA protocol is provided. After every incubation step, a washing procedure was performed three times using PBS/Tween 20 (0.2 %). MaxiSorpTM plates
(Nunc) were coated with DARPins (100 μl at 60 nM) overnight at 4◦C. After blocking with PBS/BSA (0.5 %, 2 h at room temperature), a pre-incubated protein solution containing 120 nM caspase
7 (chemically biotinylated) and 512 nM competitive DARPin was applied and incubated for 60 min at 4◦C. Streptavidin-conjugated alkaline phosphatase (Roche) was incubated for 40 min at room
temperature, and phosphatase activity was detected on a plate reader (Tecan Infinity M1000) after the addition of p-nitrophenyl phosphate (pNPP). (b) Selected DARPins are specific for caspase 7
and do not interfere with zymogen processing of procaspase 3 by active caspases 3 and 8. The cleavage assay was performed as described in the Materials and methods section of the main text using
500 nM procaspase 3 (chemically biotinylated), a 50-fold excess of DARPin and either active caspase 3 (250 nM), caspase 8 (500 nM) or caspase 9 (5000 nM). However, procaspase 3 activation by
active caspase 9 was not very efficient in presence or absence of DARPins due to the enzyme’s low activity in kosmotropic salt-free buffers [3]. Procaspase 3 was made by site-directed mutagenesis
of the active-site cysteine residue (C163A) and purified as described in [3]. Biotinylation was performed as described for procaspase 7 (see the Materials and methods section of the main text). All
blots were exposed for 5 min. Marker was digitized and inserted into the blot at the correct position using Adobe Photoshop. (c) Binding of DARPin D7.43 to active caspase 7 does not influence the
processing of PARP-1, a well-known natural substrate of caspase 7 [4]. The cleavage assay was performed exactly as described previously [5] in duplicate with 150 nM caspase 7, 180 nM PARP-1
and 10- or 50-fold excess of DARPins. Blot was exposed for 5 min and contrast was adjusted for better visualization.
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Figure S4 DARPin binding to procaspase and active caspase 7
(a) Binding of DARPins to procaspase 7 could be observed on SEC using a Superdex 200 10/300 GL column (GE Healthcare). Procaspase 7 is eluted at a retention volume of approximately 14.5 ml
(broken line), whereas the formed complex is eluted at approximately 13.6 ml (continuous line). Binding characterization by SPR analysis of DARPin to active caspase 7 (b) and procaspase 7 (c).
Both DARPins D7.18 and D7.43 are able to bind to the active and the zymogenic form of the enzyme. Binding affinities were determined by equilibrium analysis and kinetic values by curve fitting of
the measured data (summarized in Table 1 of the main text).
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Figure S5 Mutational studies of caspase 3 and 7
The crystal structure of caspase 7–D7.18 revealed that Ile109 is to a large extent responsible for the binder’s specificity. To investigate this finding further, active caspase3 was mutated at the
homologous position (Arg86) to isoleucine using QuikChange® site-directed mutagenesis kit (Stratagene) and the primers 5′-GAAACTTGAAATATGAAGTCATTAATAAAAATGATCTTACACG-3′
and 5′-CGTGTAAGATCATTTTTATTAATGACTTCATATTTCAAGTTTC-3′. In addition, Ile109 on caspase 7 was mutated to arginine (the caspase 3 homologous side chain) using primers
5′-GGGTTTTGACGTGAGGGTCTATAATGACTGC-3′ and 5′-GCAGTCATTATAGACCCTCACGTCAAAACCC-3′. Both mutants, caspase 3_R86I and caspase 7_I109R, were purified as described in
[3], processed correctly (as shown by SDS/PAGE) and eluted at the same retention volume as the wild-type form (a and b). Caspase–DARPin binding was evaluated by SEC (Superdex 200 5/150,
GE Healthcare). As intended, D7.18 and D7.43 did not bind to wild-type caspase 3 (c), but they did bind to wild-type caspase 7 (d). Successful binding to caspase 7 can be seen by the elution of
a caspase–DARPin complex at earlier retention volume (marked with an arrow and a C for complex) as well as a disappearing caspase 7 elution peak at approximately 2.0 ml (marked with F for
free/unbound caspase). The late elution peaks at larger retention volumes (>2.1 ml) corresponds to an excess of free DARPin (marked with D). D7.43 is a NI2C DARPin and elutes at higher retention
volume compared with the NI3C DARPin D7.18. Notably, the unbound caspase 3 (wild-type) shows a small shoulder at a lower retention volume, originating from impurities in the sample as seen
on SDS/PAGE (inset, a). For DARPin D7.18, no complex peak could be observed in binding studies with caspase 3_R86I (e) as well as with caspase 7_I109R (f). These findings indicate that the
hydrophobic pocket formed by Ile109 is an important interaction in the binding interface between caspase 7 and D7.18 since a single mutation (I109R) disrupts the binding. It demonstrates further
that other non-conserved residues of caspase 7 are involved in the binding interface contributing to the binder’s specificity (see also Figure S6). No complex formation occurred between D7.43 and
caspase 3_R86I (g). However, D7.43 is able to bind to caspase 7_I109R (h). This suggests that the detailed molecular interaction between caspase 7 and D7.43 are different from that of D7.18 and
does not exclude the possibility that both DARPins share a similar epitope as shown in Figure S3.
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Figure S6 Sequence alignment of interacting residues and structural conservation
(a) Sequence alignment of caspase 7 residues involved in DARPin D7.18 binding compared with other human caspases. Interacting residues were determined by the EPPIC server
(http://www.eppicweb.org [1]) and sequence alignment of human caspases was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Amino acids were classified and coloured
accordingly into five groups. The following accession numbers were used for caspase sequences: P29466 (caspase 1), P42575 (caspase 2), P42574 (caspase 3), P49662 (caspase 4), P51878
(caspase 5), P55212 (caspase 6), P55210 (caspase 7), Q14790 (caspase 8), P55211 (caspase 9), Q92851 (caspase 10) and P31944 (caspase 14). (b) Caspase 7–D7.18 complex structure with
colorization of amino acid conservation. White surface represents no conservation between caspases 3, 6 and 7, whereas dark red areas are fully conserved in these three enzymes. DARPin D7.18
is shown in ribbon representation (blue) with marked N- and C-cap. As shown in (a), Asn112 in the binding interface is fully conserved and thus coloured dark red. Colorization by amino acid
conservation was made with ProtSkin (http://www.mcgnmr.mcgill.ca/ProtSkin/ [6]) and PyMOL (http://www.pymol.org). (c) Close-up view of the hydrophobic pocket shaped by caspase 7 residues
harbouring two buried DARPin tryptophan residues (*) (see also Figure 2c of the main text). Although several residues involved in pocket formation are partially conserved, Ile109 is not conserved.
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Figure S7 Time-lapse experiments following apoptosis of HeLa cells induced by TRAIL
Double-transfected HeLa cells with E3_5–eGFP and E3_5–mCherry (a) served as a double-transfection control, whereas single-transfected cells with D7.43–mCherry (b) or D3.4S76R–eGFP (c)
should clarify the effect of each individual DARPin to the survival behaviour of double-transfected cells (see also Figure 5 of the main text and Movie S1). DARPin-expressing cells were counted
when fluorescent (e.g. green/red fluorescent in a) and compared with non-fluorescent cells (statistics are given in Table S2). Counted cells in all experiment show a Gaussian distribution (bin
width = 1000 s) and similar averages of time until rapid cell shrinkage and membrane blebbing can be observed.
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Table S1 Data collection and refinement statistics
Values in parentheses are for the highest resolution shell.
Parameter Statistic
Data collection
Space group P21
Cell dimensions
a, b, c (A˚) 59.84, 82.31, 95.08
α, β , γ (◦) 90.0, 91.9, 90.0
Resolution (A˚) 50–2.2
Wavelength (A˚) 1.0
Rsym (%) 4.4 (50.5)
Completeness (%) 99.2 (99.4)
I/σ (I) 26.94 (5.06)
Refinement
Resolution (A˚) 2.26
Rwork/R free 17.3/20.6
Number of atoms
Protein 6104
Water 161
B-factors
Protein 59.9
Water 54.4
RMSD
Bond length (A˚) 0.008
Bond angle (◦) 1.06
Ramachandran
Preferred (%) 98.6
Allowed (%) 1.4
Outliers (%) 0
Table S2 Survival statistics of transfected HeLa cells after induction of apoptosis with TRAIL (50 ng/ml)
Number of cells Number of survivors Survival (%) Mean +− S.D. time to cell death (h:min:s)
E3_5 double transfection
Green/red fluorescent 162 1 0.6 01:31:22 +− 00:44:48
Non-fluorescent 270 0 0.0 01:33:00 +− 00:41:25
Total 432 1 0.2
D7.43 transfection
Red fluorescent 216 0 0.0 01:18:25 +− 00:37:41
Non-fluorescent 369 2 0.5 01:31:06 +− 00:39:01
Total 585 2 0.3
D3.4S76R transfection
Green fluorescent 221 9 4.1 01:31:58 +− 00:41:12
Non-fluorescent 314 15 4.8 01:32:15 +− 00:43:05
Total 535 24 4.5
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ABSTRACT: Designed ankyrin repeat proteins (DARPins) are well-established binding molecules
based on a highly stable nonantibody scaffold. Building on 13 crystal structures of DARPin-target
complexes and stability measurements of DARPin mutants, we have generated a new DARPin
library containing an extended randomized surface. To counteract the enrichment of unspecific
hydrophobic binders during selections against difficult targets containing hydrophobic surfaces
such as membrane proteins, the frequency of apolar residues at diversified positions was drasti-
cally reduced and substituted by an increased number of tyrosines. Ribosome display selections
against two human caspases and membrane transporter AcrB yielded highly enriched pools of
unique and strong DARPin binders which were mainly monomeric. We noted a prominent enrich-
ment of tryptophan residues during binder selections. A crystal structure of a representative of this
library in complex with caspase-7 visualizes the key roles of both tryptophans and tyrosines in pro-
viding target contacts. These aromatic and polar side chains thus substitute the apolar residues
valine, leucine, isoleucine, methionine, and phenylalanine of the original DARPins. Our work
describes biophysical and structural analyses required to extend existing binder scaffolds and sim-
plifies an existing protocol for the assembly of highly diverse synthetic binder libraries.
Keywords: DARPins; synthetic binder libraries; library assembly; structure-based protein engineer-
ing; protein-protein interactions; in vitro selection; ribosome display
Introduction
Protein-protein interactions play an essential role in
every living organism. B cells, for example, are a
major component of the adaptive immune system
and generate specific antibodies to combat invading
pathogens and viruses. Starting in the 1970s, scien-
tists have acquired technologies enabling the selec-
tion of monoclonal antibodies against desired protein
targets initially using the hybridoma technology
which relies on the immunization of mice.1 Over the
years, selection methods have been expanded to in
vitro approaches that became available with the
development of phage display2 and ribosome dis-
play.3 Thereby, the binder selection process was
transferred from animals into the test tube where
experimental conditions can be controlled.
In vitro display methods couple the folded bind-
ing protein (phenotype) physically to the genetic
information (genotype). This is achieved by either
fusing binders to phage surface proteins in phage
display or by forming stable ternary complexes of
mRNA, ribosome, and the nascent polypeptide chain
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in ribosome display. Large combinatorial gene libra-
ries typically encoding for 109 to 1012 possible binder
molecules are the centerpiece of every in vitro selec-
tion technique. With the exception of binders based
on small peptides (e.g. bicyclic peptides4), binding
protein libraries are based on binding scaffolds. Tra-
ditionally, antibody fragments such as Fabs5 and
scFvs6 served as scaffold which were either cloned
from natural sources to form na€ıve libraries7 or con-
structed in vitro by genetic engineering into syn-
thetic libraries.8 To overcome some of the
undesirable biophysical properties of antibodies such
as disulfide bonds, protein aggregation, and low
expression yields, novel scaffolds have been
exploited to introduce randomized surfaces
(reviewed in Ref. 9–11). Among the nonantibody
scaffolds, designed ankyrin repeat proteins (DAR-
Pins) belong to the best characterized molecules.12
Naturally occurring ankyrin repeat proteins consist
of tandem arrays of ankyrin repeat modules and
mediate protein-protein interactions mainly in
eukaryotic cells.13 Each repeat module consists of 33
amino acids and folds into a b-turn followed by two
anti-parallel a-helices and a loop that connects to
the next repeat. Ankyrin repeat modules assemble
into elongated and slightly curved structures
thereby shaping a concave surface that forms spe-
cific contacts with binding partners.14 The original
DARPin library was constructed following a consen-
sus design approach, in which naturally variable
amino acid positions were subjected to randomiza-
tion and conserved residues were defined as invari-
ant framework residues.15 Typically, DARPins
consist of two to three internal repeats that are
flanked by an N- and a C-terminal capping repeat
(N- and C-cap) which are then called N2C and N3C
DARPins, respectively. DARPins are thermodynami-
cally very stable due to tight and regular packing of
the repeat segments and conserved hydrogen bond-
ing networks.16,17 DARPins have been raised against
a plethora of target proteins using ribosome and
phage display.3,18–25 Of note, several successful in
vitro selections of DARPins against integral mem-
brane proteins have been reported, underscoring the
suitability of the scaffold to target “difficult to han-
dle” proteins.26–30
Target specific binders can be used in a multi-
tude of applications: they carry drugs to the desired
target in the body (e.g. in tumor targeting19,23,31),
serve as tools in enzymology to inhibit kinases and
proteases in the reducing milieu of the cell inte-
rior,22,32,33 are used as affinity probes to discover
novel conformational states of membrane proteins,29
and have been shown to modulate the function of
membrane transport proteins in vivo.28,30
In the context of membrane protein crystallog-
raphy, the use of binders as crystallization aids has
raised particular interest.28,34,35 Although a high-
resolution structure of the membrane protein AcrB
in complex with DARPins has been reported,28,36
the selection of such binders against membrane
proteins often turned out to be difficult.26,29 A
recurrent problem is the enrichment of hydrophobic
binders that are prone to form higher oligomeric
species and unspecifically bind to transmembrane
proteins.29,30
Here we describe the design, construction, char-
acterization, and successful application of a second-
generation DARPin library that was built based on
the information provided by the many target
protein-DARPin complex structures obtained in the
past decade. We analyzed the DARPin binding inter-
faces of all available structures to modify and extend
the randomized surface. Regarding the framework,
we reduced the surface entropy of the DARPin back-
side to be favorable for forming crystal contacts. To
minimize problems in enriching unspecifically aggre-
gating binders due to hydrophobic surface patches,
apolar residues were omitted in the randomized
positions. To compensate for the reduced hydropho-
bicity, the library is enriched in tyrosines that have
been demonstrated to be particularly suited to medi-
ate molecular contacts in protein-protein interac-
tions.37 The library was validated in test selections
against caspase-3, caspase-7, and AcrB and a crystal
structure of a new DARPin in complex with caspase-
7 was solved at 1.7 A˚ resolution.
Results
Analysis of the randomized DARPin surface
based on crystal structures
Since the construction of the original DARPin
library by Binz et al.15 [Fig. 1(A)], 18 crystal struc-
tures of DARPins in complex with their target pro-
teins have been reported.12,21,22,28,36,38–46 We
analyzed all DARPin-target protein interfaces of
crystals solved at resolutions of 3 A˚ and better using
the EPPIC server (www.eppic-web.org)47 (Supporting
Information File “DARPin_interfaces.xls”). Twenty-
two interfaces found in 13 crystal structures were
taken into account for analysis (some interfaces
were present twice in the asymmetric unit). The
buried surface area (BSA) upon complex formation
of every amino acid residue position was calculated
as percentage of total BSA [Fig. 2(A), Supporting
Information File “DARPin_interfaces.xls”)]. As
intended by design, the majority (56 % of total
BSA) of protein-protein interactions were mediated
by randomized residues located at internal repeats.
Interactions involving residues of the third repeat
appear underrepresented because our dataset con-
tained numerous N2C DARPins lacking a third
repeat. The randomized residue at position 33
according to the ankyrin repeat sequence defined
by Binz et al.15 [Fig. 1(B)] is only marginally
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involved in target contacts, because it points away
from the concave randomized surface of the DAR-
Pin scaffold. In contrast, the aspartate of the DxxG
motif (position 1 of the ankyrin repeat) and a leu-
cine in the first a-helix of the ankyrin repeat (posi-
tion 10) were found to be involved in target
contacts, although these residues were not diversi-
fied in the original DARPin library [Fig. 2(A)].
Interestingly, invariant residues of the N- and
C-cap were frequently involved in molecular con-
tacts with target proteins providing 44% of total
BSA. Our analysis further allowed us to plot the
burial of each of the 20 amino acids as percentage
of total BSA and to specifically highlight contacts
mediated by diversified residues [Fig. 2(B)]. Major
contacting residues (threshold 4% of total BSA) are
D, K, R, N, L, I, M, F, Y, and W. Limiting this anal-
ysis to the diversified residues, the major players
are L, I, F, Y, and W. Cysteines which are absent in
DARPins and prolines which are completely buried
in folded DARPins are not involved in target con-
tacts. In contrast to a recent analysis of DARPin
Figure 1. Randomization of the internal DARPin repeat. The second internal repeat (IR2) of the original (off7, left panel, PDB
1SVX) and new (C7_16, right panel, PDB 4JB8) library is shown in the context of the N3C DARPin (A) and in isolation (B). Diver-
sified positions are highlighted as colored side chains shown as sticks. The repeat sequences and the permitted residues of
the randomized positions are given in (C).
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interfaces in which the number of tyrosines
involved in target contacts were counted under the
condition that burial is greater than 1 A˚2,48 our
quantitative analysis did not assign a special role
to Y relative to L, I, F, and W. Furthermore, we
found nonrandomized D, K, R, and N residues of
the capping repeats to be frequently involved in
target contacts.
Randomization scheme for the internal ankyrin
repeat module of the new DARPin library
Taking these findings into account, the randomiza-
tion pattern of the internal repeat defined by Binz et
al. was modified. As in the original DARPin library,
the ankyrin repeat positions 2, 3, 5, 13, and 14 were
subjected to randomization [Fig. 1(B)]. Randomized
position 33 of the original library was rarely
Figure 2. Analysis of target contacts by original DARPins based on 13 crystal structures. (A) The relative contribution of each
DARPin sequence position to the total buried surface area (BSA) of all analyzed DARPins is plotted (i.e. the sum of all positions
equals 100%). Randomized positions of the original library are indicated by red diamonds. Residues which were subjected to
changes or randomization in the new library are highlighted using the same color scheme as in Figure 1. (B) Amino acid usage
of the analyzed DARPins is visualized as % BSA of total BSA. Blue bars depict all contacting residues (total BSA of 100%) and
red bars depict diversified residues only (total BSA of 56%).
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involved in protein interactions and thus defined as
invariant serine. In addition, the aspartate at posi-
tion 1 and the leucine at position 10 of the ankyrin
repeat module were randomized. Because these two
residues are important for the structural integrity of
the DARPin framework,49 the randomization was
restricted to a more narrow range of permitted
amino acid residues (see sections below). By using
trinucleotides phosphoramidites for the synthesis of
oligonucleotides, the amino acid composition for
each residue position was adjusted.50,51 In the origi-
nal DARPin library, the randomized positions were
permitted to contain any amino acid except P, G,
and C.15 Small and polar/charged amino acids (A, D,
E, H, K, N, Q, R, S, T) were overrepresented with
7% each compared with bulkier and hydrophobic
residues (F, I, L, M, V, W, Y) with 4.3% each. During
DARPin selections against membrane proteins we
repeatedly observed the enrichment of hydrophobic
binders containing multiple apolar residues in the
randomized positions (not shown). Such DARPins
were found to promiscuously bind to diverse trans-
membrane proteins and were prone to form soluble
aggregates during DARPin expression and purifica-
tion.29,30 For the new DARPin library, we therefore
limited the number of permitted residues in the
randomized positions and excluded, besides G, P,
and C also the hydrophobic amino acids I, L, V, M,
and F. With these measures, we aimed at generating
more hydrophilic DARPins that are expected to be
less prone to unspecific hydrophobic interactions.
The composition of permitted amino acids in the five
randomized positions 2, 3, 5, 13, and 14 was biased
towards small and polar amino acids and tyrosine
and contain the following amino acid composition: A,
S, T, N, and Y; 12% each and D, E, R, K, Q, W, and
H; 5.7% each.
Randomization of residue D1 in the b-turn
In the analyzed DARPin structures, the b-turn
aspartate contributes 2.6% of total BSA [Fig. 2(A)]
and in naturally occurring ankyrin repeat proteins,
this position is not highly conserved.15 However,
the carboxyl moiety of this residue stabilizes the b-
turn of the DARPin scaffold by interacting via two
hydrogen bonds [Fig. 3(C)].49 To warrant stability
of the b-turn of the new DARPin library, only resi-
dues D, N, T, and S were permitted at position 1.
N, T, and S are expected to establish hydrogen
bonds similar to the ones formed by aspartate. To
verify our assumption experimentally, the b-turn
aspartate in the middle repeat of the previously
characterized unselected DARPin E3_5 was
mutated to serine (D77S). Although serine is short-
ened by one methylene group compared with the
original aspartate, E3_5_D77S was found to be
more stable in guanidinium hydrochloride
(GdnHCl) unfolding experiments as compared with
wild type E3_5 and the midpoint of unfolding (Dm)
was increased by 0.5M GdnHCl [Fig. 3(B)].
E3_5_D77S was crystallized and its structure was
solved at a resolution of 1.7 A˚ (Table I). A super-
imposition of E3_5_D77S with wild type E3_5
revealed only marginal structural changes at the
b-turn of the middle repeat [Fig. 3(C)]. As
expected, the hydroxyl group of S77 stabilizes the
b-turn by virtue of two hydrogen bonds. Tyrosine
at position 5 of the first internal repeat (Y48) fills
the space that became vacated by the D to S
mutation. As a consequence, the entire b-turn of
the first repeat is shifted towards the middle
repeat by 0.5 to 1 A˚ (measured at the Ca posi-
tions). The more intimate contacts between the
first and the second internal repeat might explain
the increased stability of the E3_5_D77S mutant
compared with wild type E3_5.
Randomization of residue L10
The leucine residue at position 10 was kept invari-
ant in the original DARPin library mainly due to
stability considerations15 although it is not con-
served in natural ankyrin repeat proteins. In
DARPin-target protein co-crystal structures, L10 is
frequently found to mediate molecular contact and
contributes 2.7% of total BSA [Fig. 2(A)]. For this
second-generation DARPin library, we therefore
permitted the five residues A, S, T, V, and L at this
position. To test for potential biochemical and struc-
tural consequences of randomizing this residue,
L10 of the middle repeat of DARPin E3_5 was
replaced by alanine (L86A) and analyzed
by GdnHCl unfolding experiments. Dm of the
E3_5_L86A mutant was decreased by 0.5M GdnHCl
[Fig. 3(B)]. The crystal structure of the E3_5_L86A
mutant was solved at a resolution of 1.6 A˚ (Table I)
containing two E3_5_L86A molecules per asymmet-
ric unit. In one DARPin of the asymmetric unit
(chain B), the highly conserved histidine in position
9 of the first internal repeat (H52) adopts two
rotamer conformations. One rotamer establishes a
hydrogen bond with the consecutive middle repeat
as in wild-type E3_5, while the second rotamer fills
the space that was occupied by the bulky L86 in
wild-type E3_5 [Fig. 3(D)]. As a consequence, the
hydrogen bonding contact between the first and the
second internal repeat segments appears to be
weakened which might explain the decreased sta-
bility of the E3_5_L86A mutant. However, in the
other E3_5_L86A molecule (chain A) of the asym-
metric unit, H52 shows a position identical to that
of wild type E3_5 (not shown).
Modification and randomization of the capping
repeats
Two non-randomized and bulky side chains of the N-
cap (E20 and R23) were frequently found to interact
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with the target protein and contribute to 1.3% and
5.6% of total BSA, respectively [Fig. 2(A)]. We chose
not to randomize the N-cap, but to replace these two
residues with smaller ones (E20D and R23S), in
order to reduce sterical interference with DARPin
binding [Fig. 4(A,C)]. Although the C-cap was not
randomized in the original library, it matches the
internal repeats with regard to surface burial upon
complex formation [Fig. 2(A)]. Furthermore, the C-
cap of the original library was found to be the least
stable repeat of DARPins. C-cap packing to the
internal repeat was stabilized employing combined
computational and experimental methods.52 For this
second generation DARPin library, we chose the
sequence for an improved C-cap corresponding to
the stabilized “mutant 5” described previously.52,53
In contrast to the original DARPin library, the
b-turn of the C-cap was subjected to randomization
Figure 3. Biophysical and structural characterization of E3_5 mutants. (A) E3_5 was mutated at the second internal repeat at
residues D77S or L86A representing randomized positions 1 and 10 in the new DARPin library. (B) The stability of the mutants
was analyzed by GdnHCl equilibrium unfolding monitored by CD spectroscopy. Data were fitted to a biphasic sigmoidal equa-
tion and the midpoints of the second transition (Dm,2) were as follows: wild type, 5.01M; D77S mutant, 5.48M; L86A mutant,
4.49M. (C and D) Structures of the D77S and the L86A mutants were solved by X-ray crystallography. (C) S77 in the D77S
mutant establishes two hydrogen bonds similar to the ones of the wild type E3_5 and thereby stabilizes the b-turn (top). A
superimposition of both structures reveals a shift of Y48 toward the middle repeat in the D77S mutant (bottom). (D) In the struc-
ture of the L86A mutant, H52 of the first repeat adopts two alternate rotamer positions, one of which occupying the space
vacated by the L to A mutation (lower panel). In wild-type E3_5, H52 stabilizes the DARPin fold by establishing a hydrogen
bond with the internal repeat (upper panel).
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using amino acid compositions identical to the ones
of the internal repeats [Fig. 4(A,C)].
Surface entropy reduction in the new DARPin
library
Derewenda and colleagues have postulated that
bulky charged side chains at the surface of proteins,
in particular lysines and glutamates form an
entropic barrier that counteracts the formation of
crystal contacts.54 The original DARPin library has
a glutamate at position 21 (E21) and a lysine at
position 25 (K25) at the DARPin backside [Figs.
1(B,C) and 4(B)]. These residues were chosen to
keep DARPins soluble. In addition, the lysine exhib-
its a high a-helical propensity,55 which appears
important for the integrity of the DARPin scaffold.
In the new library, we chose to replace E21 with a
shorter aspartate (thereby maintaining the negative
charge at this position) and K25 with an alanine,
whose a-helical propensity is even higher than the
one of lysine. To investigate whether the loss of
these changes have any adverse influence on the oli-
gomeric state of a N3C DARPin, we introduced these
mutations in DARPin_55, a specific binder of the
ABC transporter MsbA.29 Both wild-type and
mutant DARPin_55 were found to be monomers as
judged from size exclusion chromatography [Sup-
porting Information Fig. S1(A)] and thus the loss of
three positive charges due to the K25A mutations
did not lead to the formation of DARPin oligomers
in this test case. Mutant DARPin_55 was still co-
migrating with MsbA on SEC (not shown).
Equilibrium unfolding using GdnHCl revealed a sta-
bilization of DARPin_55 upon introduction of these
mutations [Supporting Information Fig. S1(A)].
Assembly and initial quality check of the new
DARPin library
An N3C DARPin library containing three internal
repeats flanked by a N- and a C-terminal cap was
assembled as described previously for the original
DARPin library.15 The caps and internal repeats
were generated by PCR followed by ligating the
fragments repeat by repeat using type IIS restriction
enzymes (a detailed protocol is given in Materials
and Methods). The theoretical library diversity of
the N3C library is calculated as follows. Each of the
three internal repeats contains five randomized posi-
tions with 12 permitted residues, position 1 with
four allowed residues, position 10 with five permit-
ted residues, and position 26 with three permitted
residues. Each internal repeat therefore exhibits a
theoretical diversity of 125 3 4 3 5 3 351.5 3 107
variants. The diversity of the C-cap is 576 owing to
two randomized positions with 12 permitted residues
(122 variants) and position 1 of the b-turn (four var-
iants). The N-cap is not randomized. The theoretical
diversity of the new N3C DARPin library is there-
fore 1.9 3 1024 and lies in a similar range as the
original DARPin library, whose theoretical diversity
amounted to 3.8 3 1023.15 The practical diversity of
the library was estimated to be 1011 variants (see
Materials and Methods). To evaluate the quality of
the new library at the DNA level, the assembled
library was cloned into an expression vector (pQE30)
and 26 randomly picked library members were
sequenced and named DARPin D1-D26. Twenty out
Table I. Data Collection and Refinement Statistics
E3_5_D77S
(PDB: 4J8Y)
E3_5_L86A
(PDB: 4J7W)
C7_16-caspase-7
(PDB: 4JB8)
Data collection
Space group P212121 (19) P212121 (19) C2 (5)
Cell dimensions
a, b, c (A˚) 34.88; 53.63; 78.38 44.37; 78.59; 82.23 143.88; 52.51; 60.09
a, b, c () 90.00; 90.00; 90.00 90.00; 90.00; 90.00 90.00; 96.92; 90.00
Resolution (A˚) 50–1.7 (1.74–1.7) 50–1.6 (1.64–1.6) 50–1.7 (1.74–1.7)
Rmerge (%) 6.0 (39.5) 9.4 (32.6) 4.0 (56.8)
I/rI 22.21 (5.37) 19.20 (11.87) 23.21 (3.11)
Completeness (%) 99.4 (99.4) 98.9 (99.4) 99.9 (99.9)
Redundancy 5.6 (5.1) 8.2 (8.8) 6.8 (6.9)
Refinement
Resolution (A˚) 50-1.7 50-1.6 50-1.7
No. reflections (work/test) 15869/836 36343/1913 47187/1967
Rwork/Rfree 17.16/20.76 16.79/19.19 17.22/19.37
No. atoms
Protein 1192 2393 3107
Water 167 414 257
B-factors
Total 21.94 11.56 41.06
R.M.S deviations
Bond lengths (A˚) 0.004 0.006 0.006
Bond angles () 0.874 1.033 1.008
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of the 26 members were found to be in frame (77%),
which indicates that the primers used to perform
the assembly PCR were of good quality (Supporting
Information Fig. S2). The codon frequencies of the
randomized positions were found to be in decent
agreement with the intended mixture (Fig. 5).
Eighteen of the 20 in-frame DARPins were tested
for expression in Escherichia coli and 16 DARPins
were purified at high yields. Fifteen out of these 16
DARPins were separated by SEC (Supporting
Figure 4. Modifications and randomizations at the capping repeats and surface entropy reduction of the DARPin backside.
DARPins of the original (off7, left, PDB 1SVX) and new (C7_16, right, PDB 4JB8) library are shown in cartoon representation
with diversified/modified residues highlighted as colored sticks or in surface representation. (A and C) Bulky E20 and R23
residues of the N-cap are frequently involved in target contacts [Fig. 2(A)] and were exchanged for the smaller D20 and S23
in the new library. The positions 1–3 of the C-cap (b-turn) were subjected to randomization in the new library following the
same scheme as depicted in Figure 1(C). (B) DARPins viewed from their backside. By mutating E21D and K25A in each inter-
nal repeat [Fig. 1(C)], the surface entropy of the DARPin backside was reduced in the new library, which is expected to facili-
tate crystallization. (C) Sequences of the N- and C-caps are shown and modifications of the original library are highlighted.
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Information Fig. S3) and further analyzed by equi-
librium unfolding using GdnHCl (see below).
DARPin selections against two human caspases
and membrane transporter AcrB
As a proof of principle we decided to select binders
of the new library against human caspase-3 and
caspase-7 and multidrug transporter AcrB from
E. coli, which served as protein targets in previous
DARPin selections in our laboratory using the origi-
nal library (Refs. 28 and 40 and unpublished
results). The first three selection rounds were car-
ried out using the surface panning method, followed
by a fourth round of solution panning. In order to
increase the specificity during selection, a pre-
panning step with biotinylated maltose binding pro-
tein (MBP) was performed in every round. Starting
from round two, a cross-panning analysis, in which
pre-panning on target protein was followed by pan-
ning on MBP was introduced. In this analysis,
target-specific binders are removed in the pre-
panning step and remaining unspecific binders are
captured by MBP in the panning step. In case of
binder enrichment against the desired target, com-
paratively low amounts of mRNA are expected to be
recovered in such cross-panning experiments.
Already in the second selection round, mRNA recov-
ery was higher in the normal panning procedure
(pre-panning on MBP followed by panning on target)
compared with the cross-panning analysis, indicat-
ing that the enriched DARPin pools were target spe-
cific [Fig. 6(A)].
ELISA - analysis and sequencing of caspase-
and AcrB- specificDARPins
From the 3rd and 4th selection round against
caspase-3, caspase-7, and AcrB, DARPins were
screened for binding by crude extract ELISA26,30
(Supporting Information Fig. S4). For caspase-3,
53% of all tested DARPins of selection round 3 and
45% of round 4 were found to be specific binders,
whereas the hit rate was lower for caspase-7 and
AcrB (13% and 16% of round 3 and 17% and 30% of
round 4, respectively). Binders exhibiting the strong-
est signals in the crude extract ELISA were
subjected to DNA sequencing (top 20 hits of the
third selection round and top 10 hits of the fourth
round). The binders were named C3_1–30, C7_1–30,
and AcrB_1–30, respectively. Seventy-five out of the
90 chosen clones exhibited unambiguous sequencing
results and unique sequences (Supporting Informa-
tion Figs. S5–S7). Forty-nine out the 75 DARPins
contained at least one unintended framework
mutation. In three AcrB DARPins a frameshift
mutation occurred, resulting in a change of the
NGADVNAS loop motif, connecting helix 2 with the
b-turn, to TVLTLTLL, and thereby rendering these
DARPins considerably more hydrophobic. All
caspase-3 DARPins harbor a conserved TXYGE
motif in the b-turn region of the second internal
repeat, suggesting that these binders recognize one
single epitope (Supporting Information Fig. S5). In
contrast, the caspase-7 and AcrB binders appeared
more diverse and therefore are likely to recognize
different epitopes (Supporting Information Figs. S6
and S7). By comparing the sequences of selected
and unselected DARPins, the influence of binder
selection on the amino acid composition of the
randomized positions can be followed (Fig. 5). In
positions 2, 3, 5, 13, and 14, residue frequency
changes greater than 40% were observed for trypto-
phan (1217%), arginine (174%) and lysine (253%)
[Fig. 5(A)]. In position 1, aspartate (153%) was
enriched and serine (260%) was depleted during
the selection process [Fig. 5(B)]. No major changes
were observed at position 10 [Fig. 5(C)].
Biochemical characterization of caspase- and
AcrB- specific DARPins
Twenty DARPins each specific for caspase-3, cas-
pase-7, and AcrB were purified and their oligomeric
Figure 5. Amino acid composition in diversified positions of
unselected library members (based on 20 DARPins, Support-
ing Information Fig. S2) and selected DARPin binders (based
on 50 DARPins, Supporting Information Figs. S5–S7). The fre-
quencies (%) are given for ankyrin repeat positions 2, 3, 5,
13, and 14 (A), position 1 (B) and position 10 (C) and are
compared with the intended frequencies.
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states were analyzed by SEC (Supporting Informa-
tion Fig. S3). The binders yielded between 4 and
66 mg pure protein per liter of culture. Eighteen out
of 20 caspase-3 DARPins, 15 out of 20 caspase-7
DARPins, and 16 out of 20 AcrB DARPins eluted as
monodisperse proteins with a retention volume cor-
responding to DARPin monomers as judged from a
SEC column calibration run (not shown). Complex
Figure 6. Validation of the new library with test selections against caspase-3, caspase-7, and AcrB (A) RT-PCR of ribosome
display selection rounds 1 to 4 with applied cross-panning in rounds 2 to 4. Retrieved mRNA of potential binders were reverse
transcribed and amplified by PCR (45, 40, 30, and 25 cycles for rounds 1, 2, 3, and 4, respectively) resulting in a 500 bp PCR
product. “i)” indicates pre-panning against MBP followed by panning against target protein and “ii)” vice versa. (B) Analysis of
ELISA-positive DARPin C7_16 (Supporting Information Fig. S4) by analytical SEC. Complex formation with caspase-7 leads to a
distinct peak shift (green, solid line) compared with caspase-7 alone (red, short dashed line) and DARPin alone (blue, dashed
line). The SDS-polyacrylamide gel of the corresponding complex peak fractions (grey bar) is shown (inset). (C and D) The affin-
ities of eleven caspase-7 DARPins were determined by SPR. Exemplary SPR traces are shown for DARPin C7_16 (C) and
kinetic binding parameters as well as dissociation constants are shown in (D). (E and F) The affinities of five AcrB DARPins of
the new library were determined by SPR alongside with the previously described AcrB DARPin 110819.28 Exemplary SPR
traces are shown for DARPin AcrB_21 (E) and kinetic binding parameters as well as dissociation constants are shown in (F).
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formation with target proteins was confirmed for
monomeric caspase-3 and -7 DARPins by a peak
shift on analytical SEC and subsequent SDS-PAGE
analysis of the complex peak fractions [Fig. 6(B),
Supporting Information Fig. S8(A,B)]. Eleven
caspase-7 DARPins and all monomeric AcrB DAR-
Pins were further analyzed by surface plasmon reso-
nance (SPR). A typical sensogram is shown for
C7_16 and AcrB_21 [Fig. 6(C,E)]. For all caspase-7
binders, the binding constants were determined
from the binding and dissociation kinetics. Binding
of caspase-7 DARPins was characterized by rather
slow on-rates and slow off-rates resulting in dissoci-
ation constants ranging from 33 nM to 364 nM [Fig.
6(D)]. Only five of the tested AcrB DARPins elicited
SPR binding curves suitable for fitting and exhibited
Kds in the range of 110 nM to 597 nM [Fig. 6(F)].
Their affinities were therefore considerably lower
than an original DARPin selected against AcrB
(DARPin 110819 described in Ref. 28) whose Kd
amounted to 53 nM in our analysis [Fig. 6(F)]. Nota-
bly, the original DARPin binders against AcrB were
identified by an in vivo assay in E. coli cells. This
allowed for screening a much larger number of
clones, which explains the better affinities observed.
The five high affinity AcrB DARPins were then ana-
lyzed for complex formation with AcrB by SEC.
They all co-migrated with the targeted transporter
[Supporting Information Fig. S8(C)], but AcrB_4 and
AcrB_23 appear to dissociate during SEC due to low
binding affinity.
Equilibrium unfolding of DARPins
To assess whether the second-generation library has
retained the high thermodynamic stability of the
original DARPins, equilibrium unfolding curves for
11 original DARPins and 25 second-generation DAR-
Pins (15 unselected DARPins and 5 DARPins each
specific for caspase-3 and caspase-7, respectively)
were determined (Supporting Information Fig. S9).
With the exception of unselected DARPin D20, equi-
librium unfolding curves for the new DARPins
appeared monophasic. On the other hand, the
unfolding curves of several original DARPins were
clearly biphasic due to the early unfolding of the
nonoptimized C-cap.52 DARPin unfolding and folding
is a complicated process involving several folding
intermediates as detailed previously using a consen-
sus repeat approach.56 Here, we will confine our
analysis to midpoints of denaturation (Dm) for
clarity of discussion. The Dm values range from
2.3M to 5.1M GdnHCl for the original DARPins and
1.9M to 4.3M GdnHCl for the second-generation
DARPins. On average, the new DARPins were less
stable than the original ones with average Dm val-
ues of 3.0M and 3.8M GdnHCl, respectively (Fig. 7).
This loss of stability might be attributed to the ran-
domization of position 10 in the second-generation
DARPins. For stability considerations, this position
was kept as invariant leucine in the original library,
and we found in this study that the E3_5_L86A
mutant was less stable than wild type E3_5 [Fig.
3(B)].
Crystal structure of DARPin C7_16 in complex
with caspase-7
DARPin C7_16 was purified in complex with
caspase-7 by SEC, crystallized and the structure
was determined at 1.7 A˚ resolution (Table I). The
structure reveals one DARPin and one caspase-7
monomer in the asymmetric unit (Fig. 8). DARPin
C7_16 superimposes well with the structure of a
full-consensus DARPin containing the identical opti-
mized C-cap53 indicating that the changes in the
framework and the extended randomization did not
alter the scaffold structure [Supporting Information
Fig. S10(A)]. DARPin C7_16 interacts exclusively
with the large subunit of caspase-7 involving resi-
dues mainly located at the second and third internal
repeat and the C-cap. The binding interface covers
an area of 843 A˚2 on the DARPin and is
stabilized by 13 hydrogen bonds and four salt
bridges. Four tryptophans and two tyrosines are
prominently involved in mediating molecular con-
tacts to caspase-7 [Fig. 8(B)] and they account for
63% of the interaction surface and establish five
hydrogen bonds. Residues of the C-cap account for
approximately 49% of the binding surface. In con-
trast, residues in the randomized ankyrin positions
1 and 10 play a minor role in this particular
DARPin-caspase-7 complex accounting for 1.6% and
0.1% of total BSA, respectively. Based on this partic-
ular crystal structure we cannot yet draw conclu-
sions whether randomization of the two additional
ankyrin repeat positions 1 and 10 was beneficial or
not. The crystal structure nevertheless provides
Figure 7. Equilibrium unfolding of DARPins. GdnHCl unfold-
ing of a set of DARPins of the original and new library was
determined by CD spectroscopy (Supporting Information Fig.
S9) which allowed the determination of midpoints of unfolding
(Dm). Dm values of individual DARPins are depicted together
with the mean Dm (vertical line) for original and new DARPins,
respectively.
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evidence that crystal contacts are mediated between
two DARPins involving residues with reduced
entropy, namely A68, A134, and D130 [Supporting
Information Fig. S10(B)]. More crystal structures
will be needed to analyze the consequences of sur-
face entropy reduction in a systematic manner.
Discussion
In vitro selected binders have become popular tools
in structural, cell, and chemical biology. Amongst
such binders, nonantibody scaffolds offer unprece-
dented advantages due to their novel shapes of
randomized surfaces and their favorable biophysical
properties such as high stability and the absence of
cysteines.11 Virtually any protein surface can be sub-
jected to randomization which explains the develop-
ment of numerous binding scaffolds in past years
and certainly many more in the future. Here, we
chose to refine the properties of an already estab-
lished scaffold, namely the well-characterized
DARPins.
Features of the second-generation DARPins
The presented second-generation library builds on an
optimized scaffold and the randomized surface was
extended based on the analysis of 13 crystal struc-
tures. Ankyrin repeat position 33 was no longer
randomized in the second-generation library and posi-
tions 1 and 10 were subjected to focused randomiza-
tion including a small number of permitted residues
which lead to a slight reduction of thermodynamic sta-
bility. However, the average midpoint of denaturation
still amounts to 3M GdnHCl and therefore, DARPins
from the library described here are based on a very
stable scaffold. The C-cap was found to be the Achilles
heel of the original DARPins and therefore we added
an optimized C-cap,52 which in contrast to the original
DARPins was subjected to randomization. Moreover,
we exchanged a lysine and a glutamate at the back-
side of each ankyrin repeat by alanine and aspartate,
respectively, in order to reduce the surface entropy of
DARPins for crystallization purposes.
Library assembly and validation
At the center of the binder selection technology
stands the binder library, which encodes the sum of
all randomized scaffolds in form of DNA. Its quality
is characterized by (i) the library diversity (typically
limited by the amount of DNA obtained in the last
step of library assembly), (ii) the sequence quality
(i.e. the percentage of library members encoded in
frame containing the intended residues), and (iii)
the biochemical property of the randomized scaffold
(i.e. the percentage of in-frame library members that
fold into monomeric proteins). For the library pre-
sented here, these three parameters are excellent.
Due to the large theoretical library diversity of 1.9
3 1024, the practical diversity of this library was
limited by the amount of assembled DNA and corre-
sponds to approximately 1011 different library mem-
bers. Seventy-seven percent of assembled library
members are devoid of frame shifts and 83% of ran-
domly picked in-frame DARPins could be purified
and run as monomers on SEC. Currently, the practi-
cal diversity of the library is limited by the final
ligation of the library into the in vitro transcription
vector pRDV.12 In future work, the library diversity
can be further increased by using type IIS restric-
tion enzymes not only for the assembly of the
repeats, but also for the cloning of the flanking ele-
ments required for in vitro transcription and trans-
lation of the library for ribosome display.57
Strong enrichment of tryptophan residues
during binder selection
In previous studies, degenerate codons were used to
construct a more hydrophilic synthetic scFv library
Figure 8. Crystal structure of the C7_16-caspase-7 complex.
(A) Standard view of caspase-7 (surface representation, light
and dark blue corresponding to the small and large subunits)
in complex with DARPin C7_16 (cartoon representation,
shades of grey). The DARPin binds side-ways to the large
subunit of the enzyme. (B) Close-up view of the binding inter-
face. Interacting DARPin residues (distance <4.5 A˚) are high-
lighted as sticks and colored according to the scheme of
Figure 1. Four tryptophans and two tyrosines play a dominant
role in providing target contacts.
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based on a stable antibody scaffold.58 In addition,
selections with Fab and monobody libraries containing
only serines and tyrosines in the randomized positions
were reported.59,60 Tyrosines were highlighted to play
a key role in such minimalist synthetic libraries to cul-
minate in a review article entitled “The Importance of
Being Tyrosine”.37 In order to reduce the accumula-
tion of “sticky” binders during the in vitro selection
process, our second-generation DARPin library was
diversified omitting the hydrophobic amino acids V, L,
I, M, and F (except for position 10, where V and L are
permitted). The diversified positions were enriched
with tyrosine expecting that they will substitute for
the hydrophobic amino acids excluded in the new
library. In test selections against caspase-3, caspase-7
and AcrB, we observed specific enrichment of binders
starting from round 2. A large proportion of binders
were monomers, including those selected against the
membrane protein AcrB, which underscores the
advantage of working with a more hydrophilic DAR-
Pin library. The affinities of eleven caspase-7 and five
AcrB DARPins measured by SPR range between
33 nM and 597 nM, which is lower than the affinities
of DARPins of the original library selected against the
same targets. However, current selections against
other targets using the new DARPin library revealed
binding affinities in the picomolar range (not shown).
In our selections we did not observe substantial fur-
ther enrichment of tyrosines, but strikingly, the num-
ber of tryptophans tripled. This result suggests that
synthetic libraries depleted of apolar amino acids in
diversified positions should be enriched in tyrosine
and tryptophan in the randomization mixtures.
Crystal structure of the DARPin C7_16-caspase-7
complex
The crystal structure of DARPin C7_16 in complex
with caspase-7 provides three important insights.
First, the scaffold structure is unchanged. Moreover,
the optimized C-cap superimposes very well with the
recently published full-consensus DARPin structure
containing this C-cap.53 Second, tyrosines and trypto-
phans in the randomized positions play a key role in
mediating contacts to the target as they contribute
23% and 40%, respectively to the buried DARPin sur-
face and five hydrogen bonds. Third, the residues
subjected to surface entropy reduction were indeed
found to be involved in crystal contacts.
Future prospects
A key motivator in designing this new library is its
future use to select binders against difficult targets
such as membrane proteins and soluble proteins exhib-
iting hydrophobic surfaces. Here, we could demon-
strate successful selections against the membrane
protein AcrB. Selections and binder analysis against a
number of challenging proteins are ongoing, but will
require several years of data accumulation to allow
meaningful conclusions. The technical quality of this
DARPin library is excellent and the test selections and
characterizations presented in this study are encourag-
ing. Library design and binder characterization is an
iterative process.48 Thanks to the numerous available
crystal structures, DARPins represent an ideal play-
ground to improve synthetic library design. We hope
that in the future more DARPin libraries will be cre-
ated to identify the best possible randomization and
selection strategy for this scaffold.
Materials and Methods
Reagents
Primers containing incorporated trinucleotide phos-
phoramidites for the targeted randomization were
obtained from Ella Biotech (Martinsried, Germany).
The other oligonucleotides were purchased from
Microsynth (Balgach, Switzerland) at PAGE-purified
quality. Restriction enzymes (if not stated other-
wise), Vent polymerase and Phusion polymerase
were from NEB. T4 DNA ligase and BpiI was pur-
chased from Thermo Scientific. PCR purification kit,
gel extraction kit, and plasmid miniprep kit were
from Qiagen. Chemicals were from Sigma/Fluka, if
not stated otherwise.
Analysis of the crystal interfaces
For the analysis of DARPin contact residues, the fol-
lowing 13 crystal structures (PDB entries) containing
22 interfaces in their asymmetric units were analyzed
using the EPPIC server (www.eppic-web.org):47 1SVX,
2BKK, 2V4H, 2V5Q, 2XZD, 2Y1L, 3HG0, 3NOC,
3ZU7, 3ZUV, 4DRX, 4DX5, 4F6R. Crystal structures
2P2C, 3NOG and 4GRG were omitted due to resolu-
tions limits (>3 A˚) and 2J8S (solved at 2.5 A˚) is repre-
sented here by the identical 1108_19-AcrB complex
4DX5 (solved at 1.9 A˚). Accessible surface areas (ASA)
and buried surface areas (BSA) upon complexation
were retrieved from the EPPIC log files and compiled
in an Excel sheet (Supporting Information File "DAR-
Pin_interfaces.xls"). In case several chains of the target
protein were involved in the binding interface, the
respective surfaces were summed up. At the transition
between two target protein chains, there were around
10 cases in which the BSA of a DARPin residue was
larger than its ASA. In these cases, the burial was set
to 100% (BSA5ASA).
Generation of E3_5 mutants and surface
entropy reduced DARPin_55
The plasmid pQE30_E3_515 served as template to
introduce single mutations (D77S and L86A) using
QuikChangeVR site-directed mutagenesis. The primer
sequences were as follows: E3_5_D77S_for (5’-GTT
AAC GCT TCT AGC CTT ACT GGT ATT AC),
E3_5_D77S_rev (5’-GTA ATA CCA GTA AGG CTA
GAA GCG TTA AC), E3_5_L86A_for (5’-CTC CGC
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TGC ACG CGG CTG CTG CTA C) and
E3_5_L86A_rev (5’-GTA GCA GCA GCC GCG TGC
AGC GGA G). The coding sequence of mutant DAR-
Pin_55 was custom-synthesized by Geneart (Regens-
burg) and cloned into pQE30.
DARPin purification and crystallization of
E3_5_D77S and E3_5_L86A
E3_5 wild type and mutants as well as DARPin_55
and its mutant were expressed and purified as pre-
viously described.15 E3_5 mutants were applied on
SEC (Superdex 200 5/150 GL, 20 mM Tris/HCl
(pH 7.4), 150 mM NaCl) for buffer exchange, concen-
trated to 15 mg/mL and subjected to crystallization
trials. For the E3_5_D77S mutant, crystals appeared
in 1.6M citrate pH 6.5 and for the E3_5_L86A
mutant, crystal grew in 0.1M citrate pH 5.6, 20%
2-propanol, 20% PEG4000. Crystals were directly
picked from the screening plate without further
cryo-protection and flash-frozen in liquid nitrogen.
PCR amplification of DARPin capping repeats
for library assembly
PCR reactions for the amplification of the caps were
carried out on a Bio-Rad PCR machine using the
temperature protocol: 2 min, 95C; 30 cycles of 30 sec
95C (melting), 30 sec 60C (annealing) and 2 min/kb
amplified DNA 72C (elongation); a final elongation
step 10 min 72C; cooling to 10C. The E20D_R23S
double mutation at the N-Cap was introduced into
pQE30_E3_5 using QuikChangeVR site-directed muta-
genesis using primers NCap_E20D_R23S_for (5’-GCT
GGA TGC TGC TAG TGC TGG TCA GG) and NCa-
p_E20D_R23S_rev (5’-CCT GAC CAG CAC TAG CAG
CAT CCA GC). This mutant served as template to
PCR amplify the N-cap using primers NCap1 (5’-
ATG GCG CGC CAT GGG TAT GAG AGG ATC G)
and NCap2 (5’-ATA AGC TTG GTC TCA CGT CAG
CAC CGT TAG CCA TCA GTA TAC G). The C-Cap
was amplified from the vector pQE30_NI3C_Mut553
using primers CCap1 (5’-ATG GCG CGC CGA AGA
CCT GAC GTC AAC GCT AAC XXX NNN NNN
GGT AAG ACC CCG TTC GAC TTA GCG, in which
XXX stands for a codon mix for D, N; 30% each and
S, T; 20% each and NNN stands for a codon mix for
A, S, T, N, and Y; 12% each and D, E, R, K, Q, W,
and H; 5.7% each) and NC_shorter (5’-ATA AGC TTC
GCC GCT TTT TGC AGC AC). Both caps were
amplified using Phusion polymerase (amounts used
as suggested by the manufacturer), 0.5 lM of each
primer and 0.2 mM of dNTPs resulting in a single
band on agarose gel (1.5%) and yielding around 3 lg
of DNA per 50 lL of PCR reaction.
PCR amplification of the internal repeats for
library assembly
The internal repeats were amplified in a single step
using a simple assembly PCR protocol.61 Low
amounts (0.05 lM final conc, each) of inner primers
Rep2 (5’-GA CCT GAC GTT AAC GCT TCT XXX
NNN NNN GGT NNN ACT CCG CTG CAC YYY
GCT GCT NNN NNN GGT CAC CTG GAA ATC
GTC G, in which XXX and NNN denote codons for
the same amino acid mixtures as specified above and
YYY stands for a codon mix for A, S, T, V, and L,
20% each), Rep3 (5’-ATA AGC TTG TCA GGT CTC
ACG TCA GCA CCG TDA GCC AGC AGA ACA TCG
ACG ATT TCC AGG TG, in which D stands for a
mixture of the bases A, G, and T) were mixed with
an excess (1 lM final conc, each) of outer primers
Rep1 (5’-ATG GCG CGC CGA AGA CCT GAC GTT
AAC GC) and Rep4 (5’- GTA CCA AGC TTG TCA
GGT CTC ACG TC). PCR was carried out using Vent
polymerase (1 mL per 100 mL PCR mix), 0.4 mM
dNTPs and 5% DMSO. The cycle protocol was: 2 min,
95C; 35 cycles of 30 sec 95C (melting), 30 sec 60C
(annealing) and 30 sec 72C (elongation); a final elon-
gation step 3 min 72C; cooling to 10C. The PCR
product ran as a single band of the expected size on a
1.5% agarose gel. The DNA was purified with a PCR
purification kit (Qiagen) to yield around 1.2 lg DNA
per 50 lL of PCR reaction volume. In order to make
the individual internal repeats of a fully assembled
DARPin distinguishable by DNA sequence the glycine
at position 27 of the ankyrin repeat module was
encoded with three different triplets in each repeat of
a N3C DARPin. To this end, the second internal
repeat was assembled as described above, but instead
of primer Rep3, Rep3_v2 (5’-ATA AGC TTG TCA
GGT CTC ACG TCA GCG CCG TDA GCC AGC AGA
ACA TCG ACG ATT TCC AGG TG, the nucleotide
that differs is underscored) was used. Rep3_v3 (5’-
ATA AGC TTG TCA GGT CTC ACG TCA GCC CCG
TDA GCC AGC AGA ACA TCG ACG ATT TCC AGG
TG) was used accordingly to assemble the third inter-
nal repeat.
Library assembly
The DARPin library was assembled repeat by repeat
as first described by Binz et al.15 In contrast to previ-
ously described protocols for DARPin and Armadillo
library assemblies.15,62 we did not subclone the repeat
segments into a plasmid in a first step, but rather
assembled them directly after PCR. Moreover, we
provide here a comprehensive protocol for library
assembly, which includes DNA and enzyme
amounts as well as reaction volumes. In the first
assembly step the N-Cap and the first internal
repeat (1.5 lg each) were digested with BsaI and
BpiI (20 units each), respectively, for 2 h in a vol-
ume of 100 lL. The small fragments containing the
typeII S restriction sites were removed using the
PCR purification kit (Qiagen) and cut N-cap and
repeat were eluted in volumes of 50 lL elution
buffer (Qiagen) each. The fragments were then
ligated in a volume of 120 lL using 20 units of T4
1252 PROTEINSCIENCE.ORG Second-Generation DARPin Library
Publication: Second-Generation DARPin Library
DOI: 10.1002/pro.2312, c©2013 The Protein Society 131
ligase for 1 h. The ligation product was separated
on a 1.5% agarose gel and the ligation efficiency
was found to exceed 90%. The fragment consisting
of the N-cap and the first internal repeat (called
NI1) was retrieved by gel extraction (elution in
50 lL elution buffer, Qiagen) yielding 0.8 lg of
DNA. DNA (0.3 lg) thereof was PCR-amplified in
200 lL using the primers NCap1 and Rep4 and
Vent polymerase following the same PCR parame-
ters as for the amplification of internal repeats (see
above) and yielding 8 lg of DNA after PCR purifica-
tion. Then 2.5 lg thereof and 1.25 lg of the second
internal repeat were digested using BsaI and BpiI
followed by PCR purification, ligation and gel
extraction under identical conditions as for the
assembly of NI1 to yield 0.86 lg NI2. Finally
0.43 lg thereof was PCR-amplified in a 400 lL
reaction mixture to yield 17.8 lg of DNA, half of
which were digested in 300 lL reaction volume
using 80 units of BsaI. The third internal repeat (3
lg) was digested with 25 units BpiI in 150 lL. After
ligation (30 units T4 ligase in 220 lL) and gel
extraction, 3.6 lg NI3 were obtained. Half of it was
amplified by PCR in 800 lL reaction mixture to
yield 21.2 lg DNA which was digested in a volume
of 600 lL using 80 units BsaI. C-cap (3 lg) was
digested using 25 units of BpiI in 150 lL. The frag-
ments were again ligated (50 units T4 ligase in 500
lL) and separated by gel electrophoresis to yield 6.5
lg assembled N3C DARPins, which corresponds to
1.2 3 1013 DNA molecules. Since the theoretical
library diversity is 1.9 3 1024 and the last step of
the assembly is a ligation (i.e. there was no amplifi-
cation of the N3C fragment by PCR at this point) it
is highly unlikely that two of these 1.2 3 1013 N3C
DARPins are identical. Hence the practical diversity
of the assembled N3C DARPins is limited by the
amount of ligated DNA and corresponds to 1.2 3
1013. One third of this ligated N3C product (thereby
limiting the practical diversity to 4 3 1012) was
amplified by PCR in a volume of 2400 lL using pri-
mers NCap1 and NC_shorter to yield 84 lg of DNA.
Ten micrograms thereof were digested with 50 units
each of NcoI and BamHI in a volume of 300 lL for
1.5 h. Using the same restriction enzymes, 60 lg of
pRDV12 was digested. Both fragments were purified
by gel extraction. About 1.25 mg digested N3C were
ligated into 9 mg of digested pRDV (25 units T4
ligase in 300 lL for 3 h). Assuming that 5% of the
digested N3C is being integrated into pRDV,57 the
final practical diversity of the library is estimated
to amount to 1011 library members. The ligation
product served as template for PCR amplification
using primers T7 and tolAk12 in a total volume of
3000 lL to yield DNA ready for in vitro transcrip-
tion.63 An estimated 5 lg DNA was used to generate
720 lg of mRNA, which was then used to perform
test selections.
Ribosome display
Ribosome display selections were carried out
following the established standard protocol with
some minor modification as indicated.63 Biotinyl-
ated caspase-3 and caspase-7 were prepared as
described previously.64 AcrB containing a C-
terminal avi-tag was biotinylated enzymatically as
described.30 Each selection round included a pre-
panning step using MBP. Biotinylated MBP12 and
caspases were immobilized on NeutrAvidin coated
surfaces as described63 (surface panning method)
or in the fourth and last round using magnetic
beads (solution panning method). The washing
times were as follows: first round, three washes w/o
incubation; second round, 3 3 10 min; third round,
3 3 15 min; fourth round, 3 3 30 min. Retrieved
mRNA of DARPins were reverse transcribed and
amplified by PCR with 45, 40, 30, and 25 cycles for
rounds 1, 2, 3, and 4, respectively. In the initial
round, the amount of in vitro translation ribosomal
complexes was increased five times compared with
the standard protocol and Nunc MaxiSorp Immuno
Tubes (Thermo Fisher Scientific) were used to immo-
bilize MBP (for prepanning) and caspases (for pan-
ning). The number of ternary ribosome complexes of
the first round was estimated to correspond to at
least 3.5 3 1011 displayed DARPin molecules.63 This
number is approximately three times higher than
the practical diversity of the DARPin library used,
thus the in vitro translation step did not represent
the bottleneck of the selection procedure. Due to an
exchanged C-cap in the second-generation DARPin
library, NC_shorter was used instead of the standard
primer WTC4.12
Crude cell extract ELISAs
Crude cell extract ELISAs were carried out as ini-
tially established by Huber et al.26 and exactly as
described in Seeger et al.30 with one notable excep-
tion. Namely, instead of using the DARPin expres-
sion vector pQE30_myc5,26 which adds five
consecutive myc-tags to the C-terminus of the DAR-
Pin leading to DARPin aggregation,30 we con-
structed a pQE30_myc1 vector adding a single myc-
tag as follows. pQE30_myc5 containing the LmrCD-
specific DARPin a-LmrCD#530 was digested using
HindIII and Bpu1102I to excise the myc5 tag, fol-
lowed by gel extraction of the backbone. The myc1-
tag was generated by annealing primers myc1_ for
(5’-AGC TTG GTT CTG GAA GTA TGG AGC AAA
AGC TCA TTT CTG AAG AGG ACT TGA ATG AAT
AAT GAG C) and myc1_rev (5’-CTC AGC TCA TTA
TTC ATT CAA GTC CTC TTC AGA AAT GAG CTT
TTG CTC CAT ACT TCC AGA ACC A) to a double-
stranded DNA product, which contains overhangs
compatible with cloning into HindIII/Bpu1102I of
the pQE30 backbone. Binding of each DARPin was
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probed against the respective caspase and as a con-
trol against MBP. Binders yielding strong ELISA
signals (at least 10 times above MBP background)
were classified as specific. Positive clones were
sequenced at Microsynth.
Small-scale purification of DARPins
Purified DARPins containing a single myc-tag were
indistinguishable by SEC from the same DARPins
without a myc-tag (not shown). Therefore, binder
characterization was carried out with DARPins
containing an N-terminal RGSHis6-tag and a
C-terminal myc-tag. DARPins were expressed over-
night at 37C in E. coli XL-1 blue cells in 100 mL
auto inducing medium containing ampicillin (100
lg/mL). After harvest, cells were resuspended in 20
mL lysis buffer (50 mM Tris/HCl (pH 7.4), 500 mM
NaCl, 20 mM imidazole, 10% glycerol, 100 mg/L
lysozyme, and 10 mg/L DNaseI) and incubated 1 h
at 4C before cell disruption by sonication for
3 min. Cell lysate was clarified by centrifugation
(10,000g, 5 min) and filtration (0.45 lm). Ni21-NTA
columns (0.5 mL resin) were equilibrated with
wash buffer (50 mM Tris/HCl (pH 7.4), 500 mM
NaCl, 20 mM imidazole, 10% glycerol) and cell
lysate was loaded on the column. The columns were
washed with 30 mL wash buffer and the proteins
eluted with 2 mL elution buffer (same as wash
buffer, but containing 250 mM imidazole). SEC was
used to analyze the oligomeric state of selected
DARPin binders as well as the formation of stable
DARPin/target protein complexes in solution. SEC
was performed at 4C on an Agilent 1200 Series
HPLC system. Sample volumes of 100 lL were
injected on a Superdex 200 5/150 GL column (GE
Healthcare) using SEC buffer (20 mM Tris/HCl (pH
7.4), 150 mM NaCl, 0.05% Tween-20) at a flow rate
of 0.08 mL/min. To study DARPin-caspase com-
plexes, DARPins (added in excess in concentrations
ranging from 8 to 24 lM) were preincubated with
caspase-3 or caspsase-7 before SEC analysis. For
the equilibrium unfolding experiments, DARPins
were purified devoid of a myc-tag. To this end, the
C-terminal myc-tag of DARPin C7_16 was removed
via an introduction of two stop-codons in front of
the tag using QuikChangeVR site-directed mutagene-
sis. The primer sequences were as follows: 5’-AAA
GCG GCG AAG CTT TGA TAA GGA AGT ATG
GAG CAA and 5’-TTG CTC CAT ACT TCC TTA
TCA AAG CTT CGC CGC TTT.
Equilibrium unfolding
DARPins were purified as described above and sepa-
rated by SEC in 20 mM Tris/HCl (pH 7.4), 150 mM
NaCl. DARPins were diluted in increasing concen-
trations of GdnHCl dissolved in SEC buffer to obtain
a final protein concentration of 10 lM and incubated
for at least 12 h in the dark at 20C. The disappear-
ance of the native CD signal at 222 nm with increas-
ing GdnHCl concentrations was determined using a
Jasco J-810 instrument (Jasco, Japan). As far as
possible, a monophasic sigmoidal equation [Eq. (1)]
was fitted to the experimental data (SigmaPlot10,
standard 4 parameter sigmoidal fit):
f5y01
a
11e2
x2x0
bð Þ (1)
where x0 denotes the inflection point corresponding
to Dm.
In cases of two distinct unfolding transition
phases, a biphasic sigmoidal equation [Eq. (2)] was
fitted to the data:
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11e
2
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with the constraints x01< x02 and a1 <0.5 3 a2.
Here, inflection points x01 and x02 correspond to
midpoints of transition Dm,1 and Dm,2. This biphasic
model was only applied if Dm,1 and Dm,2 differed by
at least 0.9M GdnHCl.
SPR analysis
The affinity of a set of caspase-7 DARPins was deter-
mined by surface plasmon resonance analysis on a
ProteOn XPR36 protein interaction array system
(Bio-Rad). Biotinylated caspase-7 (1200 RU) were
immobilized on a NeutrAvidin coated NLC sensor
chip in SPR buffer (20 mM Tris/HCl (pH 7.4),
150 mM NaCl, 0.05% Tween-20). DARPins were
injected at six different concentrations (threefold dilu-
tion series) appropriate for analysis of the interaction
with immobilized target proteins. Binding kinetics
were performed with 120 s contact time followed by
600 to 1200 s dissociation time at a flow rate of
100 lL/min. Referenced binding signals were fitted
using a 1:1 binding model (ProteOn Manager Soft-
ware) and the dissociation constant Kd was calculated
using Eq. (3) in which ka is the association rate con-
stant and kd the dissociation rate constant:
Kd5
kd
ka
(3)
Crystallization of the C7_16-caspase-7 complex
Myc-tag free C7_16 was expressed and purified as
mentioned above. Caspase-7 expression and purifica-
tion is described elsewhere.64 Caspase-7 and DARPin
C7_16 were mixed in a molar ratio of 1:3 and sepa-
rated by SEC (50 mM Tris/HCl (pH 7.4), 150 mM
NaCl; Superdex 200 10/300 GL). Fractions corre-
sponding to the C7_16-caspase-7 complex were con-
centrated to 11 mg/mg and subjected to
crystallization trials. Crystals appeared in 100 mM
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Tris/HCl (pH 8.3), 200 mM MgCl2, 9% PEG 1000,
and 9% PEG 8000. Upon cryo-protection using ethyl-
ene glycol (20%), they were frozen in liquid nitrogen.
Crystallographic methods
Crystals were measured at the protein crystallography
beamline X06SA at the Swiss Light Source (SLS) and
processed using the program XDS.65 Structures of
E3_5_D77S, E3_5_L86A and the C7_16-caspase-7
complex were solved by molecular replacement using
Phaser66 and search models 1MJ0 to solve the struc-
tures E3_5 mutants and search models 3IBC (Cas-
pase-767) and 2P2C (Caspase-2 DARPins22) to solve
the structure of the C7_16-caspase-7 complex. Models
were built manually using Coot68 and refined using
PHENIX69 including TLS refinement.70 Structural
pictures were generated using PyMOL (http://
www.pymol.org).
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D9 ....................D......................NKN.A....V..AD...........Y.......DQE. 80
D10 ...........................................STS.K....V..AY...........H.......TAS. 80
D11 ...........................................NHY.W....L..RE...........N.......NHA. 80
D12 ...........................................TNT.S....L..QY...........H.......SWK. 80
D14 ...........................................THE.Q....S..RT...........H.......TDQ. 80
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D25 ...........................................TAY.H....L..YS...........Y.......DNE. 80
D26 ...........................................DYS.W....V..DR...........Y.......SQH. 80︸ ︷︷ ︸︸ ︷︷ ︸︸ ︷︷ ︸
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D26 R....L..ST...........N.......DDE.E....V..NT...........N.......NSE............... 160︸ ︷︷ ︸︸ ︷︷ ︸ ︸ ︷︷ ︸
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200
300
400
2.14 ml
C7_15
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
125
250
375
500
2.08 ml
C7_16
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
100
200
300
400
2.22 ml
C7_17
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
150
300
450
600 1.97 ml
C7_18
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
150
300
450
600
2.25 ml
C7_19
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
200
400
600
800
2.07 ml
C7_20
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
150
300
450
600 1.93 ml
C7_21
Retention time (min)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
25
50
75
100 2.32 ml
C7_22
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
15
30
45
60
2.17 ml
C7_23
Retention time (min)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
40
80
120
160
1.87 ml
2.23 ml
C7_24
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
50
100
150
200 2.25 ml
C7_25
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
40
80
120
160
2.25 ml
C7_27
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
50
100
150
200
2.15 ml
C7_28
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
50
100
150
200 2.22 ml
C7_30
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
50
100
150
200
2.05 ml
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AcrB_1
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
250
500
750
1000
2.13 ml
AcrB_3
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
200
400
600
800
2.16 ml
AcrB_4
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
125
250
375
500
2.25 ml
AcrB_6
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
200
400
600
800
2.17 ml
AcrB_10
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
125
250
375
500
2.18 ml
AcrB_11
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
225
450
675
900
2.10 ml
AcrB_12
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
80
160
240
320
1.87 ml
AcrB_13
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
125
250
375
500
2.08 ml
AcrB_15
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
200
400
600
800
2.06 ml
AcrB_16
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
25
50
75
100
1.87 ml
AcrB_17
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
-100
0
100
200
300 2.19 ml
AcrB_18
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
200
400
600
800
2.19 ml
AcrB_20
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
150
300
450
600
1.85 ml
AcrB_21
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
60
120
180
240
2.19 ml
AcrB_22
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
100
200
300
400
1.93 ml
AcrB_23
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
50
100
150
200
2.27 ml
AcrB_26
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
40
80
120
160
2.18 ml
AcrB_28
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
80
160
240
320
2.17 ml
AcrB_29
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
100
200
300
400
2.17 ml
AcrB_30
Retention volume (ml)
A
2
8
0
 
(m
A
U
)
1.5 2.0 2.5
0
60
120
180
240
2.17 ml
Supporting Information Figure S3: Analytical SEC profiles of all DARPins of the new 
library appearing in this study.  
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AB
Caspase-3 binders, after selection round 3
Caspase-3 binders, after selection round 4
Caspase-7 binders, after selection round 3
Caspase-7 binders, after selection round 4
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Supporting Information Figure S4: Crude cell extract ELISAs. DARPins selected against 
caspase-3 (A), caspase-7 (B) and AcrB (C) were probed for binding against the respective 
target and the control protein MBP.  
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β-turn helix 1 helix 2
o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^
10. 20. 30. 40. 50. 60. 70.
N3C MRGSHHHHHHGSDLGKKLLDAASAGQDDEVRILMANGADVNASXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNA 75
C3_1 ...........................................DRQ.A....T..YE...........H...... 75
C3_2 ...........................................DNW.A....S..YY...........H....D. 75
C3_3 ...........................................DND.A....S..YY...........Y.V.... 75
C3_4 .................................L.........DHA.S....L..YN...........H...... 75
C3_5 ...........................................DWH.S....T..YH...........N...... 75
C3_7 ...........................................TQT.T....S..QA...........N...... 75
C3_8 ...........................................TEH.A....V..YT...........Y...... 75
C3_9 ...........................................NWH.S....T..NA...........H...... 75
C3_10 ...........................................DWN.T....L..WS...........N...... 75
C3_11 ...........................................SYA.E....S..WY...........H...... 75
C3_12 ...........................................TTN.Q....S..WH...........H...... 75
C3_13 ...........................................DTN.V....L..TT...........N...... 75
C3_15 ...........................................TAT.S....L..EQ...........H...... 75
C3_16 ...........................................NQY.S....L..WY.........M.H...... 75
C3_17 ...........................................DHN.S....V..YR...........H...... 75
C3_18 ..........................E................DSY.A....A..YT...........C...... 75
C3_19 ...........................................SAY.Q....T..SS...........N...... 75
C3_20 ...........................................TDS.A....V..NA...........N...... 75
C3_21 ...........................................TDE.A....V..YH...........N...... 75
C3_22 ...........................................DYY.T....V..WH...........H...... 75
C3_23 ...........................N...............SEY.A....V..QD...........H...... 75
C3_24 ...........................................DKHDA....L..YR...........Y...... 75
C3_25 ......................................E....SDY.A....V..NA...........H...... 75
C3_26 ............................K..............TNA.A....T..YH...........Y...... 75
C3_27 ...........................................DNS.N....L..YR...........Y...... 75
C3_28 ...........................................DKY.T....S..YN.......G...H...... 75
C3_29 ...........................................DNN.T....A..WD...........H...... 75
C3_30 ...........................................SNW.A....A..KA...........H...... 75︸ ︷︷ ︸︸ ︷︷ ︸
N-Cap Repeat 1
β-turn helix 1 helix 2 β-turn helix 1 helix 2
o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^
80. 90. 100. 110. 120. 130. 140. 150.
N3C SXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNASXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNANXXXGKTPF 150
C3_1 .TYY.E....A..R-...........N.......TQW.A....S.TSH...........N.......DYT..... 149
C3_2 .TNY.E....A..YA...........N.......TAW.S....T..QS...........H.......SHY..... 150
C3_3 .TDY.E....L..YE...........H.......TNW.Y....V..KN...........H.......DYA..... 150
C3_4 .TDY.E....L..YR...........H.......TSW.H....A..RH...........Y.......DYA..... 150
C3_5 .TEY.E....A..AQ...........N.......THW.Y....S..SR...........N.......DYN..... 150
C3_7 .TAY.E....V..QN...........N.......TNW.Y....V..KT...........H.......DWE..... 150
C3_8 .TDY.E....V..YT..........TN......YTTW.W....A..HH...........H.......NHW..... 150
C3_9 .TYY.E....A..ET...........H.....T.TEW.S....V..AR...........H.......DWN..... 150
C3_10 .TQY.E....A..QA.....I.....N.......TVW.Y....TS.NT...........N.......DYE..... 150
C3_11 .TYY.E....V..YS...........N.......TQH.N....V..RH...........H.......SYE..... 150
C3_12 .TAY.E....V..RY...........N.......TQW.N....S..SY...........N.......TYA..... 150
C3_13 .TYY.E....A..YA...........N.......SHW.D....A..KR...........N.......DNR..... 150
C3_15 .TYY.E....A..YT...........N.......TNW.Y....V..AY...........H.......DYN..... 150
C3_16 .TWH.E....V..YR...........N.......TDW.Y....V..AN...........H.......TWA..... 150
C3_17 .TWY.E....V..YS...........N.......TAW.T....V..SE...........H.......SHR..... 150
C3_18 .TNY.E....V..YK...........N.......TTW.Y....V..HH...........H.......DAN..... 150
C3_19 .TAY.E....V..TR...........H.......TAW.S....S..RD...........H.......DWQ..... 150
C3_20 .TYY.E....V..YR...........Y.......TNW.N....T..RY......N....Y.......DTH..... 150
C3_21 .TNY.E....V..NA...........N.......TAY.R....A..RW.......F...Y.....T.DYS..... 150
C3_22 .THY.E....L..TN...........N.......NNW.Y....T..AR...........H.......DYQ..... 150
C3_23 .TAY.E....T..NN...........N.......SNW.A....S..AW...........N.......NYQ..... 150
C3_24 .TAY.E....A..NS...........Y.......NNW.Q....S..YH...........H.......DSN..... 150
C3_25 .TAY.E....V..YS...........Y.......SQW.A....S..HR...........H.......NHN..... 150
C3_26 .TDY.E....T..YA...........Y.......TQW.N....V..AY...........H.......NHQ..... 150
C3_27 .NHY.E....A..SK...........N.......SNW.A....V..RH...........H.......TYE..... 150
C3_28 .TDY.E....AT.SA...........N.......TAW.R....V..YA..........VH.......DYR..... 150
C3_29 .TDY.E....V..YT...........N.......THW.T....A..TY...........H.......NYR..... 150
C3_30 .TDY.E....V..QE...........H.......TAW.N....V..KY..........TY.......DAS..... 150︸︷︷︸︸ ︷︷ ︸︸ ︷︷ ︸ ︸ ︷︷ ︸
Repeat 1 Repeat 2 Repeat 3 C-Cap
1
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160. 170. 180.
N3C DLAIDNGNEDIAEVLQKAAKLGSGSMEQKLISEEDLNE 188
C3_1 ...................................... 187
C3_2 ...................................... 188
C3_3 ................N..................... 188
C3_4 ...................................... 188
C3_5 ...................................... 188
C3_7 ...................................... 188
C3_8 ...................................... 188
C3_9 ...................................... 188
C3_10 ...................................... 188
C3_11 ...................................... 188
C3_12 ...........V.......................... 188
C3_13 ...................................... 188
C3_15 N..................................... 188
C3_16 ...................................... 188
C3_17 ...................................... 188
C3_18 ...................................... 188
C3_19 ...................................... 188
C3_20 ...................................... 188
C3_21 ...................................... 188
C3_22 ...................................... 188
C3_23 ...................................... 188
C3_24 .................G.................... 188
C3_25 ...........T.......................... 188
C3_26 ...................................... 188
C3_27 ...................................... 188
C3_28 ...................................... 188
C3_29 ...................................... 188
C3_30 ...................................... 188︸ ︷︷ ︸
C-Cap
2
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β-turn helix 1 helix 2
o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^
10. 20. 30. 40. 50. 60. 70.
N3C MRGSHHHHHHGSDLGKKLLDAASAGQDDEVRILMANGADVNASXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNA 75
C7_1 ...........................................DYA.W....T..WN...........H...... 75
C7_3 ...........................................DAY.W....S..WH...........N...... 75
C7_5 ...........................................NRR.Y....V..AH...........H...... 75
C7_6 ...........................................DAW.R....S..TW...........N...... 75
C7_7 ...........................................DWT.H....S..RN...........Y...... 75
C7_9 ...........................................DYA.Q....L..HY...........Y...... 75
C7_14 ...........................................DSW.R....A..HY...........H...... 75
C7_15 ...........................................SWE.H....L..AY...........Y...... 75
C7_16 ...........................................NQQ.W....AT.EY...........Y...... 75
C7_17 ...........................................DWY.W....T..NH...........H...... 75
C7_19 ...........................................DNS.W....V..AW...........H...... 75
C7_20 ...........................................DSW.R....V..YH...........Y...... 75
C7_21 ...........................................DTY.E....V..WR...........N...... 75
C7_22 ...........................................NWE.Y....L..WW...........N...... 75
C7_23 ...........................................SWE.Y....L..YA...........N...... 75
C7_24 ...........................................DAW.Q....L..QW......Y....H...... 75
C7_25 ................E..........................DSW.T....A..YA...........H...... 75
C7_26 ...........................................NSW.W....T..WK...........N...... 75
C7_27 ...........................................DSW.S....S..SN...........N...... 75
C7_28 ...........................................DAW.Q....L..QW......Y....H...... 75
C7_29 ...........................................NWE.Y....V..YY...........Y...... 75
C7_30 ...........................................SDN.E....A..HH...........N...... 75︸ ︷︷ ︸︸ ︷︷ ︸
N-Cap Repeat 1
β-turn helix 1 helix 2 β-turn helix 1 helix 2
o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^
80. 90. 100. 110. 120. 130. 140. 150.
N3C SXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNASXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNANXXXGKTPF 150
C7_1 .DHT.Y....V..QQ...........N.......DKW.T....A..SS...........Y.......NTD..... 150
C7_3 .DHT.Y....V..QQ.......I...N.......DDY.Y....T..RK...........H.......DQY..... 150
C7_5 .DQW.W....V..QY...........N.......DEY.S....A..HY...........Y.......SWW..... 150
C7_6 .DWY.D....L..TQ...........H.......NTA.A....S..YS.....I.....HE......SAQ..... 150
C7_7 .DWT.N....S..RS...........Y.......DEY.Y....V..HS...........H.......SWW..... 150
C7_9 .DTW.W....A..TS...........H.......DWY.Y....S..HS...........H.......NTW..... 150
C7_14 .DWY.E....L..NT...........Y.......DQN.E....V..HQ...........Y.......NTS..... 150
C7_15 .NQE.E....L..DY...........N.......NQT.Q....T..QW......A....Y.......TRD..... 150
C7_16 .DSY.S....S..WA...........H.......DNY.W....L..HT...........N.......NWW..... 150
C7_17 .DKA.S....V..WH...........N.......DSH.E....V..YA...........H.......DAT..... 150
C7_19 .STW.T....T..YT...........N.......ATQ.Y..M.L..EE...........H.......NTS..... 150
C7_20 .DWY.E....L..DY...........N.......DAT.T....V..WY...........N.......DKQ..... 150
C7_21 .DRS.Y....A..TR...........N.......DWY.Y....A..HY...........H.......TYW..... 150
C7_22 .DTY.Y....L..HR...........H.......DKD.E....V..YY...........H.......STW..... 150
C7_23 .NQE.A....L..YQ...........N.......DNY.W....V..WK...........H.......TSS..... 150
C7_24 .DWY.S....S..AK...........N.......TQY.E....V..NQ...........Y.......DNT..... 150
C7_25 .DWY.T....L..NN...........H.......DSY.N....S..SR...........N.T.....DAA..... 150
C7_26 .DWT.S....V..TQ...........N.......TAY.E....V..TA...........H.......DSW..... 150
C7_27 .DWY.N....A..AY...........N.......DSW.T....T..QQ...........N.T.....DNE..... 150
C7_28 .DWY.S....S..AK...........N.......TQY.E....V..NQ...........Y.......DNT..... 150
C7_29 .DNW.A....L..NY...........H.......NSW.R....S..WN...........H.....D.SAY..... 150
C7_30 .DQW.W....S..HE...........Y.......DTY.Y....S..HA...........H.......NYW..... 150︸︷︷︸︸ ︷︷ ︸︸ ︷︷ ︸ ︸ ︷︷ ︸
Repeat 1 Repeat 2 Repeat 3 C-Cap
1
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160. 170. 180.
N3C DLAIDNGNEDIAEVLQKAAKLGSGSMEQKLISEEDLNE 188
C7_1 ...................................... 188
C7_3 ...................................... 188
C7_5 ...................................... 188
C7_6 ...................................... 188
C7_7 ...................................... 188
C7_9 ...................................... 188
C7_14 ...................................... 188
C7_15 ...................................... 188
C7_16 ...................................... 188
C7_17 ...................................... 188
C7_19 .....S................................ 188
C7_20 ...................................... 188
C7_21 ................I..................... 188
C7_22 ...................................... 188
C7_23 ...................................... 188
C7_24 ....N................................. 188
C7_25 ........G............................. 188
C7_26 ..V................................... 188
C7_27 ...................................... 188
C7_28 ...................................... 188
C7_29 ...................................... 188
C7_30 .................V.................... 188︸ ︷︷ ︸
C-Cap
2
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β-turn helix 1 helix 2
o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^
10. 20. 30. 40. 50. 60. 70.
N3C MRGSHHHHHHGSDLGKKLLDAASAGQDDEVRILMANGADVNASXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNA 75
AcrB_1 ...........................................DWY.Y....I..YT.....A.....H...... 75
AcrB_3 ...........................................DWY.Y....V..YT...........H...... 75
AcrB_4 ...........................................NAW.W....V..YY...........N...... 75
AcrB_5 ...........................................DWY.E....V..HW......A....N...... 75
AcrB_6 ...........................................DWY.E....A..WA...........H...... 75
AcrB_7 ...........................................TWW.T....T..QT...........H...... 75
AcrB_9 ...........................................NQQ.N....L..AD...........TVLTLTL 75
AcrB_10 ...........................................DYY.E....A..RK...........N...... 75
AcrB_11 ...........................................DWW.W....D..SY...........H...... 75
AcrB_12 ...................................TVLTLTLLTTD.N....A..ST...........N...... 75
AcrB_13 ...........................................DWY.Y....A..WA...........H...... 75
AcrB_15 ...........................................DWY.T....S..AH...........H...... 75
AcrB_16 ...........................................NYW.S....L..SN...........N...... 75
AcrB_17 ...........................................DWY.D....L..HY...........Y...... 75
AcrB_18 ...........................................DWY.T....A..AY...........N...... 75
AcrB_20 ...................................TVLTLTLLT-A.YA...T..QV...........H...... 74
AcrB_21 ...........................................TAY.A....L..YS...D.......N...... 75
AcrB_22 ...........................................DWT.S....S..RY...K.......H...... 75
AcrB_23 ...........................................NYA.Y....A..YY...........N...... 75
AcrB_25 ...........................................STD.A....A..YR...........N.....S 75
AcrB_26 ...........................................DYS.W....L..TA...........H...... 75
AcrB_27 ...........................................NSY.H....A..QE...........N.T.... 75
AcrB_28 ...........................................TDY.S....L..WH...........H...... 75
AcrB_29 ...........................................DWY.A....A..AS...........H...... 75
AcrB_30 ...........................................DTW.R....T..QH...........H...... 75︸ ︷︷ ︸︸ ︷︷ ︸
N-Cap Repeat 1
β-turn helix 1 helix 2 β-turn helix 1 helix 2
o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^^ o^ o^ o^ o^ o^ o^
80. 90. 100. 110. 120. 130. 140.
N3C S-XXXGXTPLHXAAXX-GHLEIVDVLLAZGADVNASXXXGXTPLHXAAXXGHLEIVDVLLAZGADVNANXXX-GK 147
AcrB_1 .-DNY.Y....L..KH-...........N.......NTA.Y....V..RR...........H.......NNS-.. 147
AcrB_3 .-DSA.S....L..KH-...........N.......NDS.A....A..TY...........H.......TWQ-.. 147
AcrB_4 .-DTN.T....V..QW-.......G...Y.......DYW.E....V..WKD.....N....H.......NAR-.. 147
AcrB_5 .-DWA.S....S..NK-.....I.....N.T.....DWT.N....V..EY...........N.......TWN-.. 147
AcrB_6 .-NYN.Y....L..KH-...........N.......DSA.N....L..VY...........H.......DTS-.. 147
AcrB_7 .-DWW.A....V.T-H-...........N.......DHW.A....L..TR...........H.......DHWA.. 147
AcrB_9 L-THS.A....A..DS-...........N.......NYQ.R....S..QS...........N.......DTR-.. 147
AcrB_10 .-DWD.Y....A..DA-..M........N.......TWR.W....V..WY..........DN.......TWT-.. 147
AcrB_11 .-TSA.R....L..KR-..V........N.......DTY.H....V..ST...........H.......SWQ-.. 147
AcrB_12 .-NAT.T....S..KQ-...........N.......DAQ.A....S..WY...........N.......DSS-.. 147
AcrB_13 .-DNY.Y....V..RH-...........N.......TDQ.T....S..SR...........N.......NNS-.. 147
AcrB_15 .-NTS.Y....L..KH-...........N.......DYS.K....L..WR...........H.......NDY-.. 147
AcrB_16 .-DYW.W....V..SE-...........N.......SWE.S....S..RN...........H.......NAW-.. 147
AcrB_17 .-DWD.S....L..EY-...........N.......TWS.S....V..WH...........H.......DRY-.. 147
AcrB_18 .-NSS.S....L..RH-...........N.......DTS.Q....T..TR...........N.......TAY-.. 147
AcrB_20 .-DDY.Y....T..HA-......N....N.......DWS.A....V..NY...........N.......DSN-.. 146
AcrB_21 .-NWS.W....S..TS-...........N.......NRH.R....V..AN...........N.......DNY-.. 147
AcrB_22 .DDWD.Y....V..RT-...........N.......TWS.N....L..HR...........H.T.....NAA-.. 148
AcrB_23 .-NHS.Y....S..HK-...........N.......DSY.A....L..TQ...........Y.......DWR-.. 147
AcrB_25 .-SAY.Y..V.S..SW-...........H.......TAT.Y....V..SY...........H.......DYT-.. 147
AcrB_26 .-TWY.Y....L..AHT..P........N.......SEA.A....S..EW...........H.......NAW-.. 148
AcrB_27 .-DWA.W....V..HQ-...........H.......TNA.K....L..SA...........N.......DRR-.. 147
AcrB_28 .-NWS.W....A..KA-...........Y.......DAA.Y....L..QH...........H.......DNE-.. 147
AcrB_29 .-DSQ.R....A..RH-...........N.......DSA.S....L..DY...........N.......TWY-.. 147
AcrB_30 .-DYW.R....T..ST-...........N.......TAN.A....V..YT...........H.....S.SAR-.. 147︸︷︷︸︸ ︷︷ ︸︸ ︷︷ ︸ ︸ ︷︷ ︸
Repeat 1 Repeat 2 Repeat 3 C-Cap
1
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150. 160. 170. 180.
N3C TPFDLAIDNGNEDIAEVLQKAAKLGSGSMEQKLISEEDLNE 188
AcrB_1 ......................................... 188
AcrB_3 ......................................... 188
AcrB_4 ......................................... 188
AcrB_5 ......................................... 188
AcrB_6 ......................................... 188
AcrB_7 ......................................... 188
AcrB_9 ......................................... 188
AcrB_10 ...................E..................... 188
AcrB_11 ......................................... 188
AcrB_12 ......................................... 188
AcrB_13 ......................................... 188
AcrB_15 ......................................... 188
AcrB_16 ......................................... 188
AcrB_17 ......................................... 188
AcrB_18 ......................................... 188
AcrB_20 ......................................... 187
AcrB_21 ......................................... 188
AcrB_22 ......................................... 189
AcrB_23 ............N............................ 188
AcrB_25 ...E..................................... 188
AcrB_26 ......................................... 189
AcrB_27 ............E............................ 188
AcrB_28 ......................................... 188
AcrB_29 ......................................... 188
AcrB_30 ......................................... 188︸ ︷︷ ︸
C-Cap
2
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Supporting Information Figure S8: DARPins specific for caspase-3 (A), caspase-7 (B) and 
AcrB (C) were co-purified by SEC with their targets (example in Figure 6B) and the complex 
peak fractions were analyzed by SDS-PAGE. The double band for C3_16 in (A) can be 
explained by incomplete denaturation of this DARPin during SDS-PAGE. AcrB_4 and 
AcrB_23 in (C) appear to partially dissociate from AcrB during SEC analysis, owing to their 
modest affinity (Figure 6F).  
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Supporting Information Figure S9: Equilibrium unfolding curves of original and new 
DARPins. 25 new DARPins (15 unselected DARPins (denoted by a “D” before the number), 
5 DARPins each specific for caspase-3 and caspase-7 (denoted by “C3_” and “C7_” before 
the number)) and original DARPins off7 (PDB 1SVX, against MBP)
12
, 11_0819 (PDBs 2J8S 
and 4DX5, against AcrB)
28,36
, DARPin#2 and #3 (PDBs 3NOC and 3NOG, against AcrB)
42
, 
α-LmrCD#3 and #4 (against LmrCD)
30
, DARPin#55 (against MsbA)
29
, D3.4 (PBD 2XZD, 
against caspase-3)
40
, D7.18 (against caspase-7, to be published) and D8.14 (PDB 2Y1L, to be 
published) were analyzed by GdnHCl unfolding. Monophasic or biphasic sigmoidal equations 
were fitted to the experimental data (Equations 1 and 2, see Materials and Methods) to 
determine midpoints of denaturation (Dm for monophasic and Dm,1 and Dm,2 for biphasic 
unfolding curves).  
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A134
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C-Cap
Supporting Information Figure S10: (A) DARPin C7_16 (red) is superimposed with a full-
consensus DARPin containing an optimized C-cap (2XEE, Kramer et al. 2010, all four chains 
of the asymmetric unit are shown in grey). (B) Analysis of DARPin-mediated crystal contact 
of the C7_16-caspase-7 complex structure. The crystal contact interface involves low-entropy 
residues A68, A130 and D134 (highlighted in red), which were lysines and glutamates, 
respectively, in the original DARPin library.  
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HIV-1 protease inhibition potential of functionalized polyoxometalates
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a b s t r a c t
Polyoxometalates (POMs) are interesting biomedical agents due to their versatile anticancer and antiviral
properties, such as remarkable anti-HIV activity. Although POMs are tunable and easily accessible inor-
ganic drug prototypes in principle, their full potential can only be tapped by enhancing their biocompat-
ibility, for example, through organic functionalization. We have therefore investigated the HIV-1 protease
inhibition potential of functionalized Keggin- and Dawson-type POMs with organic side chains. Their
inhibitory performance was furthermore compared to other POM types, and the buffer dependence of
the results is discussed. In addition, chemical shift mapping NMR experiments were performed to exclude
POM–substrate interactions. Whereas the introduction of organic side chains into POMs is a promising
approach in principle, the inﬂuence of secondary effects on the reaction system also merits detailed
investigation.
 2010 Elsevier Ltd. All rights reserved.
Polyoxometalates (POMs) are transition metal oxide clusters
that are preferably formed with W, Mo and V in their high oxida-
tion states.1 Their ever growing number of complex structural
architectures brings forward an impressive application potential
that attracts widespread research attention, for example, with re-
spect to key technological applications,2 (electro)catalytic pro-
cesses,3 magnetic materials4 and nanotechnology.5 Another
special feature of POMs is their versatile bioactivity that leads to
antibacterial, anticancer and antiviral properties.6 These have been
widely reviewed over the past years and POMs have been proven
to be active against a wide range of viruses, including different
inﬂuenza strains, Dengue fever virus and SARS coronavirus.7 They
have furthermore been tested as promising anti-HIV agents since
the full outbreak of the AIDS epidemic in the 1980s. The ﬁrst break-
through was reported in 1988 when the ﬁrst in vivo studies on hu-
mans were performed with the [NaSb9W21O86]18 polyanion
(commonly abbreviated as HPA-23).8 However, HPA-23 caused se-
vere side effects at higher dosages that forced the patients to dis-
continue the therapy.8 Since then, the search for ‘second
generation’ anti-HIV POMs with reduced toxicity was continued
and the [PTi2W10O40]7 polyanion (abbreviated as PM-19) was,
for example, identiﬁed as a potential antiviral drug capable of
inhibiting the replication of HIV-19 and herpes simplex virus
(HSV)10 in vitro.
Despite the multitude of empirical investigations on the antivi-
ral activity of POMs, little is known about their interaction mecha-
nisms with viruses or cells.11 Concerning the anti-HIV activity,
Inoue et al. investigated the inhibition of HIV-1 reverse transcrip-
tase (RT) by various POMs.12 Interestingly, cell culture experiments
showed that the anti-HIV-1 activity of the POMs under consider-
ation was not correlated with their HIV-1 RT inhibition.12 A fol-
low-up study by the same group identiﬁed the Keggin- and
Dawson-POM types as possible ‘lead compounds’ for anti-HIV
activity.13 In 2001, a novel inhibition mechanism of HIV-1 protease
by Dawson-type POMs was proposed in a pioneering study by Hill
et al.14 The high activity of the niobium-substituted tungstate a2-
[P2W17NbO62]7 was explained with its binding to the ﬂexible
hinge regions on the surface of the HIV-1 protease. As most organic
HIV-1 protease inhibitors bind into the active site, larger inorganic
cluster molecules, such as POMs, would thus open up new ways of
inhibition. Such alternative interaction pathways of POMs with
HIV-1 protease would render them less sensitive towards the fre-
quently occurring mutations of HIV-1, thereby circumventing the
problem of therapeutic resistance in current AIDS therapy.15 In
addition, most anti-AIDS drugs are costly compounds that have
to be administered in inconveniently high doses several times a
day. POMs would offer economic advantage over the current
anti-AIDS drugs in principle, because they can easily be synthe-
sized from readily available precursors in a few synthetic steps.
The following years witnessed further reports on antiviral
POMs6a and new insights were obtained regarding the interaction
of POMs with human/bovine serum albumin16 or protein kinase
CK2.17 Nevertheless, the fundamental issue of POM toxicity still
remains to be overcome in order to turn them into powerful, ver-
satile and low-cost inorganic anti-HIV agents. However, the devel-
opment of hybrid and functionalized POMs is now proceeding
rapidly18 and thus provides new inspirations for research on inor-
ganic anti-HIV agents together with the incorporation of antiviral
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POMs into biomacromolecular matrices as an additional strategy.19
The increasing gap between these growing classes of novel POMs
and their biomedical characterization inspired us to screen a se-
lected variety of POM types with respect to their inhibitory effect
on HIV-1 protease. Firstly, we compared the inhibitory potential
of POMs with different cluster sizes. We then focused on Keggin-
and Dawson-type POMs with different organic side chains in order
to evaluate the inﬂuence of the functionalization on the inhibitory
performance. In addition, we placed emphasis on methodological
issues: the results are critically discussed with respect to their con-
siderable buffer dependence. Furthermore, we present NMR stud-
ies in solution to exclude the possibility of POM–substrate
interactions.
All POMs were synthesized according to published procedures
and they are summarized in Table 1. Figure 1 illustrates the struc-
tural motifs (Keggin- and Dawson-type) for the majority of the
investigated POMs and their organically substituted derivatives.
They have emerged from recently developed novel functionaliza-
tion approaches.20 POM 1 has been included as a representative
of ‘sandwich-type’ lacunary POM building blocks with embedded
transition metal cations. POMs 2–5 are based on the recently dis-
covered {Ln6W63} cluster21 as the largest polyoxotungstate type
among the present selection. These compounds are of general
interest, because the incorporation of lanthanoid cations into
POMs is promising with respect to their potential double function
as diagnostic (e.g., luminescence or MRI) and therapeutic
agents.16a,22 POM 20 (Preyssler type) bears resemblance to the
Dawson typedue to thearrangementof itsﬁvePW5units intoaDaw-
son-related surface. POM 28 (Lindqvist type) as the most compact
and smallest structure type rounds off the ‘classic’ POM spectrum.
The POMs were characterized by IR spectroscopy and other ana-
lytical methods if required (e.g., NMR or single crystal structure
determination) and they were stable under the applied experimen-
tal conditions. HIV-1 protease was expressed in Escherichia coli
BL21 (DE3) pLysS cells and puriﬁed by anionic exchange and size
exclusion chromatography according to literature protocols (for
further experimental details cf. Supplementary data).23 Given that
HIV-1 protease has an autocatalytic activation site as well as
autoprotolytic activity,24 special attention must be paid to the high
purity of the protein to precisely determine its concentration and
to prevent possible interaction of the POMs with degraded prote-
ase fragments during the protease assays. For that reason, the sub-
stitution of one single amino acid, namely glutamine at position 7
to lysine (Q7K), has been performed to reach a 100-fold increase of
the protein stability.24 This residue is located in the ﬁrst loop after
the ﬁrst b-strand in the protein and at a considerable spatial
distance to the ﬂexible hinge regions that were proposed as POM
binding sites.14 Therefore, it can be practically excluded that the
use of the HIV-1 mutant Q7K affects the inhibitory potential of
the POMs in comparison with the wild type. The introduction of
the positively charged lysine might even exert a productive elec-
Table 1
Survey of the POMs screened for HIV-1 protease inhibition
No. Formula Cations Type Solvent Ref.
1 [Na3Cu3(H2O)9(AsW9O33)2]9 Na9 Dimer H2O 28
2 [CsTb6As6W63O218(H2O)14(OH)4]25 Na21Cs4 Hexamer H2O 21
3 [CsDy6As6W63O218(H2O)14(OH)4]27Cl2 Na22Cs5 Hexamer H2O 21
4 [CsHo6As6W63O218(H2O)14(OH)4]27Cl2 Na22Cs5 Hexamer H2O 21
5 [CsEr6As6W63O218(H2O)14(OH)4]25 Na21Cs4 Hexamer H2O 21
6 a2-[P2W17O61SnR]7 (R = C3H5O2) TBA6H Dawson DMSO 20
7 a2-[P2W17O61SnR]6 (R = C4H6O) TBA6 Dawson DMSO 20
8 a2-P2W17O61SnR]7 (R = C6H8NO) TBA7 Dawson DMSO 20
9 a2-[P2W17O61SnR]7 (R = C4H9) TBA6H Dawson DMSO 20
10 a2-[P2W17O61SnR]7 (R = C18H32N3O5S) TBA7 Dawson DMSO 20
11 a2-[PW11O39SnR]4 (R = C3H5O2) TBA4 Keggin DMSO 20
12 a2-[PW11O39SnR]4 (R = C4H9) TBA4 Keggin DMSO 20
13 a2- [PW11O39SnR]4 (R = C18H32N3O5S) TBA4 Keggin DMSO 20
14 a1-[P2W17O61SnR]7 (R = C3H5O2) TBA6H Dawson DMSO 20
15 a1-[P2W17O61SnR]7 (R = C6H8NO) TBA7 Dawson DMSO 20
16 a1-[P2W17O61SnR]7 (R = C4H9) TBA6H Dawson DMSO 20
17 a2-[P2V3W15O63R]7 (R = C13H19N) TBA5 Dawson DMSO 20
18 [H2W12O42]6 (NH4)6 Individual H2O 23
19 [NaSb9W21O86]18 (NH4)18 Individual H2O 29
20 [NaP5W30O110]14 K14 Preyssler H2O 29
21 a/b-[P2W18O62]6 K6 Dawson H2O 29
22 a1-[LiP2W17O61]9 K9 Monolacunary Dawson H2O 29
23 a2-[P2W17O61]10 K10 Monolacunary Dawson H2O 29
24 a1-[P2W17(NbO2)O61]7 K7 Dawson H2O 14
25 a1-[P2W17(NbO2)O61]7 K7 Dawson H2O 14
26 [PW12O40]3 NaH2 Keggin H2O 30
27 [PTi2W10O40]7 K7 Keggin H2O 31
28 [Pr(W5O18)2]9 K9 Lindqvist H2O 32
Figure 1. Overview of the most important POM types investigated in the present
study: (a) Keggin type, (b) Dawson type, (c) a2-substituted Dawson type,
(d) a1-substituted Dawson type.
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trostatic effect upon the binding of the highly negatively charged
POMs to the protease. Standardized protease assays25 were per-
formed as described in the Supplementary data and an inﬂuence
of POM absorbance on the measurements was excluded. The prote-
ase substrate was dissolved in dimethyl sulfoxide (DMSO) and two
different buffer solutions were applied: buffer 1 contained a ﬁnal
DMSO concentration of 10%, whereas the DMSO content of buffer
2 was 1% (for details cf. Supplementary data). The stability of the
protease during the assays was conﬁrmed by Selwyn tests,26
known as the standardized enzymatic stability test till date,
under both buffer conditions. The inhibitory potential of all POMs
was analyzed in triplicate measurements with Saquinavir as a
standard inhibitor under both buffer conditions. Furthermore, the
ingredients of the two different buffers were compared under the
above conditions using POM 25 with a known high inhibitory
activity14 (cf. Table 1 and Table S-1). The higher concentration of
DMSO and the additional detergent Nonidet P-40 obviously
exerted the most signiﬁcant inﬂuence on the measured inhibition
(cf. Fig. S-1). Although the additional detergent Nonidet P-40 is
supposed to stabilize the protease during the assay,25 the enzy-
matic reaction also worked in the detergent-free buffer 2 with a
lower DMSO concentration. Most importantly, these buffer addi-
tive tests show that the POM-induced protease inhibition is not a
mere artefact arising from precipitation of protease or substrate
during the reaction.
The relative activity of HIV-1 protease Q7K in buffers 1 and 2 is
shown in Figure 2: the POMs were added in a 10- or 100-fold ex-
cess relative to the protease in buffer 1 and the relative protease
activity remained higher than 70% in all reactions, whereas Saquin-
avir applied in an 1:1 ratio led to 100% inhibition. This excludes
experimental setup errors and indicates that no inhibition of the
enzymatic reaction by POMs occurred under these conditions.
Especially for POMs 24 and 25, this result was unexpected in com-
parison with their previously reported high potential for HIV-1
protease inhibition.14
However, changing the conditions to buffer 2 completely al-
tered the overall activity pattern. Although the use of detergent
at 10% DMSO concentration had been reported to exert a stabiliz-
ing effect on HIV protease activity,22 buffer 1 with 1% DMSO and
less ingredients was sufﬁcient to keep the protease active. A de-
cline of the enzymatic reaction was observed in almost all experi-
ments, in line with the preceding results:14 POMs 21, 24 and 25 led
to total protease inhibition as well as POMs 9, 12, 14 and 16. For a
more detailed discussion of the results obtained in buffer 2, the
POMs are classiﬁed into water-soluble POMs (1–5, 18–28) and
functionalized DMSO-soluble POMs (6–17) with organic side
chains. Interestingly, previous studies have pointed out that DMSO
inﬂuences enzymatic reactions in a rather complex manner that
varies widely—from stimulation to inhibitory effects—for the dif-
ferent systems under investigation.27 However, this does not apply
for the pristine HIV-1 protease in the present case and the DMSO
dependence of POM-induced HIV-1 protease inhibition in contrast
to its general inhibition by Saquinavir points to differences in the
interaction mechanisms of organic and inorganic inhibitors, as
had been suggested in earlier studies.14
A comparison of the water-soluble POMs with signiﬁcant inhib-
itory potential (20–25) indicates that POMs related to the Dawson
type are generally superior to the remaining POM architectures
investigated in this study. POMs 21, 24 and 25 are Dawson struc-
tures and POMs 22 and 23 are monolacunary Dawson POMs (a1-
and a2-isomers, respectively). In comparison with the Dawson
type POMs, even the most prominent POMs, namely the aforemen-
tioned HPA-23 (POM 19) that was implemented in the ﬁrst clinical
studies8 and the well-known anti-HIV agent PM-19 of the Keggin
type (POM 27),9 displayed a remarkably lower inhibitory effect.
Concerning POMs 2–5, their larger cluster size did not promote
HIV-1 protease inhibition. Likewise, the dimeric structure of POMs
1 and 28 did not bring forward signiﬁcant inhibitory activity—nor
did the smaller [H2W12O42]6 anion (POM 18) that performed even
slightly worse than the Keggin compounds of related size (POMs
26 and 27). These results render the Dawson type especially prom-
ising for construction of functionalized antiviral POMs, provided
that the above-mentioned buffer inﬂuence is taken into account.
The dimensions of the Dawson cluster indeed appear to be in the
appropriate range for POM/protein interactions as indicated in pre-
ceding theoretical studies.14
A more detailed comparison of the inhibitory effect among the
DMSO-soluble POMs can be found in Figure 3: POMs 11–13 are
Keggin type derivatives, whereas POMs 6–10 and 14–17 are Daw-
son type POMs that were functionalized with organic side chains at
the a1- (POMs 14–16) and a2-position (POMs 6–10 and 17),
respectively. A ﬁrst glance at Figure 3 shows that the distinction
between Keggin and Dawson type POMs is evened out through
the introduction of organic residues: the Keggin type POM 12 with
a butyl side chain induced complete inhibition of the protease
activity (Fig. 3c). Generally, the introduction of a butyl side chain
exerted the strongest inhibitory effect among the DMSO-soluble
POMs, regardless of the POM framework or the Dawson regiosom-
er. This effect is even maintained with a 10-fold excess of the bu-
tyl-substituted POM 9. In the case of a propionic acid residue, the
Keggin type derivative can as well compete with its Dawson ana-
logs in terms of inhibitory effect (Fig. 3a). In parallel, the attach-
Figure 2. Relative activity of HIV-1 protease in the presence of different POMs as potential inhibitors (cf. Table 1). The reactions were performed in buffer 1 and buffer 2,
respectively, and the total reaction volume was 200 ll. POMs were added to a concentration of 3 lM or 300 nM (asterisk). The activity of the protease in reactions without
POMs was deﬁned as 100% (Saq = Saquinavir).
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ment of a more complex peptide-based side chain signiﬁcantly re-
duced the protease activity irrespective of the POM host structure
(Keggin or Dawson type, cf. Fig. 3d).
Although these results have to be interpreted with caution due
to the limited number of POMs involved in the present study in
comparison with the manifold experimental variables (such as buf-
fer composition and POM concentration), their entirety indicates
that the functionalization of POMs with organic moieties exerts a
productive effect on their potential for HIV-1 protease inhibition.
All in all, the Dawson type POMs displayed the most promising
overall inhibitory performance in the present study and it seems
that the generally high antiviral potential of this ‘classic’ type is dif-
ﬁcult to obtain with many newly discovered larger polyoxotung-
states such as the investigated {Ln6W63} type.21 In this context,
our recent luminescence studies on the interaction of {Eu6W63}
and {Tb6W63} with human/bovine serum albumine16a also showed
that their protein binding modes differ considerably from those of
the smaller decatungstate cluster, thus pointing to the POM size as
an important factor in structure–activity relationships. However,
the introduction of organic side chains may be an important tool
to modify structure activity relationships among the different
POM cluster types in order to amplify the antiviral potential of
POMs in general. This is supported by the fact that the introduction
of a butyl group into the Keggin type (POM 12) drastically im-
proves the inhibitory performance in comparison with the pristine
Keggin POM 26. Such ‘amphiphilic’ POMs with unpolar organic
substituents turned out to perform quite well in HIV-1 protease
inhibition. For that reason, the inhibitory potential of the pristine
organic compounds might also be tested as a reference.
However, this result also raises a critical point that should be ta-
ken into account for future studies: based on the present buffer
additive tests, an interaction of the POMs with the substrate cannot
be completely excluded. In order to detect possible interactions of
the peptide substrate with POMs, we used solution NMR tech-
niques. In particular, chemical shift mapping 600 MHz proton
spectra were recorded on an approx. 100 lM peptide solution at
pH 5.0 (100 mM acetate buffer) at 27 C both in the absence and
in the presence of POM 24 that displays signiﬁcant HIV-1 protease
inhibition.14 The two samples were prepared from the same pep-
tide stock solution, to one of which POM 24 was added. The pH
was carefully controlled, and differed by less than 0.1 pH units in
the two samples. The region of aliphatic protons displayed very lit-
tle differences, whereas some amide protons experienced small
shift changes. Nevertheless, the observed differences in the spectra
were very minor (Fig. 4). From these changes we estimate that the
Kd is likely to be in the molar range, strongly disfavoring a speciﬁc
interaction with reasonable afﬁnity and indicating the presence of
a low-afﬁnity, non-speciﬁc interaction. We conclude from these
data that while a low-afﬁnity non-speciﬁc interaction of the POM
with the peptide does occur, its strength is so weak that it cannot
be the reason for the observed inhibition of the substrate cleavage
by the HIV-1 protease.
The ultimate proof of POM–protease interactions would
certainly be the crystallization of a POM–protein complex. This
challenging goal has never been reached over several decades of
anti-HIV studies with POMs. Another option would be a pull-down
experiment: POMs linked to beads that are incubated with HIV-1
protease or with substrate, respectively, followed by washing steps
and analysis of the residues. This, however, would be a study in its
own right, because POM/bead linking methods would have to be
developed or, alternatively, HIV-1 protease would have to be stabi-
lized during the coupling.
In summary, the present screening study outlines several
methodological issues in the screening of POMs for anti-HIV-1 pro-
tease activity that have to be considered in follow-up experiments,
namely the composition of the buffer system and the exclusion of
POM/substrate interactions. Optimization studies, however, are
now worthwhile, because we demonstrated that the functionaliza-
tion of Dawson and Keggin type POMs with organic moieties is
likely to enhance the inhibitory potential and to amplify the range
of antiviral POM types, thus rendering them more biocompatible.
Further studies concerning the cytotoxicity and cellular uptake of
antiviral POMs are under way.
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Materials: All chemicals were purchased from Fluka (Sigma-Aldrich, Switzerland) and used 
without further purification if not otherwise mentioned. The following reagent was obtained 
through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 
Saquinavir. Protease substrate DABCYL-γ-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS 
was purchased from Bachem (Heidelberg, Germany). 
 
Expression and purification of HIV-1 protease: The production of HIV-1 protease, which 
includes cloning into pET21c vector, expression in E.coli BL21 (DE3) pLysS cells and 
purification by anionic exchange and size exclusion chromatography, was performed 
according to literature.1, 2 A template plasmid, containing the HIV-1 wild type genome, was 
kindly provided by Dr. Jovan Pavlovic (Institute of Medical Virology, University of Zurich, 
Switzerland). To prevent autoproteolytic degradation of the enzyme, a single amino acid 
substitution (Q7K) was performed using the QuikChange® Site-Directed Mutagenesis Kit 
(Stratagene). This mutation was proposed to stabilize the protein of at least 100-fold without 
affecting the enzyme activity.3 
 
Synthesis of POMs: The arsenal of polyoxometalates (POMs) were synthesized according to 
literature4-8 and routinely analyzed by IR spectroscopy (KBr pellets). Additional POMs were 
kindly provided by Dr. Firasat Hussain, University of Zurich, Switzerland, and Prof. Dr. 
Emmanuel Lacôte, Prof. Serge Thorimbert and Prof. Bernold Hasenknopf,  ((UPMC Univ 
Paris 6, Institut Parisien de Chimie Moléculaire (UMR CNRS 7201)). 
 
Inhibitor screening of POMs: The stability of the HIV-1 protease Q7K was confirmed by a 
Selwyn test9 and protease inhibitory measurements were performed according to a 
standardized protease activity assay reported by Hoffmann et al.10 The inhibitory potential of 
all POMs was analyzed by a protease assay in 96-well microtiter plates using a Tecan GENios 
microplate reader: 30 nM HIV-1 protease Q7K and 10 µM substrate were used in all 
reactions, which were monitored every 90 s for 60 min in a total volume of 200 µl in two 
different buffers (Table 1). POMs were added to reactions in 100- or 10-fold excess (3 µM or 
300 nM), depending upon the solubility of the POMs. The substrate is 8 amino acids long and 
contains a cleavage site for the HIV-1 protease between the residues tyrosine and proline. The 
measured fluorescence of the EDANS group at the C-term is quenched by the DABCYL 
group at the N-term over an intramolecular fluorescence resonance energy transfer. Cleavage 
of the substrate leads to a separation of the two groups that results in an increase of 
A. Flütsch et al.: HIV-1 protease inhibitory polyoxometalates
164 Bioorg Med Chem Lett. 2011 Feb 15;21(4):1162-6
 S-3
fluorescence. The enzymatic reaction is thus observed by measuring the increase of the 
fluorescence signal at 485 nm over time with an excitation at 380 nm and a gain of 60. All 
POMs showed no absorbance at 380 nm in assay concentration and do therefore not interfere 
with the excitation of the fluorophore at 380 nm. Saquinavir was measured as a standard 
inhibitor in concentrations of 30 nM. All potential inhibitors were measured in triplicates to 
obtain a standard deviation. The slope of the linear region of a RFU vs. time plot corresponds 
to the reaction rate. The mean value of the triplets was compared to a positive control without 
inhibitor, which was defined as 100 % of the reaction velocity. 
 
Additive test screen comparing the two different buffers: Every ingredient of buffer 1 was 
added to different reactions in buffer 2 in equal concentrations as in buffer 1. The reactions 
were set up with 30 nM HIV-1 protease Q7K, 3 µM POM 25 and 10 µM substrate. Reactions 
in buffer 1 and buffer 2 without additives were measured at the same time as buffer controls. 
Reaction rates of additive reactions were compared to buffer controls. 
 
 
 
Table 1. Additive test screen with buffers 1 and 2. 
 
Ingredient Buffer 1 (ref. 10) Buffer 2 (ref. 5) 
Sodium acetate 50 mM 100 mM 
NaCl 1 M 100 mM 
EDTA 1 mM -- 
DTT 2.5 mM -- 
Glycerol 2.5 % (v/v) -- 
Nonidet P-40 0.1 % (v/v) -- 
DMSO 10 % 1 % 
pH 4.7 5.0 
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Figure S-1. Buffer additive test: reactions were performed with 30 nM protease and POM 25 
(3 µM). Activity of the protease in buffer 1 without POM 25 was defined as 100 %. The 
measurement in buffer 2 with POM 25 showed no relative activity. 
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